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Abstract 
Reciprocal physiological modulation of heart rate is controlled by the sympathetic and 
parasympathetic systems acting on the sino-atrial (SA) node. However there is little 
direct in vivo work examining the role of stimulatory and inhibitory G-protein 
signalling in the SA node. We have previously shown that the inhibitory G-proteins 
Gαi2, is important in mediating vagal tone to the murine heart with global Gαi2 knock-
out mice developing tachycardia with loss of high frequency power and being resistant 
to the effects of the muscarinic agonist, carbachol (Zuberi et al. 2008). However, it is 
unclear whether the effect is mediated entirely via Gαi2 signalling at the end-organ 
level or whether there is a central component. I sought to investigate this by studying 
mice with conditional knock outs (KO) of Gαi2 and Gαo in cardiac tissue by using 
αMHC cre mice. Studies with αMHC cre mice using the cre lox-P approach were 
negative as there was no difference in heart rate variability (HRV) and 
electrocardiograph (ECG) parameters between controls and conditional KO of Gαi2 
and Gαo, though by real-time polymerase chain reaction (RT-PCR) we could see 
reduction in the level of their expression. I assumed deletion of Gαi2 and Gαo may not 
be complete in the SA nodal region where G-protein inwardly rectifying K+ channels 
(GIRK) channels are active. I sought to investigate this further by studying mice with 
conditional deletion of Gαi2 and Gαs in the conduction system of the murine heart 
using cre lox-P technology. I crossed mice in which cre recombinase expression was 
driven by a tamoxifen-inducible conduction system-specific construct with Gαs floxed 
and Gαi2 floxed mice. I studied the heart rate responses of adult mice compared with 
littermate controls by using ECG radio-telemetry before and after administration of 
tamoxifen. The mice with conditional deletion of Gαs and Gαi2 had a loss of diurnal 
variation and were bradycardic or tachycardic in the daytime respectively. In mice 
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with conditional deletion of Gαs there was a selective loss of low frequency power 
whilst with deletion of Gαi2 there was a loss of high frequency power in power 
spectral analysis of heart rate variability. There was no evidence of pathological 
arrhythmia. Pharmacological modulation of heart rate by isoprenaline was impaired in 
the Gαs conditional knock-out mice but a muscarinic agonist was still able to slow the 
heart rate in Gαi2 conditional knock-out mice. We conclude that Gαs and Gαi2 
mediated signalling in the sino-atrial node is important in the reciprocal regulation of 
heart rate through the autonomic nervous system.  
Another way to look at the role of specific gene function is via gain of function 
mutation. Regulators of G-protein signalling (RGS) proteins are a recently discovered 
family of proteins that negatively regulate G-protein-coupled signalling pathways. 
Thus, I used RGS-insensitive (RGSi) mutant Gα subunits, which contain a G184S point 
mutation in their switch I region that prevents binding of RGS proteins and the 
subsequent Gα deactivation. RGS insensitive Gαi2 and Gαo mice (RGSiGαi2 and 
RGSiGαo) were found to be tachycardic and lost diurnal variation in heart rate. The A1 
receptor agonist, 2-chloro-N6-cyclo-pentlyadenosine (CCPA) and M2 receptor 
agonist, carbachol showed an enhanced inhibitory response (bradycardic) to RGSiGαo 
but this enhanced bradycardic response was observed only with carbachol for 
RGSiGαi2. HRV signature was found to be lost in RGSiGαo but not with RGSiGαi2. 
Interestingly, studies with RGSiGαi2 and RGSiGαo prove a role of the central nervous 
system in controlling the heart rate in these knock-ins. 
Gαi2 levels are up-regulated in heart failure. However, it was not clear whether its role 
is protective or maladaptive in the context of heart failure. Hence, I subjected the mice 
in which cre recombinase expression was driven by a tamoxifen-inducible conduction 
system-specific construct with Gαs floxed and Gαi2 floxed mice to myocardial 
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infarction by left anterior descending (LAD) artery ligation. I found that cardiac-
specific knock-out of Gαs attenuates left ventricular (LV) dilation and improves LV 
contractile function after myocardial infarction (MI). Conditional deletion of Gαs was 
found to be protective as this was reflected in increased fractional shortening (FS%), 
ejection fraction (EF%) and fractional area change (FAC%) on echocardiographic 
analysis after MI. LV remodelling was observed in cardiac-specific knock-out of Gαi2 
to a certain extent with chamber dilatation and decreased EF% and FS% and FAC%.  
In summary absence of Gαs is found to preserve LV function may be by its 
bradycardic nature may protect the heart against the ischemic insult, although the 
precise mechanism that helps against the adverse LV remodelling need to be explored. 
On the other hand absence of Gαi2 and moderate tachycardia in these mice didn’t have 
any detrimental effects on LV remodelling. 
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Introduction 
Cardiovascular disease (CVD) includes all the diseases of the heart and circulation 
including coronary heart disease (CHD) which includes angina and myocardial 
infarction, heart failure, congenital heart disease, stroke and peripheral vascular 
disease - caused by narrowing of the arteries to the peripheries. CVD continues to be 
the most common threat to life and health in spite of a major decrease in mortality 
rates. The life time risk of developing CHD after 40 is 49% in men and 32% in 
women (Lloyd-Jones et al. 1999). In 2010 CVD was the UK’s biggest killer. Almost 
180,000 people died from CVD, around 80,000 of these deaths being from CHD and 
around 49,000 from stroke. In the same year CVD caused 46,000 premature deaths in 
UK; 68% of these were men. Collectively, heart and circulatory diseases cause more 
than a quarter of all deaths in the UK (BHF statistics 2012). It is predicted that by 
2020, CVD will annually claim 25 million deaths worldwide, and will surpass 
infectious disease as the world’s number one cause of death and disability (Braunwald 
et al. 2001). Myocardial infarction (MI) is the most common presentation of CVD. A 
heart attack (myocardial infarction) is usually caused by a blood clot (thrombosis), 
which precipitates as a result of rupture of plaques or deposits (atheroma) in the inner 
lining of arteries, which in turn initiates blood clot formation and stops the blood 
flowing to a part of the heart muscle. This puts the heart muscle at high risk of dying 
unless the blockage is quickly removed. Myocardial infarction (MI) leads to necrotic 
heart muscle and hence leads to impaired cardiac function. If left untreated, this can 
lead to further complications such as heart failure (which is discussed in depth in this 
thesis), abnormal heart rhythm or a further MI. The good news is that mortality from 
CVD is falling and the credit for this can be attributed to the use of innovative, 
preventive and therapeutic measures developed as a result of cardiovascular research.  
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There is an increase in use of laboratory animals for cardiovascular research and a vast 
number of animal models have been developed to model human diseases and 
investigate their physiological and pathological processes. Animal models of heart 
failure play an important role here by helping us to analyse physiological effects of 
cardiac dysfunction and also to understand the genetic mechanism underlying heart 
failure which will further help to improve therapies for the future. It has become clear 
that the analysis of rodent and in particular gene-targeted murine models of cardiac 
disease gives important insights into the pathogenesis of abnormal heart function and 
rhythm in man. This gives us an experimental platform to further investigate and 
explore more developmental pharmacological agents that might be of benefit to 
patients. In this thesis I will discuss the role of the well-known signalling proteins - G-
proteins (Gαs - stimulatory G-protein and Gαi - inhibitory G-protein), in controlling 
the heart rate and their role in heart failure using murine models. 
1.1 Heart Failure  
Heart failure (HF) is the end stage of many cardiac diseases. It is a growing public 
health concern for which, despite effective therapy, outcome remains poor with a 5-
year mortality at 50% (Braunwald, Zipes, & Libby 2001). Clinically, HF is a chronic 
and severely debilitating syndrome that generally ends up in a vicious cycle of 
progressive functional decline and it is characterized by the insufficient pumping of 
blood to meet the needs of the body (Cannavo et al. 2013). It is estimated that over 
100,000 annual admissions to hospital medical wards in the UK have heart failure and 
this accounts for 5% of total admissions. In the UK the overall prevalence of heart 
failure is 3-20 per 1000 population, although this exceeds 100 per 1000 in those aged 
65, years and over. Although the annual incidence of heart failure is 1-5 per 1000, the 
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relative incidence doubles for each decade of life after age 45. With an increasingly 
ageing population and improved survival of patients with impaired cardiac function 
due to newer therapeutic advances in the management of acute MI, the overall 
percentage is likely to increase in the future (Davis et al. 2000). Two million new 
cases of HF are diagnosed worldwide, leading to a prevalence of over 22 million 
people across the globe (WHO, Cardiovascular Diseases, Fact sheet no.317). The 30 
year follow up Framingham epidemiological heart study (a longitudinal study on HF) 
which started in 1948, shows that prevalence of HF increased dramatically with 
increasing age, with doubling of prevalence with each decade and it is more common 
in males until the age of 65, after which the prevalence is equal among both the sexes 
and the survival rate in women is much better than in males (Ho et al. 1993). But later 
studies show that at any given age prevalence of CVD is more among men (12-15%) 
than in women (Roger et al. 2011). Data from Framingham study also indicates that 
hypertension, coronary heart diseases, diabetes mellitus and ventricular hypertrophy 
are associated with increased risk of heart failure. Unfortunately, as many features of 
heart failure are not organ specific, in the past it was difficult to diagnose clinically 
and there may be few clinical features in the early stages of the disease. Due to 
advancement in technologies, early recognition of heart failure is now possible and it 
is important also, as modern drug treatment has the potential to reduce hospital 
admission rates, slow the rate of disease progression, improve symptoms and quality 
of life and improve survival (Davis, Hobbs, & Lip 2000).  
1.1.1 Etiology 
Sir Thomas Lewis (1933) said it very well, “The very essence of cardiovascular 
practice is the early detection of heart failure” (Lewis 1933). Heart failure emanates 
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from injury to the myocardium from a variety of causes including ischemic heart 
disease, hypertension and diabetes. Less common etiologies include 
cardiomyopathies, valvular disease, myocarditis, infections, systemic toxins, and 
cardio toxic drugs. Pre-existing hypertension is quite common in HF patients and this 
risk factor alone doubles the risk of developing HF compared to normotensive 
patients. As the heart fails, patients develop symptoms which include dyspnea from 
pulmonary congestion, and peripheral oedema and ascites from impaired venous 
return. Symptoms such as nausea, lack of appetite, and fatigue are also prevalent. 
Heart failure involves changes in the contractility, electrical conduction and energy 
metabolism of the heart, making it difficult to cope with circulatory demands (Stanley 
et al. 2005). This in turn leads to neurohormonal compensatory mechanisms that occur 
as the failing heart attempts to maintain adequate function. Although initially 
beneficial in the early stages of heart failure, compensatory mechanisms eventually 
lead to a vicious cycle of worsening heart failure. Henceforth, the physiological and 
gene expression changes observed in heart failure are not constantly ‘adaptive’ or 
‘maladaptive’ and because of this reason it is not easily responsive to pharmacological 
modulations and thus has introduced therapeutic confusion over the years 
(Breckenridge 2010). 
1.1.2 Pathophysiology 
 
Cardiac output (CO) is defined as the amount of blood pumped by the heart over a 
given time period and is the product of heart rate (HR) and stroke volume (SV). SV is 
the blood ejected by the ventricle per beat and is affected by various factors like 
synergistic ventricular contraction, wall integrity and valvular competence. The 
primary abnormality in non-valvular heart failure is impairment in left ventricular 
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function, leading to a fall in cardiac output. This left ventricular (LV) dysfunction can 
be either systolic (impaired contraction and ejection) or diastolic (impaired relaxation 
and filling) and 70% of the patients with HF have systolic dysfunction. LV systolic 
dysfunction is defined as a LVEF (Left Ventricle Ejection Fraction) less than 40% and 
the leading cause of LV systolic dysfunction is due to the loss of functional 
myocardium due to ischemic disease and infarction, uncontrolled hypertension leading 
to excessive pressure overload and also from impaired contractility from cardiotoxic 
drugs. One of the consequences of LV dysfunction is decreased CO and this causes an 
increase in the amount of blood in the ventricle and therefore an increase in both end-
systolic and end-diastolic volumes. This further leads to an increase in LV end-
diastolic pressure (LVEDP) which causes increase in left atrial pressures which 
further lead to an increase in the pressure of the capillaries in the lungs. The fluid from 
the pulmonary capillaries is forced out due to this elevated pressure in the lungs and 
leads to pulmonary congestion and is the major clinical symptom of dyspnea. On the 
other hand the most common cause of right ventricular (RV) failure is LV failure. As 
the RV fails, there is a similar reduction in CO, increase in the amount of blood in the 
ventricle, which further leads to increased right atrial pressure and increased pressure 
in the venacaval system which diminishes venous drainage from the body. This leads 
to increased pressure in organs like the liver, the gastrointestinal tract and the lower 
extremities which further leads to the clinical signs and symptoms of abdominal pain,  
hepatomegaly, and peripheral oedema (Kemp and Conte 2012).  
 
1.1.3 Compensatory mechanisms 
The fall in cardiac output sparks the stimulation of several neurohormonal 
compensatory mechanisms which play a crucial role in the early stages of HF, directed 
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at improving the mechanical neighbourhood of the heart (Fig 1.1). For example, 
activation of the sympathetic system, with an increase in heart rate, increased 
myocardial contractility and peripheral vasoconstriction (increased catecholamines- 
norepinephrine and epinephrine) tries to maintain cardiac output. Chronic sympathetic 
activation however has detrimental effects, causing a further deterioration in cardiac 
function. Sympathetic activity in the heart, further leads to an increase in sympathetic 
outflow to the skeletal muscle and the kidneys. Continued sympathetic stimulation 
activates the renin-angiotensin-aldosterone system (RAAS) and other neurohormones, 
leading to increased vascular tone, increased plasma noradrenaline concentrations, 
progressive retention of salt and water and finally edema. Excessive sympathetic 
activity is also associated with cardiac myocyte apoptosis, hypertrophy and 
myocardial necrosis (Jackson, Gibbs, Davies, & Lip 2000). The sympathetic nervous 
system exerts its effects through the adrenoreceptors: β1, β2, and α2. In HF patients, 
along with the α2 receptors, both β1 and β2 receptors are activated which eventually 
leads to myocardial toxicity, marked by decreased EF, arrhythmias and tachycardia 
due to overstimulation by the sympathetic nervous system (SNS) (Kemp & Conte 
2012). Activation of the β1 and α1 receptors in the peripheral vasculature, leads to 
activation of RAAS which causes vasoconstriction, sodium retention and thirst 
(Chaggar et al. 2009). In the long run, by a down regulation in β receptors, the ability 
of the myocardium to respond to chronic high concentrations of catecholamines is 
crippled, although this may be associated with baroreceptor dysfunction and a further 
increase in sympathetic activity. Abnormalities of baroreceptor function are well 
reported in chronic heart failure, along with reduced parasympathetic tone, leading to 
abnormal autonomic modulation of the sinus node. In chronic heart failure patients, a 
reduction in heart rate variability (HRV) has consistently been observed potentially 
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due to excess SNS activity and concurrent reduced vagal modulation of the sinus 
node. Reduced HRV is a prognostic marker in patients with chronic heart failure 
(Jackson, Gibbs, Davies, & Lip 2000). 
Stimulation of RAAS also results in vasoconstriction (increased angiotensin II), an 
increase in blood volume with the retention of salt and water (increased aldosterone). 
Renin is secreted by the kidneys in response to this sympathetic activation and also 
due to diminished renal blood flow from a decrease in mean arterial pressure (MAP). 
Renin then acts on angiotensinogen in the liver to make angiotensin I. Angiotensin-
converting enzyme (ACE) converts circulating angiotensin I in the lungs to 
angiotensin II which directly increases vasoconstriction and promotes the release of 
aldosterone. Activation of this particular neurohormonal system facilitates release of 
norepinephrine, promotes sodium reabsorption, stimulates vasopressin release, and 
increases contractility in the end. Vasopressin a peptide hormone and a 
vasoconstrictor, is synthesized in the hypothalamus and secreted by the posterior 
pituitary gland. Its release is facilitated by angiotensin II formation and is also 
controlled via a negative feedback loop. In HF patients the central baroreceptors 
detect the fall in MAP, which decreases their inhibitory impulses to the hypothalamus, 
thereby lifting the negative regulation and leading to an increase in vasopressin 
release. Increased vasopressin causes vasoconstriction as well as increased water 
retention, both of which enhance the decrease in MAP in HF (Kemp & Conte 
2012;Rea and Dunlap 2008). 
Natriuretic peptides exert a wide range of effects on different organs like the heart, 
kidneys and central nervous system. Atria release atrial natriuretic peptide in response 
to an increase in cardiac chamber volume, leading to natriuresis (excretion of sodium 
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via urine) and vasodilatation. In humans, brain natriuretic peptide is also released from 
the heart, predominantly from the ventricles, and its actions are similar to those of 
atrial natriuretic peptide. Another variant, C-type natriuretic peptide has less effect on 
natriuresis and vasodilatation and is limited to the vascular endothelium and central 
nervous system. The atrial and brain natriuretic peptides act as physiological 
antagonists to the effects of angiotensin II on vascular tone, aldosterone secretion and 
renal-tubule sodium reabsorption and their levels increase in response to volume 
expansion and pressure overload of the heart. There has been interest in modulating 
natriuretic peptide pathways in patients with heart failure in the diagnostic and 
therapeutic potential of these peptides (Jackson, Gibbs, Davies, & Lip 2000).  
Another potent vasoconstrictor is endothelin which is secreted by vascular endothelial 
cells and it has definite vasoconstrictor effects on the renal vasculature, promoting the 
retention of sodium. The concentration of endothelin-1 in plasma is increased in 
proportion to the symptomatic and haemodynamic severity of heart failure and has 
prognostic significance. Due to the vasoconstrictor properties of endothelin, there is 
an interest in developing endothelin receptor antagonists as cardio-protective agents 
which inhibit endothelin-mediated vascular and myocardial remodelling (Jackson, 
Gibbs, Davies, & Lip 2000). 
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During early-stages of HF, these neurohormonal systems play an important role, 
nevertheless long-term results of activation of these systems result in ventricular 
remodelling which further accelerates myocardial dysfunction. Furthermore, there 
may be progressive cardiac dilatation or alterations in cardiac structure (remodelling) 
or both. The sustained haemodynamic stresses on the heart lead to alterations in the 
size, shape, structure and function of the ventricle in a process known as remodelling 
(Curry et al. 2000). There are changes in ventricular mass, composition and volume as 
Figure 1.1 Neurohormonal and compensatory mechanisms in heart failure.  Adapted 
from (Jackson et al. 2000). 
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remodelling happens and the overall geometry of the ventricles changes as it becomes 
less elliptical and more spherical. These remodelling-induced geometric changes 
initially are compensatory as a failing heart enlarges to increase ventricular volume 
which leads to greater SV and higher CO despite a reduced EF. Ventricular 
contractility is also increased by myocardial wall thickness and an overall increase in 
ventricular mass. The remodelling process in HF is progressive and eventually 
becomes deleterious. The enlargement of the ventricles further leads to hypertrophy of 
the myocardium, this leads to increased ventricular wall tension and later fibrosis. All 
this impairs the contractility of the cardiac muscles and eventually leads to an increase 
in myocardial apoptosis. In addition, the pumping action of the heart is impaired as 
there is significant contractile dyssynchrony in the dilated and remodelled ventricle. 
The neurohormonal systems that are activated in HF are constantly switched on in an 
attempt to compensate for the failing heart's inability to maintain normal 
cardiovascular homeostasis. The haemodynamic abnormalities present in HF are 
aggravated by the sustained presence of the circulating neurohormones which, in a 
vicious cycle, encourage further remodelling and neurohormone release and further 
haemodynamic deterioration. Continued progression of HF eventually leads to a 
severe reduction in blood flow to all vital organs. In this terminal phase, to redirect 
blood flow to these critical organ systems the body maximizes all of its 
vasoconstrictive mechanisms, which only add to the haemodynamic burden of the 
failing heart; thus, ventricular function continuously worsens, and terminal HF sets in 
(Kemp & Conte 2012). 
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1.1.4 Clinical outcome of HF and treatment  
Diagnosis of heart failure is made by observing clinical symptoms and signs 
consistent with heart failure, which are reduced LVF (left ventricular function), 
dyspnea, elevated jugular venous pressure, ankle oedema, hepatomegaly, enlarged 
heart silhouette and presence of pulmonary congestion or pleural effusion on chest x-
ray and also by the presence of arrhythmias or conduction disturbances by 
electrocardiogram (ECG). Initially during HF, SNS hyperactivity serves to 
compensate for the reduced cardiac output, but long-term exposure to high levels of 
circulating catecholamines causes maladaptive changes to the heart through 
dysregulation of their β-adrenergic receptor (β-AR) targets and also causes myocyte 
death that leads to maladaptive remodelling of the stressed and failing heart (Woo and 
Xiao 2012). Pharmacological intervention with β-AR antagonists, inhibitors of 
angiotensin II and aldosterone and diuretics are currently standard treatments for HF 
(Table 1.1).  Diuretics relieve fluid retention and improve exercise tolerance. ACE 
inhibitors block the conversion of angiotensin I to angiotensin II and reduce activation 
of RAAS. β-blockers help to slow down the heart rate and allow efficient contraction 
(Kemp & Conte 2012). Introduction of these pharmacological interventions have 
substantially increased survival and decreased morbidity in HF. However, β-blockers 
and other neurohormonal blocking strategies are still not ideal therapies as not all 
patients respond favourably to these agents. Also anti arrhythmic drugs can increase 
the risk of new arrhythmias while suppressing others (Coplen et al. 1990;Echt et al. 
1991). Electronic devices resynchronize the normal ventricular activation cycle and 
terminate life-threatening arrhythmias. However, there are limitations to this 
technology featuring complications such as pulmonary collapse, haemorrhage, 
bacterial infection and lead/ generator failure (Cho and Marban 2010). So currently 
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HF therapy is nonspecific or rather palliative and thus, new therapeutic strategies are 
urgently needed. In this regard, a deeper understanding of the underlying biology and 
molecular mechanisms contributing to the development and progression of the disease 
will open up prospects for new alternatives for future therapeutic advances. 
Table 1.1 Current management of HF patients (Kemp & Conte 2012) 
 
 
1.2 Epidemiological studies 
 
1.2.1 Framingham study 
The Framingham study is one of the first epidemiological studies which examined 
incidence, prevalence and prognosis of congestive heart failure where patients and 
their offspring were followed for four decades. The study enrolled 5,209 residents of 
Framingham, Massachusetts aged between 28 and 62 in 1948 who were evaluated at 2 
year intervals for medical history, physical examination, investigations like an ECG, 
incidence of angina, myocardial infarction, blood pressure monitoring and other 
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laboratory tests. In 1971 offspring of these participants and their spouses aged 6 to 70 
years were studied in the Framingham offspring study with a follow-up after 8 and 12 
years. The mean age for incidence of heart failure (presence of either diastolic or 
systolic dysfunction) was 70 ± 10.8 years. The incidence of heart failure dramatically 
increased with age and was one third lower in women than in men after adjustment for 
age. The prevalence of congestive heart failure also increased with age. It was found 
that hypertension, diabetes and left ventricular hypertrophy were the main risk factors 
contributing to heart failure while serum cholesterol and smoking had less effect. 
Even though improved therapies became available to treat ischemic heart disease and 
hypertension, the age-adjusted incidence of heart failure has decreased only by 11-
17% per decade during this 40 year period of the study and is associated with a shorter 
life-span than many other diseases. Use of vasodilators and ACE inhibitors can 
prolong survival but come with their own disadvantages. So improved therapies and 
strategies are in demand for the treatment of heart failure by taking into consideration 
the heterogeneous nature of this syndrome (Ho, Pinsky, Kannel, & Levy 1993).  
 
1.2.2 Ivabradine SHIFT (systolic heart failure treatment with If inhibitor 
Ivabradine trial) in human heart failure treatment  
 
Clinical trials, along with epidemiological studies clearly establish a strong link 
between heart rate and associated risk in patients with a wide range of cardiac 
diseases. At present, β-blockers are widely in use to treat heart failure and acute 
myocardial infarction and due to their heart rate lowering effect; their usage has 
reduced morbidity and mortality in the past few decades. Raised resting heart rate is a 
major risk factor for fatality for all cardiovascular diseases. In patients with coronary 
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artery disease and left-ventricular dysfunction, a heart rate of 70 beats per minute 
(bpm) or higher is associated with a 34% increased risk of cardiovascular death and a 
53% increase in admission to hospital for heart failure compared with heart rate lower 
than 70 bpm (Fox et al. 2008). Despite treatment with β-blockers, heart rate remains 
increased in most patients which necessitate new therapeutic strategies. Ivabradine is a 
selective inhibitor of the If ion channel found in cardiac pacemaker cells of the sino-
atrial node (DiFrancesco 2006). This drug reduces heart rate at rest while maintaining 
myocardial contractility and atrioventricular conduction even in patients with 
impaired systolic function and it was used in this trial to tease out the effect of heart 
rate lowering (Fox, Ford, Steg, Tendera, Robertson, & Ferrari 2008). The SHIFT trial 
was reported in 2010 with the aim of evaluating the addition of ivabradine to standard 
therapy on the symptoms, quality of life and mortality in participants with chronic 
heart failure. SHIFT was a multinational, randomised, double blind, placebo 
controlled clinical trial in patients with moderate to severe heart failure with a heart of 
rate 70 bpm and above and on treatment with β-blockers and RAAS antagonists. With 
an ivabradine dose of 7.5 mg twice daily along with other treatment drugs, heart rate 
was maintained between 50-60 bpm in most of the patients and primary end point was 
a combination of cardiovascular death or hospital admission for worsening heart 
failure. The main findings were that 29% of the placebo group had a cardiovascular 
death or hospital admission for worsening heart failure (primary end point) compared 
to 24% in the ivabradine group. Hospital admissions (other end point) were found to 
be only 16% in the ivabradine group compared to 21% in the placebo group. Deaths 
(mortality end point) from heart failure were 3% in the ivabradine group compared to 
5% in the placebo group. Treatment with ivabradine was associated with an average 
reduction in heart rate of 15 bpm from a baseline value of 80bpm which was 
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maintained largely throughout the course of the study (Fig. 1.2). Symptomatic and 
asymptomatic bradycardia was more commonly observed in the ivabradine group than 
in the placebo group. These findings support the idea that heart rate plays a significant 
role in the pathophysiology of heart failure and the modulation of heart rate can hinder 
the progression of the disease. The effect of ivabradine was achieved together with β-
blockers, so assumptions about the effect of ivabradine per se in the absence of β-
blockers cannot be drawn. But SHIFT was the first trial to explicitly study the effect 
of isolated heart rate reduction in a population with heart failure. So these results 
suggest the role of ivabradine in reducing the heart rate and improving clinical 
outcomes in heart failure (Swedberg, Komajda, Bohm, Borer, Ford, Dubost-Brama, 
Lerebours, & Tavazzi 2010).  
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1.3 Autonomic control of heart rate 
Cardiac automaticity or heart rate is controlled by both the sympathetic and the 
parasympathetic nervous system and they are opposing in nature. More specifically 
release of acetylcholine (Ach) from vagal nerve efferents slows down the heart rate 
while stimulation by β adrenergic signals has the opposite effect. There are two 
potential electrophysiological mechanisms in cardiac pacemaking tissues i.e. sino-
atrial node (SAN) and atrio-ventricular node (AVN). Stimulation of the sympathetic 
nervous system in response to exercise or stress results in a rapid increase in heart 
rate, which is mediated by activation of the stimulatory G-proteins (Gαs) coupled to β-
AR. Subsequently, adenylyl cyclase is activated, which leads to an increase in cAMP 
level and activation of protein kinase A (PKA). A wide spectrum of ion channels 
(pacemaker current (If), delayed rectifier current (IKs), L-type Ca
2+ current (ICa L)) can 
Figure 1.2 Mean heart rate in ivabradine and placebo group over the study period. 
There was a significant reduction in heart rate in the ivabradine group compared to the 
placebo group (Swedberg et al. 2010). 
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be regulated by phosphorylation or by direct binding of cyclic nucleotides, leading to 
increased pacemaker currents (If or Ih) (DiFrancesco 2006;Robishaw and Foster 
1989).  On the other hand, vagal stimulation by Ach suppresses activation of adenylyl 
cyclase through muscarinic receptors (M2R) which are coupled to inhibitory G- 
proteins (Gαi/o), there by counteracting the effect of the sympathetic activation. 
Meanwhile, Gβγ subunits released from Gαi/o can directly activate G protein-coupled 
inward rectifying K+ channels (GIRK) (Fig. 1.3). This GIRK channel activation 
results in membrane hyperpolarisation and heart rate slowing (Wickman et al. 
1998;Yamada et al. 1998). The generation of GIRK4 knockout mice (Wickman, 
Nemec, Gendler, & Clapham 1998) clearly demonstrated that this second-messenger-
independent pathway contributes to ~50% of the bradycardic response mediated by 
M2R without affecting basal heart rate. Even though the GIRK channel is 
characteristically activated by Ach binding to muscarinic (M2) receptors they are also 
stimulated via adenosine, sphingosine-1-phosphate and endothelin-A receptors in the 
heart (Bosche et al. 2003;Ochi et al. 2006;Ono et al. 1994;Ono et al. 2001). 
 
Adenosine a catabolite of ATP reduces myocardial injury by binding to four specific 
adenosine receptors or purinergic receptors: A1, A2a, A2b, and A3. A1 and A3 receptors 
are coupled through Gαi protein to adenylate cyclase (AC) inhibition, while A2a and 
A2b receptors are coupled to AC activation through Gαs protein. However, adenosine 
metabolism and its receptor mediated signalling in patients with chronic heart failure 
remain unclear (Asakura et al. 2007). Ischemic preconditioning involves a series of 
intracellular events that are initiated with the activation of the A1 receptor, and end at 
the K+ sensitive ATP channels of the mitochondria. The phosphorylation and opening 
of these channels would cause the protective effect (Donato et al. 2003). Another 
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study (Kirchhof et al. 2003) used transgenic mice over expressing A1R and found that 
these mice had an increased tolerance to ischemia. A1R
 overexpression slows heart 
rate in isolated hearts suggesting that A1R contribute to the physiological
 regulation of 
heart rate and AV nodal function in mice in vivo and that an enhanced expression or 
function of A1R
 may represent a potential patho-mechanism by which A1R could
 
contribute to sinus node and AV nodal dysfunction in patients. 
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Figure 1.3 The opposing effect of sympathetic and parasympathetic system. Stimulation 
of the sympathetic nervous system in response to exercise or stress results in a rapid increase 
in heart rate, which is mediated by activation of the Gαs-coupled β-AR. Subsequently, AC is 
activated, which leads to an increase in cAMP level and activation of PKA leading to an 
increase in heart rate. On the other hand, vagal stimulation suppresses activation of AC 
through M2R, which are coupled to Gαi/o, thereby counteracting the effect of sympathetic 
activation. Meanwhile, Gβγ subunits released from Gαi/o can directly activate G protein-
coupled inward rectifying K channels (GIRK), causing a decrease in heart rate. R=receptor, 
L=ligand. 
Sympathetic Parasympathetic 
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1.4 Control of sino-atrial automaticity 
The pacemaker cells in the sino-atrial node have an intrinsic electrical excitability 
which leads to firing spontaneous regular action potentials even in the absence of 
nervous innervation. Initiation of each heart beat by SA nodal cells automaticity 
initiates atrial depolarisation\contraction, conduction through the AV node and His 
purkinje system and subsequent excitation of the ventricles and ventricular 
contraction. It is known that spontaneous diastolic depolarization of SAN cells 
regularly initiates action potentials to generate the rhythm of the heart but the exact 
mechanism is unclear. It is understood that ion channels and intracellular Ca2+ 
signalling are necessary for pacemaker automaticity. Recent evidence indicates that 
the voltage clock/M clock (cyclic activation and deactivation of membrane ion 
channels) and Ca2+ clock (rhythmic spontaneous sarcoplasmic reticulum Ca2+ release) 
jointly regulate SAN automaticity (Joung et al. 2009). It was thought that voltage 
clock mediated by voltage-sensitive membrane currents like hyperpolarization- 
activated cyclic nucleotide (HCN)\If currents regulated by cAMP controls the 
spontaneous diastolic depolarisations. If is a non-selective cation current activated by 
hyperpolarization and unlike voltage-sensitive currents, it is modulated by autonomic 
nervous system. The HCN or If channel then depolarises the membrane to a level at 
which Ca2+ channels open to initiate the action potential (DiFrancesco 1985). 
Mutation in these channels and treatment with drugs which block If (ivabradine) are 
associated with reduced baseline heart rate, which further confirms their role in 
controlling cardiac automaticity (Noble 1960;Zhang and Vassalle 2001). Apart from 
the If current, Ca
2+ release from sarcoplasmic reticulum (SR) in response to Ca2+ 
inside the cell though the membrane Ca2+ channels, has also been suggested for sinus 
rhythm generation. It is important to understand that SR Ca2+ is controlled in part by 
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the membrane voltage, so the Ca2+ clock and membrane ionic clock are 
interdependent. Spontaneous rhythmic Ca2+ release from the SR in SAN cells is 
manifested as Ca2+ sparks or Ca2+ clock. The elevated intracellular Ca2+ causes 
diastolic depolarization via Na-Ca exchange current (INCX) activation (Bogdanov et al. 
2001;Maltsev and Lakatta 2008;Vinogradova et al. 2002). Studies on isolated SAN 
myocytes showed that late diastolic intracellular Ca2+ elevation relative to action 
potential upstroke is the key determinant of pacemaking by Ca2+ clock (Huser et al. 
2000). Various voltage-dependent ionic currents have been established in cardiac 
pacemaker cells which might contribute to diastolic depolarisation and this includes 
ICa L, T-type Ca current (ICa T) and delayed rectifier currents like (fast IKr) and (slow 
IKs). ICa L also enhances late diastolic intracellular Ca
2+ levels and so the stimulation of 
sinus rate by both voltage clock and Ca2+ clock. SR inhibitors and If blockers curtail 
the sinus rate under normal conditions and also attenuate the isoprenaline-induced 
increase in sinus rate. Consequently, association and harmony between the voltage 
clock and Ca2+ clock is evident (Dobrzynski et al. 2007). 
During exercise SNS activation results in increased levels of catecholamines that 
activate β-AR-mediated Gαs activation which in turn leads to an increased level of 
cAMP that further activates cAMP-dependent PKA. PKA phosphorylates key Ca2+ 
handling proteins like ICa L, ryanodine receptor (RyR2) and phospholamban (PLB) 
(Wehrens et al. 2006). The net result is increased Ca2+ influx through voltage-gated ICa 
L, increased sarcoplasmic reticulum (SR) Ca
2+ release via RyR2 and enhanced SR 
Ca2+ uptake by the SR Ca2+pump (SERCA2a) pump. SERCA2a pump is activated by 
the phosphorylation of PLB which removes its inhibition. These increased Ca2+ 
transients significantly enhance contractility of the heart (Ginsburg and Bers 2004). 
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1.5 G-proteins  
Cells in organisms are in constant communication with each other. Signal 
transduction, represents a cellular communication mechanism crucial to all living 
organisms. All transmembrane signalling has two basic elements: a receptor which is 
able to recognize an external stimulus and an effector which can generate intracellular 
stimulus (Wettschureck and Offermanns 2005). G-proteins are a family of 
transmembrane cellular signalling systems that provide the basis for signalling 
pathways to serve particular functions in different cell types. G-proteins are called so 
because they bind the guanine nucleotides GDP and GTP and they are heterotrimers 
(i.e. made of three different subunits α, β and γ) and are associated with 
transmembrane receptors of hormones called G-protein coupled receptors (GPCRs). 
The interaction between a specific membrane receptor and an individual G-protein 
determines the pattern of downstream signal effector activity, and thus its specific 
physiological effect. Binding of the heterotrimer to the agonist occupied receptor 
catalyses the exchange of GTP for GDP on the Gα subunit, and subsequent 
dissociation of Gα and Gβγ. These individual functional units are then free to 
modulate the activity of downstream signalling effectors, typically AC. Two main 
classes of Gα subunits discussed in this thesis are Gαs - the stimulatory G-protein and 
Gαi - the inhibitory G-protein. In the context of cardiac function and pathology, these 
two classes of G-proteins are most important in transducing signals through the β AR 
and M2R systems, respectively. 
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1.5.1 History and discovery of G-proteins  
Heterotrimeric G-proteins function to transduce signals from a wide range of GPCRs 
to effector systems including enzymes and ion channels that release or alter the rate of 
production or degradation of intracellular secondary messengers. But the mere 
existence of G-proteins was suggested only by 1970s. The Nobel Prize in Physiology 
or Medicine for 1994 was awarded jointly to Alfred G. Gilman and Martin Rodbell for 
their discovery of "G-proteins and the role of these proteins in signal transduction in 
cells". Much of our present knowledge comes from the studies of bacterial toxins and 
mutant cell lines. Studies on the action of cholera exotoxin showed that the addition of 
toxin to cells produced sustained generation and elevation of cAMP levels via the 
action of mono ADP ribosyl transferase (Gill and Meren 1978). Another mutagenesis 
study on mouse lymphoma cell lines S49, showed treatment of membranes of wild-
type S49 cells with activated cholera toxin and [32P] NAD+ resulted in incorporation 
of radioactivity into a 45 kDa polypeptide, and this did not occur when membranes of 
S49cyc_cells (mutant) were used. Membranes of S49cyc_ cells thus lacked a key 
component of the cAMP generation cascade and hence provided a background for 
studies designed to purify the cholera toxin substrate (Coffino et al. 1975). Using 
rabbit liver as a source, it was identified that this 45 kDa polypeptide corresponds to 
the cholera toxin substrate and transducing protein (Northup et al. 1980). By using a 
range of chromatographic steps, the 45 kDa polypeptide co-purified with a 35 kDa and 
a 8–10 kDa polypeptide. The 45 kDa protein was thus defined as the α subunit of the 
stimulatory G-protein and the corresponding 35 and 8–10 kDa polypeptides as the β 
and γ subunits that make up the functional G-protein heterotrimer. For this, and a host 
of other key studies on the function and structure of heterotrimeric G-proteins Alfred 
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G. Gilman was awarded the Nobel Prize for Physiology or Medicine in 1994 along 
with Martin Rodbell (Gilman 1995;Rodbell 1995).  
From ligand binding studies it was well accepted that certain receptor ligands were 
able to reduce, rather than increase, cAMP levels and serious efforts  were undertaken 
to identify an equivalent adenylyl cyclase inhibitory G-protein (Gi). This study was 
further enlightened with information from an apparently unrelated research area and 
the consolidation of relevant information in a review from Martin Rodbell (Rodbell 
1980). Studies on the action of an exotoxin produced by Bordetella pertussis, the 
causative agent of whooping cough, showed the exotoxin as a mono-ADP-ribosyl 
transferase which is able to modify covalently a 41 kDa polypeptide present in the 
membranes of essentially all cells (Katada and Ui 1982). Additionally, in a 
physiological context, this exotoxin (now known as ‘pertussis toxin'-PTX)) disabled 
α2-adrenoceptor regulation of insulin secretion from islet cells, implying that the 
molecular target for PTX might be Gi. Later purification of the PTX substrate in 
fractions enriched in high-affinity GTPase activity resulted in the identification of the 
41 kDa polypeptide as the α-subunit of Gi, along with 35 and 8–10 kDa polypeptides 
that appeared identical to the β- and γ-subunits of Gs (Bokoch et al. 1984). 
 
Research on cholera toxin-catalysed [32P] ADP-ribosylation had indicated the 
prevalence of two forms of Gαs with varying amounts of the two forms between 
tissues. Cloning of cDNAs encoding Gαs now revealed that these variants were 
derived from a single gene via alternative splicing of exon 3 (Bray et al. 1986). On the 
other hand, cloning of cDNAs encoding the various PTX-sensitive Gi -protein α-
subunits indicated each of Gαi1 Gαi2 and Gαi3 to be the products of different genes. 
‘Gαo’ was also the product of a separate gene that can be differentially spliced to 
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generate at least two polypeptides, GαoA and GαoB. Both Gαi1 and the forms of Gαo 
have more restricted distribution patterns that can generally be described as 
‘neuroendocrine’ but the Gαi2 and Gαi3 gene products are widely expressed. Studies 
on specialized sensory systems, including olfactory, visual and lingual tissues 
uncovered other G-protein α subunits, Golfactory (Golf), cone transducin (Gt2) and 
Ggustducin, (Ggust) respectively, with highly restricted distribution patterns that were 
highly related to, but different from Gs or the previously identified Gi family members 
(Milligan and Kostenis 2006). 
 
1.5.2 G-protein signalling 
Three mechanisms of membrane-dependent signalling are commonly employed. 
These typically operate over distinct time courses. However they all share the 
common features of an extracellular ligand, a membrane-linked receptor and an 
effector mechanism. 
 Ligand-gated ion channel receptor systems such as the nicotinic acetylcholine 
receptor have extremely rapid kinetic properties. Neuronally released ACh 
binds to a receptor site on the channel/receptor complex causing 
conformational change to facilitate rapid channel opening and membrane 
depolarisation.  
 In contrast, receptor tyrosine kinases (RTK’s) such as the Erb-2 receptor for 
example, operate over much slower time courses. RTK pathways are typically 
involved in modulating cell growth, apoptosis and differentiation processes. 
 However the most widely employed membrane-dependent receptor system, 
involves heterotrimeric G-proteins which interact with a large superfamily of 
GPCRs to facilitate guanine nucleotide exchange protein signalling. The 
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GPCRs represent a very large superfamily of receptors that are capable of 
responding to an enormous number and variety of extracellular stimuli (light, 
odorant, neurotransmitters, hormones and proteases). They are coupled to the 
heterotrimeric G-proteins that function as the transducers to relay information 
to different signalling pathways. This complex design of G-proteins allows 
assembling and scattering at the interfaces of receptor and G-proteins as well 
as of G-protein and effector. Also each component in the transmembrane 
signalling cascade can be further controlled by various means - proteins, 
soluble mediators - or at transcriptional level. This highly complex and 
versatile system of G-protein mediated transmembrane signalling provides a 
variety of transmembrane signalling pathways that are adapted to each 
particular cell types. Fig. 1.4 (Wettschureck & Offermanns 2005). 
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1.5.3 G-protein coupled receptor (GPCR) superfamily 
As their name implies, GPCRs interact with G-proteins in the plasma membrane. 
When an external signalling molecule binds to a GPCR, it causes a conformational 
change in the GPCR. The common architecture of these GPCR receptors (comprised 
of an extracellular N- terminus, 7 membrane spanning domains- TM I-TM VII- 
connected by 3 intracellular and 3 extracellular loops, and an intracellular C- terminal 
Figure 1.4 Heterotrimeric G-protein signalling External stimuli that bind to GPCRs act as 
guanine nucleotide exchange factors (GEFs) for the heterotrimeric G proteins. When the GDP 
on the Gα subunit is replaced with GTP, the complex dissociates into Gα/GTP and Gβγ 
subunits that are then capable of activating or inhibiting a wide range of signalling systems. 
Most of the actions are stimulatory, but some are inhibitory, as illustrated by the yellow 
arrows. The regulators of G protein signalling (RGS) proteins function as GTPase-activating 
proteins (GAPs) to facilitate the GTPase activity of the Gα subunit, which is the OFF reaction 
that terminates signalling. G protein receptor kinase (GRK) phosphorylates active receptors 
and provides binding sites for arrestin that result in receptor desensitization by preventing the 
heterotrimeric G proteins from binding the receptor. Adapted from Cell Signaling Biology 
(Berridge 2006). 
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tail) allows the receptor protein to transduce signals across the cell membrane 
(Kobilka 2007). Additionally, GPCRs feature an extracellular largely variable N-
terminus important for ligand specificity and an intracellular C-terminus. Within the 
structure there is an obligate requirement to be able to interact with heterotrimeric G-
proteins in a dynamic fashion to facilitate G-protein cycling (Oldham and Hamm 
2008). Large variations in the length and sequence of extracellular loops contribute to 
the profound differences in ligand binding between the GPCRs. Also the variability 
within the intracellular terminus and the three intracellular loops of GPCRs govern the 
specificity of activating certain G-protein subfamilies and therefore their ability to 
target a distinct subset of effectors. Binding of an activating ligand (or agonist) to the 
extracellular face of GPCR induces a conformational change in the GPCR that triggers 
an interaction on its cytoplasmic face with heterotrimeric G-proteins (Oldham & 
Hamm 2008).  
GPCRs are one of the largest families of proteins encoded within the human genome. 
More than 1000 GPCRs are encoded in mammalian genomes. GPCRs have been the 
focus of intense clinical research and commercial interest. They are key modulators of 
disease pathogenesis and some 30-40% of all therapeutic agents used in clinical 
practice target GPCR’s (Overington et al. 2006). Within the cardiovascular system, 
adrenergic and muscarinic receptors are two prototypical GPCRs, whose signal 
transduction cascades modulate critical cardiovascular functions such as heart rate and 
contractile response via autonomic efferents (Wettschureck & Offermanns 2005). 
Different classes of GPCR exist and despite the lack of sequence homology between 
classes, all GPCRs share a common structure and mechanism of signal transduction. 
In view of the known existence of alternatively spliced variants of GPCRs, it is likely 
that the true number of GPCR is higher than estimated. The human genome encodes 
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several hundreds of G-coupled receptors, about 350 of which detect hormones, growth 
factors, and other endogenous ligands. Approximately 150 of the GPCRs found in the 
human genome have unknown functions (Fredriksson et al. 2003).  
1.5.4 G-protein cycle 
As mentioned earlier heterotrimeric G-proteins are composed of , β and -subunits 
which dynamically interact with GPCRs within the plasma membrane as part of the 
G-protein cycle. Under basal conditions, in the inactivated state, the heterotrimer 
exists as a GDP-bound -subunit associated tightly with a β-dimer. GPCR activation 
by ligand binding to the extracellular face causes conformational change such that the 
intracellular face can act as a guanine nucleotide exchange factor (GEF). Receptor 
activation then facilitates “nucleotide exchange” of GDP for free cytoplasmic GTP 
which is present at high concentration. GTP binding transforms the G-protein into an 
“activated” configuration causing dissociation of GPCR, GTP-bound G and β. This 
event provides 2 separate signals for interaction with various effectors such as K+-
channels, Ca2+ channels and secondary messenger systems such as AC (Wickman and 
Clapham 1995). For example activation of the inhibitory G-protein, Gαi2 as a result of  
Ach binding to M2 muscarinic receptor results in the βγ- dimer directly activating the 
GIRK channel to cause membrane hyperpolarisation, slowing down pacemaker 
depolarisation and sinus rate (Robinson and Siegelbaum 2003). More over the 
activation of the inhibitory Gα subunit will inhibit AC and thus modulate Ih/If also 
slowing the pacemaker depolarisation and sinus rate. The system is switched 
off/deactivated by GTP-ase activity intrinsic to G. GTP is hydrolysed back to GDP 
allowing re-association of GDP-bound G with free β to begin another cycle. 
Activation of the stimulatory G-protein by β-AR will have the opposite effects. 
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GTPase activity of the α subunit in vitro has been found to be slower than in vivo 
suggesting that termination of G-protein activity is not due to the α subunit alone. This 
has led to the identification of GTPase accelerating proteins (GAP), which include 
regulators of G-protein signalling (RGS) (Dohlman and Thorner 1997;Tinker 2006). 
 
 
Figure 1.5 The G-protein cycle The Gα subunit bound to GDP, which is the inactive state 
interacts with Gβ subunit through the N terminal domain and GTP binding domain. Agonist 
binding to the GPCR/G-protein complex facilitates GDP/GTP nucleotide exchange on the G 
subunit. This activated state allows for G subunit and Gβ to interact freely with effectors. 
The G subunit had intrinsic capacity to hydrolyse GTP to GDP allowing reassembly with 
Gβ to return to the resting state. G subunit responses are terminated by GTP hydrolysis. 
RGS proteins facilitate GAP and help terminate response. Gβ responses are also terminated 
by recombining with GDP-bound G to form the heterotrimeric G-protein complex. PTX 
modifies the G-protein α subunit and prevents interactions of the GαGDPβ-heterotrimer with 
GPCR. Figure adapted from (Wettschureck & Offermanns 2005).  
 
1.5.5 G-protein  subunit 
Gβ and G form a functional dimer which never dissociates under physiological 
conditions. In comparison GTP bound-G can freely dissociate from Gβ upon 
receptor-mediated activation. A major focus of this work is the potential selective 
 
PTX 
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function of inhibitory G-proteins (Gi/o). The G-subunit has a conserved structure 
consisting of a ras like-GTPase domain (15kDa) and an -helical domain (25kDa). A 
guanine nucleotide binding cleft is sandwiched between the two domains. The GTP-
ase domain is conserved amongst all GPCRs so far identified. Additional to GTP-
hydrolysis, it provides binding sites for Gβ, GPCRs and effector proteins. Within the 
domain there are 3 flexible loops, named switches I, II and III. These “switches” 
undergo dramatic conformational change between GDP-bound and GTP-bound states 
shown from crystallography studies. The crystal structures of Gt/iβ11 and G1β12 
suggest that GDP-bound -subunit and β interaction occurs primarily in a 
hydrophobic pocket between switch 1 and switch 2 of G. GTP binding attenuates the 
polarity of this binding domain substantially resulting in reduced binding affinity  of 
G with Gβ allowing separation (Oldham & Hamm 2008). 
All Gα subunits are GTP hydrolases. The intrinsic hydrolysis rates by different G- 
protein isoforms vary differently. Turnover numbers for Gs are low (~0.3min-1) while 
Gi/o α subunits have greater hydrolysis rates of (~1.3min-1) (Gilman 1987). GTP 
hydrolysis is rate-limited by the dissociation rate of the product, GDP. Different Gα 
isoforms also have different rates of GDP release. For example receptor stimulated 
GDP/GTP exchange is faster for Gi/o G-proteins while Gt, Gs, Gq/11 have slower 
exchange rates and G12/13 are very slow exchangers (Kleuss et al. 1994;McCudden et 
al. 2005).  
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1.5.6 The 4 G-subclasses 
 Gαs is expressed ubiquitously and stimulates all isoforms of AC. It is encoded by the 
complex imprinted GNAS gene locus that can give rise to several gene products 
(discussed later in section 1.7.4). Gαs couples GPCRs exclusively to AC activation 
and thereby increases cAMP concentration. This in turn activates cAMP-dependent 
PKA which phosphorylates target proteins. In the heart these include effectors such as 
cardiac Ca2+ channels, phospholamban and troponin which mediate the acute 
physiological effects of sympathetic activation (Kim et al. 1999;Rockman et al. 
1997;Rockman et al. 2002). Chronic Gαs activation (Iwase et al. 1997) however, is 
associated with pathological myocyte hypertrophy, cardiac apoptosis and abnormal 
Ca2+ handling involving CaM Kinase II (Ca2+/calmodulin-dependent protein kinase II) 
in particular (Grueter et al. 2007;Zhang et al. 2005). One of the chapters in this study 
is focused on this stimulatory subunit of Gαs. 
 Gαq/11 couple to various  isoforms of phospholipase C (PLC) initiating signalling 
via Diacylglycerol (DAG) and Inositol Phosphate (IP3) pathways. Activation of PLC 
results in breakdown of a membrane phosphatidylinositol 4,5-bisphosphate (PIP2) into 
2 signals: cytoplasmic IP3 that releases Ca
2+ from intracellular stores, and membrane-
bound DAG that is a potent activator of certain isozymes of PKC. Gαq/11 subfamily 
also modulates the activity of certain families of non-receptor tyrosine kinases. The 
constitutively active cardiac restricted Gαq overexpression in transgenic mice is 
associated with cardiac hypertrophy (D'Angelo et al. 1997) whilst Gq blockade 
(Esposito et al. 2001) prevents cardiac hypertrophy responses. 
 Gα12/13 is expressed ubiquitously and often activated by receptors that couple to 
Gq/11. Identifying their function has been hampered by the lack of specific inhibitors 
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and their ability to activate other G-proteins. They have however been associated with 
effectors such as phospholipase A2, Na
+/H+ exchangers and activation of the RhoA 
pathway which modulates cytoskeletal activity such as platelet activation. 
 Gi/o Inhibitory G-proteins were initially discovered on the basis of their ability to 
“inhibit” AC activity and so lower cAMP concentration (Rudolph et al. 1996;Wong et 
al. 1991). They are now known to additionally modulate several key “effectors” 
including Ca2+ channels, (Zhang et al. 2001), (Nagata et al. 2000) the PI3 Kinase 
pathway, MAP-Kinase and  GIRK channels (Reuveny et al. 1994;Wickman & 
Clapham 1995) via the activation of Gβγ subunit of G-protein. GIRK channels are 
expressed in brain and atrial tissue and within the heart they are involved with vagal 
modulation and slowing of the heart rate (Wickman, Nemec, Gendler, & Clapham 
1998) (discussed later). Different isoforms of Gi/o exists namely Gi1, Gi2, Gi3 and 
Go (with splice variants GαoA and GαoB) all known to regulate cAMP dependent 
heart rate modulation. All isoforms are widely expressed with Gi2 being the 
prominent cardiac isoform (Gohla et al. 2007) and Go abundantly expressed in 
neuronal cells (Wettschureck & Offermanns 2005).The structural similarity between 
G isoforms suggests they might have partially overlapping functions. 
The study of Gi/o has been particularly advanced with the use of PTX toxin isolated 
from the bacterial species Bordetella pertussis. PTX toxin, encodes a region termed a 
promoter A subunit and a B subunit (pentameric protein assembly important for cell 
binding). The A subunit selectively and irreversibly ADP-ribosylates a C-terminal 
cysteine residue in Gi/o subunits (Pizza et al. 1988;Vivaudou et al. 1997). This 
covalent modification prevents selective Gi/o interaction with GPCRs and results in 
functional uncoupling of the receptor mediated signal transduction cascade. Use of 
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PTX toxin has been a critical tool in our understanding of the selective function of 
inhibitory G-subunits. Interestingly, site-directed mutagenesis of this C-terminal 
cysteine residue to leucine/isoleucine renders the Gi/o-subunit PTX resistant yet still 
functional. In this way it becomes possible to delineate the individual coupling of 
GPCRs to Gi/o isoforms (Leaney and Tinker 2000). Tissue expression patterns 
suggest relatively widespread Gi/o distribution but specific tissue expression profiles 
exist. For example, Go is expressed at high levels in neurons (Jiang et al. 1998) whilst 
in cardiac tissue, Gi2 appears to be the predominant inhibitory G-protein isoform 
(DeGeorge and Koch 2008;Gohla, Klement, Piekorz, Pexa, vom, Spicher, Dreval, 
Haussinger, Birnbaumer, & Nurnberg 2007). Absolute quantification of inhibitory G-
protein expression has been problematic on account of generating truly isoform-
specific Gi antibodies for Western blot on account of structural homology. Within 
Gi1,2,3 and Go isoforms there appears to be 87-94% primary sequence homology 
(Birnbaumer 2004). Some have taken this to mean that different Gi isoforms are 
capable of at least partially overlapping function, especially when expressed 
artificially in in vitro systems (Yatani et al. 1988). However there are now numerous 
examples of receptor mediated Gi/o selectivity documented within the literature. 
There appears to be inter-species conservation of individual Gi/o isoform structure, for 
example, human and rat Gi2 show 98% sequence homology which suggests an 
evolutionary conservation of structure and biological function (Birnbaumer 2004). 
Inhibitory G-proteins (Gαi/o) are considered the predominant species followed by Gs, 
then Gq/11 and finally G12/13 shows limited expression relatively. Each subclass 
consists of various members with functional and structural similarities. Some GPCRs 
couple specifically with one G-protein subclass, the muscarinic M2 receptor couples 
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faithfully to Gi/o signalling pathways  (Sadja et al. 2003;Sowell et al. 1997) whilst 
other GPCRs such as the 2 adrenergic receptor are capable of coupling via multiple 
G-proteins including Gs and Gi/o (Foerster et al. 2003;Xiao et al. 2003). 
Interestingly, GPCR phosphorylation can act as a molecular switch to channel 
inactivation preferentially down a particular G-protein pathway (Oldham & Hamm 
2008). 
1.5.7 Activation of Gβγ signalling 
Apart from its role in supporting GPCR-dependent Gα interactions, Gβγ acts to 
directly regulate downstream signalling in its own way. The first candidate found to 
be activated by Gβγ was the acetylcholine-regulated inwardly-rectifying K+ channel in 
atrial myocytes (Logothetis et al. 1987). It was observed in isolated inside-out patches 
from atrial myocytes that the acetylcholine driven channel activation was independent 
of soluble second messengers, suggesting that the subunits of the Gαi protein could 
directly activate the channel. This tempted various groups to directly activate the 
channel in excised atrial membrane patches with Gβγ and Gα subunits (Logothetis, 
Kurachi, Galper, Neer, & Clapham 1987) (Codina et al. 1987). After much 
controversy it was concluded that Gβγ subunits are the primary mediators of channel 
activation through direct binding to the channel (Clapham and Neer 1997;Wickman et 
al. 1994). It was quite controversial in the beginning to recognize Gβγ as the primary 
mediator of channel activation because Gβγ mediating direct downstream functions 
had not been previously demonstrated, and also because precedent with AC 
demonstrated that Gαs was responsible for direct stimulation of AC activity. Further 
evidence to support its role as a signal mediator in its own right came from genetic 
analysis of the pheromone signalling pathway in yeast, indicating that Gβγ is the key 
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activator of downstream signalling from the G-protein coupled pheromone receptor 
(Whiteway et al. 1989). In the case of MAPK/ERK (Mitogen-activated protein 
kinases/ Extracellular signal-regulated kinases) pathway, expression of Gβγ in cells 
leads to ERK activation, but the exact mechanism and the direct binding target for this 
activation has not been fully understood. However, it is now well established that the 
Gβγ subunits play major roles in mediating downstream signalling from GPCRs and 
may be as prevalent as those mediated by Gα subunits. 
1.6 Regulators of G-protein signalling (RGS)  
RGS proteins are critical to signal modulation through G-proteins. They were first 
discovered in yeast and C. Elegans (Dohlman & Thorner 1997). Besides being a 
major effector mechanism for negative chronotropic regulation upon vagal 
stimulation, GIRK currents are highly regulated by endogenous RGS proteins 
(Doupnik et al. 1997). RGS function primarily as GAPs through their conserved RGS 
domains (Geurts et al. 2003;Hollinger and Hepler 2002). RGS proteins enhance the 
intrinsic GTPase activity of G-proteins and accelerate the turn-off step of the G-
protein cycle, thereby serving as negative modulators (Fig. 1.6). More than 10 
mammalian RGS proteins have been found in myocardium (Doupnik et al. 
2001;Kardestuncer et al. 1998;Wieland and Mittmann 2003) with minimal distinction 
in their expression pattern between atria and ventricles (Wieland & Mittmann 2003). 
In addition, the specificity of different RGS proteins toward G- protein isoforms is 
rather loose. The majority of these RGS proteins can act as a GAPs for most members 
of the Gαi/o and Gαq families (Hollinger & Hepler 2002). 
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Even though there is scant knowledge about the role of endogenous cardiac RGS 
proteins, they are dynamically regulated in a variety of pathophysiological conditions, 
like cardiac hypertrophy (Rogers et al. 1999) and heart failure (Owen et al. 2001). 
Recently RGS proteins have become a potential new therapeutic target for 
cardiovascular diseases (Riddle et al. 2005). Because of their functional redundancy 
properties, it has been difficult to ascertain the full physiological role of endogenous 
RGS proteins in vivo. Thus, I used RGS-insensitive (RGSi) mutant Gα subunits, 
which contain a G184S point mutation in their switch I region that prevents binding of 
RGS proteins and the subsequent Gα deactivation (Lan et al. 1998) Fig. 1.7. 
Importantly these Gα mutations do not affect the intrinsic GTPase activity, Gβγ 
subunit binding, receptor stimulation or the ability to signal to downstream effectors 
(Fu et al. 2004). At the same time expression of these RGSi Gα subunits significantly 
enhances Gαi/o-mediated signalling. 
 
 
Figure 1.6 Activity of RGS proteins: GPCRs bind to ligand and catalyse nucleotide 
exchange; free Gβγ then binds and activates GIRK channels. RGS bound to Gα hydrolyse 
GTP back to GDP returning Gα to it inactive form where it is associated with Gβγ. 
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The first reported mammalian RGS effect was the rapid deactivation of GIRK currents 
in atrium (Doupnik, Davidson, Lester, & Kofuji 1997) and RGS proteins also 
contribute to agonist, calcium, and voltage-dependent relaxation of GIRK currents 
(Fujita et al. 2000;Inanobe et al. 2001;Ishii et al. 2001). These results suggest an 
important role for RGS proteins in SA node function and potentially in atrial 
arrhythmias. More recently, hypertension in the RGS-2 knockout mouse illustrates the 
importance of RGS proteins in cardiovascular regulation (Heximer et al. 2003;Tang et 
al. 2003). 
RGS-proteins have a role in determining signalling selectivity. For example, different 
RGS isoforms preferentially modulate signalling through opioid, somatostatin and 
Figure 1.7 RGS-insensitive mutation or RGS knock-ins. Gly184 located in the switch I 
region of the Gα subunit constitutes critical interaction site within the conserved RGS 
domain. The G→S mutation in the switch region of Gαi/o specifically inhibits its ability to 
interact with RGS proteins without altering other aspects of Gα function or else called as 
RGSi mutation. This will lead to a constantly active Gαi/o and βγ subunits, leading to 
decreased level of cAMP and heart rate. 
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muscarinic receptors (Tinker 2006). It has been observed that RGS’s translocate to the 
membrane on expression with particular GPCRs e.g. β2-AR with RGS-2 and the M2R 
with RGS-4 (Roy et al. 2003). The latter observation has been strengthened by the 
recent demonstration that sinus node myocytes isolated from RGS-4 deficient mice 
have enhanced M2 receptor mediated KACh currents (Cifelli et al. 2008). RGS 
discovery has had important consequences for our understanding of GIRK channel 
kinetics. When GIRK channels are expressed in Xenopus oocytes, they deactivate 
more slowly than native atrial currents upon termination of receptor stimulus. Co-
expression of RGS-4 or RGS-8 could recapitulate native GIRK deactivation profiles 
(Doupnik, Davidson, Lester, & Kofuji 1997).  
Six main subclasses of RGS exist: R4, R7, R12, RA, RL and RZ (Ross and Wilkie 
2000). These are based on sequence similarities within the RGS domain and named 
according to the prototypical member of each group. Each subclass also displays 
sequence homology in the regions flanking the RGS domain. The R4 family consists 
of RGS 1 to 5, 8,13,16,18 and 21 and members have small N- and C- termini as well 
as a conserved domain. The R7 family which consists of RGS 6, 7, 9 and 11 are more 
complex than the R4 family and have several additional domains which mediate 
protein-protein interactions and stability (Anderson et al. 2009). Each member of the 
RGS protein family contains a highly conserved domain of 120-130 amino acids 
known as the RGS box (De et al. 1995;Siderovski et al. 1996). The vast majority of 
RGSs are GAPs for inhibitory G-proteins but some have activity to Gα q/11 family as 
well. For example RGS4 inhibits inhibitory G-protein Gαi/o and Gαq/11 signalling 
through this GAP activity (Mittmann et al. 2002;Snabaitis et al. 2005;Tamirisa et al. 
1999). RGS-2 has greater selectivity for Gαq/11, whereas the R7 family have GAP 
activity solely for Gαi/o. RGS-4 and RGS-16 accelerate hydrolysis on both Gαq and 
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Gαi/o subunits while RGS-8 and 10 are selective for Gαi/o subfamily (Ross & Wilkie 
2000). 
1.7 G-proteins and Heart rate 
The Gα subunit of the G-protein is the major element of signalling selectivity which is 
largely carried out by a) stimulatory subunit of Gα (Gαs) by activation of AC, b) 
inhibitory subunit of Gα (Gαi/o) by inhibition of AC, and c) Gαq by activation of 
phospholipase C (Feuerstein and Rozanski 2000). The importance of research on 
cardiac G-proteins is relevant due to 3 main reasons. First and foremost, GPCRs exists 
in the heart and major signalling pathways associated with cardiac remodelling are 
handled by them as manifested by the action of angiotensin-II, endothelin-1 and the 
sympathetic neurohormonal systems. Secondly, heart failure is characterized by 
significant alteration in the expression and function of Gα proteins, e.g. increase in 
Gαi (Braunwald, Zipes, & Libby 2001). Lastly, in heart failure patients there are 
proven benefits of specific antagonists of GPCRs like that of angiotensin II, AT1 
receptors and β-AR blockers to induce beneficial reversal of cardiac remodelling 
(Braunwald 1997). G-proteins are regulators of cardiac calcium, potassium and 
pacemaker currents so it paves the way to speculate that G-protein modifications or 
alterations can contribute to arrhythmias and sudden cardiac death. I will be 
concentrating on 2 major classes of Gα subunit which are the primary elements of 
receptor effector coupling: Gαs (stimulatory subunit) and Gαi (inhibitory subunit) 
which conducts signals through β-AR and M2R respectively and has opposing 
physiological effects. 
 
 
 
65 
 
1.7.1 Inhibitory G-proteins Gαi 
Actions of the parasympathetic system on the heart rate are negatively inotropic (force 
of contraction), chronotropic (heart rate) and lusitropic (rate of relaxation). 
Acetylcholine released from the vagus nerve acts via muscarinic receptors and PTX- 
sensitive α subunit of inhibitory G-proteins to bring forth this action and inhibitory G- 
proteins can also be activated by β2-AR (Robishaw and Hansen 1994;Xiao et al. 
1995). In addition, Gβγ subunit released from Gαi/o directly activates GIRK channels 
leading to membrane hyperpolarisation and all these mechanism contribute to 
modulating the heart rate (Ang et al. 2012). In the heart different types of PTX-
sensitive α subunits are expressed: αi1, αi2, αi3 and αo with significant possibility of 
redundancy (Birnbaumer 2007). In our lab we addressed the question of which 
inhibitory G-protein isoform in vivo governs heart rate modulation and dynamics 
using mice with global genetic deletion of Gαi2, Gαi1 and Gαi3 combined and Gαo 
(Zuberi et al., 2008). This was done by implanting telemetry probes in these global 
transgenic knockout mice and measuring heart rate dynamics and ECG parameters in 
conscious awake mice in the time and frequency-domain. We found that Gαi2 deﬁcient 
mice were generally tachycardic with preservation of diurnal variation, and had 
attenuated bradycardic response to the muscarinic agonist carbachol. These 
abnormalities on heart rate modulation were compatible with a role of that protein in 
the SA node and so I focussed my studies on the deletion of Gαi2 in the SA node. There 
is one conﬂicting study suggesting inhibitory  subunit Gαo and not Gαi2 is necessary in 
muscarinic-mediated parasympathetic activity which may be due to methodological 
issues as the mice were studied very early after probe implantation (Duan et al. 2007). 
In keeping with our observations, (where we found an attenuated bradycardic response 
to the muscarinic agonist carbachol) mice with a G184S knock-in point mutation in the 
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switch I region of Gαi2, preventing the binding of RGS proteins and deactivation of 
Gαi2, had marked enhancement of muscarinic agonist mediated bradycardia (Fu et al. 
2007). 
Differential coupling of G-protein subtypes to adenosine A1 and muscarinic M2R 
mediated heart rate slowing was also demonstrated in vitro using RGS-insensitive Gαo 
and Gαi2 ES-derived cardiomyocytes (Fu et al. 2006). The RGS-insensitive Gαo 
homozygous knock-in cells demonstrated enhanced adenosine A1 and muscarinic M2 
receptor mediated bradycardic responses. In contrast, RGS-insensitive Gαi2 
homozygous knock-in cells showed enhanced responses to M2 but not A1 receptors. 
Blocking GIRK channels largely abolished the mutation-induced enhancement of the 
M2 receptor-mediated response but had a minimal effect on A1 responses. Taken 
together, the evidence suggests that M2-mediated GIRK channel activation is coupled 
preferentially to the Gαi2 subunit whereas coupling to voltage-gated L-type calcium 
channel appears to be less speciﬁc with both Gαo and Gαi2 implicated (Ang, Opel, & 
Tinker 2012). It is clear then, that there are a number of isoforms of inhibitory G-
proteins and RGSs expressed in the heart and other tissues, which have potentially 
overlapping functions. Using PTX-insensitive point mutants of Gi/o in vitro cellular 
systems (HEK cell lines), it was shown that G-protein coupled receptors couple well 
with a number of isoforms and there is variable preferences of a receptor for an 
inhibitory G-protein isoform and there are only minor differences in the ability of 
these variants to activate the channel (Leaney & Tinker 2000). 
 
1.7.2 Gαi
 expression and clinical relevance 
The evidence for up-regulation of Gαi occurring in heart failure comes from a study 
by Neumann and colleagues in 1988  where they found an association between 
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catecholamine desensitization and heart failure (Neumann et al. 1988). In that study, 
where they compared failing hearts (idiopathic dilated cardiomyopathy) with non-
failing hearts, they found that Gαi protein content was increased with an impaired 
responsiveness to isoprenaline. In the same study, in another patient with 
inflammatory heart disease, the contractile response to isoprenaline was not reduced 
and likewise content of Gi-proteins was not changed. Another study by Hershberger 
and colleagues compared myocardial tissue from failing and non-failing hearts for 
cAMP response to Gαi coupled A1 receptors and non-Gαi mediated activation of AC 
by forskolin, fluoride and manganese and found similar activities of AC in both failing 
and non-failing hearts. There were no differences in adenosine receptor-mediated AC 
inhibition. However, Gαi was found to be increased by 30% in failing hearts and basal 
cyclase activity was decreased by 70% (Hershberger et al. 1991). In animal models of 
heart failure there was an increase in the amount of Gαi protein assessed by 
immunoblotting, and an increase in Gαi function assessed by Ach induced inhibition 
of AC (Kawamoto et al. 1994). Increased levels of Gαi and decreased AC activity 
cannot be looked upon as a primary event in cardiac hypertrophy as they are 
demonstrated in various forms of experimental and genetic hypertension models 
where there is hypertrophy without heart failure (Bohm et al. 1995). Feldman and co-
workers examined RNA levels by northern blot analysis and found that in failing 
human hearts there is an increase in both Gαi and Gαs but later by real time PCR 
found no differences in Gαi and Gαs (Feldman et al. 1989;Feldman et al. 1991). Later 
studies in human and experimental heart failure further reported an increase in Gαi 
mRNA levels (Eschenhagen et al. 1992). In cultured cardiac myocytes using Gαi2 
gene promoter reporter constructs it was demonstrated that increase in cAMP levels 
upregulate Gαi2 promoter activity by CREB binding which could provide a credible 
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mechanism for transcriptional up-regulation of Gαi2 in heart diseases (Eschenhagen et 
al. 1996a).  
Ventricular myocytes taken from patients with cardiac failure demonstrate poor 
contractile reserve to -adrenergic stimulation accompanied by 1-AR down-
regulation (resulting in a higher 2/1 ratio) and increased expression of PTX-sensitive 
Gi (with no changes in Gαs expression) (Xiao, Zhang, Chakir, Avdonin, Zhu, Bond, 
Balke, Lakatta, & Cheng 2003;Zheng et al. 2005). These events correlate with 
attenuation of AC activity and isoprenaline-stimulated cAMP production. However 
pharmacological data suggests that cardiomyocytes can in principle develop maximal 
contractile force by cAMP independent means e.g. Ca2+ loading (Brown and Harding 
1992). Therefore abnormal cAMP-generation by the receptor G-protein AC system 
appears to be of central importance for the reduced inotropic state seen in clinical 
heart failure. Also these studies suggest that increased levels of noradrenaline reported 
in heart failure lead to raised levels of the inhibitory G-protein, and that this 
contributes to the observed β-AR desensitization in patients with moderate or end-
stage heart failure. 
 
1.7.3 Stimulatory G-protein Gαs 
 
Heterotrimeric Gαs subunit is ubiquitously expressed and binding of β-AR to 
stimulatory G-proteins leads to its dissociation into Gαs-GTP bound and Gβγ complex  
similar to that of inhibitory G-protein. The Gαs-GTP complex, which dissociates from 
the Gβγ complex, then binds to and activates AC. This activation leads to generation of 
cAMP and increased levels of cAMP can directly modulate HCN channels (Ih/If) 
leading to an increase in heart rate (DiFrancesco and Tortora 1991). This also leads to 
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increased activity of PKA, resulting in modulation of downstream effectors such as 
intracellular Ca2+ handling pathways for example phospholamban and the ryanodine 
receptor leading to increased contractility of cardiac muscles (Weinstein et al. 2001). 
Gαs is deactivated by intrinsic GTPase activity of G-protein itself which hydrolyses 
bound GTP to GDP. RGS proteins appear to play much less of a role in modulating 
GAP activity (Zheng et al. 2001). Apart from regulation of cardiac contraction, 
stimulation of AC is also important for many physiological processes including 
growth and development, learning and memory and endocrine functions, including 
those of the thyroid, pituitary, and parathyroid glands. In addition to activation of AC, 
Gαs has been implicated in a number of processes for which the effector protein is 
unknown, such as adipogenesis and regulation of vesicular trafficking (Berlot and 
Bourne 1992). 
 
GNAS is a complex gene with imprinting that encodes multiple gene products through 
the use of alternative promoters and first exons. In addition to Gαs, the gene also 
encodes for  a neuroendocrine specific Gαs isoform (XLαs) which is expressed from 
paternal allele and chromogranin like protein NESP55 which is expressed from 
maternal allele (Weinstein et al. 2007). Gαs itself is imprinted (though not in cardiac 
tissues) in tissue specific manner, in both mice and humans being expressed primarily 
from maternal allele (but paternally silenced) in several tissues including pituitary, 
thyroid, renal proximal tubules and gonads, but biallelically expressed in most tissues 
(Table 1.2). Mice which are homozygous knockouts of Gnas die early in embryonic 
development (Yu et al. 1998). Heterozygous inactivation of Gαs mutations results in 
Albright Hereditary Osteodystrophy (AHO) and it presents a skeletal phenotype 
characterized by subcutaneous ossifications, short stature and brachydactyly 
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(shortening and widening of long bones in the hands and feet). Heterozygous mutation 
of Gαs on the maternal (but not the paternal) allele also leads to early lethality, severe 
obesity and multihormone resistance (parathyroid stimulating hormone -PTH, thyroid 
stimulating hormone TSH and gonadotropins) while the paternal mutation leads to 
only mild obesity and insulin resistance along with AHO. This is due to the fact that 
Gαs is mainly expressed from maternal allele in the target tissues of these hormones 
(thyroid, ovaries, renal proximal tubules) and mutations in the maternal allele lead to 
Gαs deficiency and hormone resistance on the other hand mutation on the dormant 
paternal allele have no effect on Gαs expression. These parent-of-origin differences 
are the result of tissue-specific Gαs imprinting (Weinstein 2001). XLαs (which has a 
long amino terminal extension) deficiency leads to a perinatal suckling defect and a 
lean phenotype with increased insulin sensitivity. The opposite metabolic effects of 
Gαs and XLαs deficiency are associated with decreased and increased sympathetic 
nervous system activity, respectively. NESP55 deficiency has no metabolic 
consequences (Weinstein, Xie, Zhang, & Chen 2007). 
 
Table 1.2 Imprinting pattern of GNAS locus 
GNAS Locus  Imprinting Pattern 
Gαs Tissue specific, expressed mainly from maternal allele in various 
hormone target tissues, biallelicaly expressed in most tissues 
GXLαs Paternally 
NESP55 Maternally 
Exon 1A Paternally 
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1.7.4 GNAS gene and products encoded by Gnas 
Genomic imprinting is a epigenetic phenomenon which results in partial or complete 
suppression of gene expression from one parental allele (Reik and Walter 2001). The 
imprinting is either by allele specific DNA methylation or histone modification which 
distinguish the 2 parental alleles which are wiped out in primordial germ cells and re-
established in either male or female gametes, and maintained in somatic tissues 
throughout development. DNA methylation is the most well-established imprint mark, 
as all imprinted genes have one or more regions in which the maternal and paternal 
allele are differentially methylated. The mouse and human Gαs gene (gnas and GNAS 
respectively) generates multiple gene products through the use of 4 alternative 
promoters and first exons that splice onto a common exon (Fig. 1.8). The major 
product Gαs, is generated from the  most downstream alternative exon Gαs exon 1, 
which generates transcripts encoding Gαs and it spans 13 exons (12 exons in mice) 
and generates 2 long and 2 short forms of Gsα protein by alternative splicing of exon 3  
and both are biologically active and similar in function (Bray, Carter, Simons, Guo, 
Puckett, Kamholz, Spiegel, & Nirenberg 1986;Kozasa et al. 1988) (Jones et al. 1990).  
 Gαs is imprinted in a tissue-specific manner in both mice and humans, being 
expressed primarily from the maternal allele in several tissues, including pituitary, 
thyroid, renal proximal tubules and gonads but biallelicaly expressed in most tissues 
(Davies and Hughes 1993;Hayward et al. 2001;Weinstein 2001).  
 
Another alternative promoter which is most upstream of GNAS locus (∼ 45 kb 
upstream of Gαs exon 1), generates transcript that encode the neuroendocrine-specific 
protein of 55 kDa (NESP55) which is structurally and functionally unrelated to Gαs 
(Hayward et al. 1998;Peters et al. 1999) (Fig. 1.8). The entire NESP55 coding 
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sequence is within its specific first upstream exon and Gαs exons 2–13 form majority 
of 3′ untranslated region of NESP55-specific transcripts. NESP55 is only transcribed 
from the maternal allele and its promoter region is methylated only on the paternal 
allele (Li et al. 2000). In adults, it is primarily expressed in neuroendocrine tissues, 
like adrenal medulla, pituitary, hypothalamus and brain stem regions and a 
proteoltytic product of NESP55 has been shown to be an endogenous antagonist to 
serotonin receptors (Ischia et al. 1997) and deficiency of NESP55 in humans does not 
produce any pronounced phonotype so its role is presently unknown (Liu et al. 2000). 
 
Lying ∼30 kb upstream of Gαs exon 1 is the third alternative promoter which 
generates transcripts encoding neuroendocrine specific Gαs isoform, XLαs 
(Kehlenbach et al. 1994). GXLαs has a long amino-terminal extension encoded by its 
specific first exon (422, 367, and 551 amino acids in mice, rats, and humans, 
respectively) while the rest of the protein is identical to Gαs, being encoded by Gαs 
exons 2–13. In GXLαs 47 amino acids of Gαs are replaced by a large amino terminal 
domain with manifold repeat regions which are encoded by its specific 1st exon. 
GXLαs is oppositely imprinted to NESP55, being methylated on the maternal allele 
and transcriptionally active only on the paternal allele (Hayward, Moran, Strain, & 
Bonthron 1998;Li, Vu, Zeng, Nguyen, Hayward, Bonthron, Hu, & Hoffman 
2000;Peters, Wroe, Wells, Miller, Bodle, Beechey, Williamson, & Kelsey 1999). 
GXLαs mutations have little effect in humans though its biological functions are not 
fully established.  
 
Located ∼ 2.5 kb upstream of Gαs exon 1 is a fifth alternative promoter referred to as 
exon 1A and is methylated on the maternal allele and generates paternal-specific 
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transcripts that are presumably untranslated (Ishikawa et al. 1990). The exon 1A 
region appears to be a primary imprinting control centre as its maternal-specific 
methylation is established during gametogenesis and maintained throughout 
development in mice (Liu, Litman, Rosenberg, Yu, Biesecker, & Weinstein 2000). 
Pseudohypoparathyroidism type 1b (PHP1b) is a form of parathyroid hormone 
resistance resulting from an imprinting defect leading to tissue specific Gsα 
deficiency.  
 
 
 
                        
 
 
 
Tissue-specific Gαs knockout models have identified important roles for Gαs signaling 
pathways in skeletal development, renal function and glucose and lipid metabolism 
but not in relation to cardiac function. Here in this present study I have explored the 
Figure 1.8 Organisation and imprinting of GNAS locus. Maternal and paternal alleles of 
GNAS are shown here with alternative first exons for NESP55 (NESP), XLαs, untranslated 
(exon 1A) and Gαs (exon 1) and their mRNAs splicing to a common exon (exon 2). The 
exons further extend till exon 13 in the sense direction (not shown). Methylated promoters 
(Meth) are shown above, and splicing patterns of each gene are shown below each panel. 
Transcriptionally active promoters are indicated by horizontal arrows in the direction of 
transcription. Transcription from the paternal Gαs (exon 1) promoter is suppressed in some 
tissues, which is indicated with a dashed arrow. Figure modified from (Weinstein et al. 
2004). 
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role of Gαs in relation to cardiac function using tissue specific knockouts in vivo 
studies. 
 
1.7.5 Gαs
 expression and clinical relevance 
 
Increased expression of inhibitory G-proteins has been widely accepted as a 
contributing factor for β-AR desensitization in heart failure models but the exact act of 
altered Gαs is not clear. Gαs activity and Gαs mRNA is decreased by approximately 
30% both in the failing and non-failing pressure overload hearts of animal models. 
Followed by this decrement in these models there was a decrease in AC, both basal 
and stimulated (Chen et al. 1991). Low levels of Gαs have been observed in rat post 
infarction heart failure models (Sethi et al. 1998) and pacing induced heart failure in 
swine models (Roth et al. 1993). Although in human and experimental heart failure 
models there was no report of decreased Gαs, though most of these studies did find 
increased Gαi and decreased AC activity in the heart tissues (Bohm et al. 1993;Brodde 
et al. 1998;Eschenhagen, Mende, Nose, Schmitz, Scholz, Haverich, Hirt, Doring, 
Kalmar, & Hoppner 1992). And there are even reports supporting that Gαs content is 
upregulated in heart failure (Feldman, Cates, Bristow, & Van 1989;Sethi et al. 1994). 
As a result the current literature is not ample enough to conclude that regulation of 
Gαs contributes to the pathophysiology of human heart failure. Studies using 
transgenic mice overexpressing Gαs under the control of myosin heavy chain promoter 
(which achieves cardiomyocyte-specific post natal gene expression), showed that 
there was an increase in Gαs activity along with an increase in the amount of β-AR 
coupled to Gαs (Gaudin et al. 1995). In a separate study, Iwase and colleagues found 
that overexpression of Gαs leads to enhanced isoprenaline stimulation but with basal 
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ventricular systolic function (FS) measured by echocardiography (Iwase et al. 1996). 
These mice also exhibited increased collagen content with fibrosis and cardiomyocyte 
hypertrophy with age. These findings in mice are consistent with increased 
cardiomyocyte death by apoptosis and replacement fibrosis in Gαs overexpressing 
hearts (Geng et al. 1999).   
1.8 Gi/o versus Gs mediated signalling imbalance in cardiac pathology  
 
In addition to modulation of cardiac automaticity, inhibitory G-proteins appear to 
regulate a number of distinct biological processes at the level of the ventricular 
cardiomyocyte. Signalling through Gi/o by β2-AR affects cardiac contractility 
(Brown & Harding 1992), cardiac apoptosis (DeGeorge & Koch 2008) and has a 
direct role in modulating several cardiac ion channels (Nagata, Ye, Jain, Milstone, 
Liao, & Mortensen 2000). During exercise an appropriate increase in sympathetic tone 
(and parasympathetic withdrawal) occurs to increased inotropic and chronotropic 
function with reference to metabolic requirements. This is beneficial in acute 
physiological circumstances; however abnormal sympatho-vagal balance (sympathetic 
predominance) occurring in heart failure appears maladaptive. At a cellular level, 
sympathetic Gs activation of AC is inhibited by Gi signalling to control a multitude of 
cellular processes. Transgenic models of Gs and Gi have got different informative 
stories to reveal with regards to heart failure. In vivo expression of GiCT, a specific Gi 
inhibitor peptide, that inhibits Gi signals and not Gs or Gq in transgenic mice 
effectively causes a “functional knockout” of cardiac Gαi2 signalling and these mice 
when subjected to ischemia/reperfusion injury demonstrated a significant increase in 
infarct size, increased myocardial apoptosis and the resultant decreased contractile 
performance indicating  that up-regulation of Gαi2 is an adaptive protective response 
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(Degeorge, Jr. et al. 2008). Thus Gi component on balance provides cardio protection 
against cardiac hypertrophy/apoptosis/progressive cardiac failure. Fig 1.9 shows 
different effects of sympathetic and parasympathetic control. 
 
Activation of cardiac β1-adrenergic receptors via stimulatory G-proteins is the main 
mechanism that increases heart rate and contractility. Therefore several 
pharmacological and gene transfer strategies employed for the prevention of heart 
failure aim at improving the function of the cardiac β-AR system. Several studies have 
been undertaken to address this issue but still the answer is not complete. In acute MI, 
increase in cardiac specific AC type IV expression is associated with reduced 
mortality (Takahashi et al. 2006). The authors of this study found that cardiac directed 
expression of AC type IV mice had less LV dilation and increased ejection fractions. 
On the other hand in another study cardiac specific overexpression of β1-AR lead to a 
transitory improvement of cardiac function (at a young age), but developed marked 
myocyte hypertrophy followed by progressive heart failure with functional and 
histological deficits typical for humans with heart failure (Engelhardt et al. 1999). 
Another study with cardiac specific overexpression of Gαs showed enhanced β1-
adrenergic receptor signalling with elevated heart rate due to enhanced sympathetic 
activity and ultimately led to cardiomyopathy (Uechi et al. 1998). Studies in 
transgenic mice over expressing β2-AR display increased contractility (Milano et al. 
1994a;Rockman et al. 1996)  and they appear to have normal life expectancy.  It is 
tempting to hypothesize that β2-AR, besides its known cardiac stimulatory effects, 
exerts some sort of protection against hypertrophy and heart failure, possibly by 
parallel chronic Gαi signalling compared to β1-AR activated by stimulatory G-protein 
Gαs. Testing this idea could shed some light on the question whether the well-known 
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up-regulation of Gαi found in human heart failure (Neumann, Schmitz, Scholz, von, 
Doring, & Kalmar 1988) is maladaptive or beneficial (Eschenhagen et al. 
1996b;Grimm et al. 1998).  
 
 
 
 
In recent years a clearer understanding of the biological impact of individual proteins 
within the heart has been determined at a molecular level by combining transgenic 
technology with physiological analysis of cardiovascular phenotype.  This combined 
approach has been informative in several situations (Berul et al. 1997;Gehrmann and 
Berul 2000;James et al. 1998) and may be applied to the study of G-protein signalling 
in the context of physiological measurement of autonomic tone which can be 
measured using heart rate variability (HRV) analysis which I have employed in my 
studies.  
 
Figure 1.9 Sympathetic and parasympathetic interactions. Sympathetic and 
parasympathetic signals (e.g. from baroreceptors and chemoreceptors) are integrated by 
specific brainstem centres. Efferent impulses are then transmitted to the heart to modulate 
heart rate and contractility via the sympathetic chain and parasympathetic vagus nerve. 
Central to cardiac failure is the balance between Gs and Gi/o signalling as modulators of 
AC activity. Chronic elevation in cAMP concentration may for example trigger abnormal 
Ca2+ handling, cAMP triggered arrhythmia and apoptosis. 
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1.9 Heart Rate Variability (HRV) as measurement of autonomic tone 
As its name suggests HRV refers to patterns of heart rate change (beat to beat interval 
variation) during physiological recording (Pumprla et al. 2002;Stauss 2003). Cardiac 
automaticity originating from the sinus node is the heart’s primary pacemaker and is 
modulated by several factors including sympathetic (causing tachycardia via Gαs 
signalling) and parasympathetic (causing bradycardia via Gαi/o signalling) afferents 
that add variability to the basic heart rate (R-R interval) signal at different 
characteristic frequencies over time. Analysis of these patterns of variation constitutes 
HRV analysis. 
Patterns of heart rate variation can be divided into particular frequency ranges. Whilst 
parasympathetic responses slow heart rate, their signal transduction mechanisms are 
rapid with fast turnover allowing for fast (high frequency) beat to beat changes in 
heart rate. In contrast, sympathetic responses operate over a “relatively” slower 
timescale contributing to slow (low frequency) beat to beat changes in heart rate. 
From looking at a sufficiently long trace of sinus rhythm it is possible to discern 
specific patterns in heart rate variation. 
HRV frequency ranges in humans include (Pumprla, Howorka, Groves, Chester, & 
Nolan 2002): 
 Ultra low frequency (ULF; > 5 hr. cycle length) that underlies circadian rhythm.  
 Very low frequency (VLF; > 25s cycle length) modulated by temperature 
regulation mechanisms. 
 Low frequency (LF; >6s cycle length) represents combined sympathetic and 
parasympathetic nerve activity. 
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 High frequency (HF; 2.5 – 6s cycle length) exclusively parasympathetic 
modulation. 
HRV has been correlated with clinical outcome and represents a reproducible non-
invasive measurement as a quantitative measure of cardiac autonomic modulation. A 
high variability in heart rate is generally considered as a sign of good cardiovascular 
adaptability, implying a healthy individual with well-functioning autonomic control 
mechanisms. In contrast, attenuation of HRV, particularly HF power is associated 
with adverse cardiovascular outcome in myocardial infarction (Bigger et al. 1993), 
heart failure (Adamson et al. 2004), mitral valve disease (Stein et al. 1992) and 
hypertension (Frenneaux 2004). Using prospectively recorded HRV data, prognostic 
insight can be determined, which could be used as an adjunct to guide treatment 
decisions e.g. consideration of implantable cardioverter-defibrillator (ICD) 
implantation therapy in patients at risk of sudden cardiac death (Pruvot et al. 2000).  
1.10 The mouse as a model system to study cardiac electrophysiology in vivo 
The mouse has turned out to be a potentially invaluable tool in cardiovascular research 
due to progress in molecular genetics. There are several reasons for this (Doevendans 
et al. 1998). 
 It is relatively easy to perform gene targeting and transgenic experiments in 
mice. 
 It is fairly reproducible to manipulate mouse embryonic stem cells with a very 
good success rate. 
 There is an ever expanding knowledge of the mouse genome available. 
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 Gestation period of mice is short and it is relatively low cost for breeding and 
housing compared to other mammalian models. 
More recently, technological advances such as the mapping of the murine genome 
have enabled investigators to modify genes quickly and with great accuracy to study 
various aspects of cardiovascular biology. The availability of genetically engineered 
transgenic mice has allowed for detailed investigation of the in vivo, ex vivo, and in 
vitro electrophysiological consequences of human mutations associated with 
arrhythmias (Remme 2013). However certain cardiac electrophysiological properties 
are inherently different between mouse and man reviewed by (Kaese and Verheule 
2012). Transgenic mouse models may nevertheless successfully mimic human 
arrhythmia syndromes although observations regarding arrhythmia mechanisms may 
only be extrapolated to the human situation with caution. For example, mice with 
genetic alterations in the Scn5a gene encoding the cardiac sodium channel have 
provided insight into the role of this channel in both progressive cardiac conduction 
disease and Brugada syndrome, as detailed by (Huang et al. 2012). However the 
currents responsible for repolarization are different in the mouse (see below). 
Technical developments have reduced the size of the equipment for physiological 
measurements to the mouse level. It is possible to obtain functional data from mouse 
circulation both ex vivo and in vivo (Grupp et al. 1993). Micro-surgery has developed 
to the level where most manipulations previously performed in larger animals can now 
be applied to mice. Although there are some major differences in the morphology of 
the heart between genera, the differences within mammalian species are only subtle 
(reviewed later). In terms of ventricular structure, the mouse heart is similar to the 
human heart, with the arrangement of valves providing the best discriminator between 
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the morphological right and left ventricle. In contrast to the human heart, there is little 
distinction between the apical trabeculations of the left and right ventricle in mice. 
The most important differences in cardiac structure of man and mouse are confined to 
the atrial and venous parts. In the mouse heart, unlike the human heart, the left 
superior caval vein persists and drains into the right atrium. The pulmonary vein has a 
solitary opening in the left atrium (Doevendans et al. 1998). 
Coronary artery anatomy in the mouse is comparable to that of other mammals, with 
early branching of a large septal coronary artery (also seen in hamsters and rabbits) 
from the left coronary system. Controversy exists on the origin and importance of the 
circumflex branch in the mouse. The existence of a minor or rudimentary circumflex 
coronary artery was suggested by (Michael et al. 1995) in male FVB mice. 
Doevendans and group observed in 6 Swiss adult mice, the coronary system through a 
casting technique, and found a single left coronary artery, which branches into a large 
septal artery and left anterior descending artery, supplying the left ventricular free 
wall. In addition the right coronary artery branches proximal into a right ventricular 
and circumflex vessel supplying the left ventricular posterior wall. 
The heart weight of an adult mouse shows considerable strain differences, and varies 
between 150 mg in FVB mice to 180 mg in Swiss mice (Gottshall et al. 1997). This 
implies a heart to body weight ratio of approximately 5.0–6.0 mg/g. The mouse body 
weight is approximately 0.05% of the average adult human. The heart weight is 
proportionally reduced in size, although 20% smaller than predicted from the 
regression equation developed by Stahl (Hein et al. 1997;Reiss et al. 1996). A 
significant increase in heart to body weight ratio to 7 mg/g was found in transgenic 
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mice overexpressing a constitutively active α1B- adrenergic receptor in the heart 
(Milano et al. 1994b). 
The murine conduction system is similar to larger mammalian systems in a number of 
ways. A sinoatrial (SA), atrioventricular (AV) and a His-Purkinje conduction network 
exist. A number of cardiac ion channels in humans and mice are generally conserved 
(Nerbonne et al. 2001) and so the transmural conduction velocities. Action potential 
heterogeneity, a critical substrate for arrhythmia mechanisms, is displayed by both 
mouse and human and it is similar. (Killeen et al. 2008). Various forms of heart block 
(Hagendorff et al. 1999), long QT with spontaneous ventricular torsades de pointes 
(Nuyens et al. 2001) and sudden cardiac death secondary to ventricular fibrillation 
(Danik et al. 2008) have been reported in murine models. Additionally, atrial (Kovoor 
et al. 2001) and ventricular arrhythmia (Berul et al. 1996;Korte et al. 2002;Park et al. 
2008) can be recorded in mice using programmed electrical stimulation, however they 
are typically non-sustained compared to man. Whilst similarity exists there are notable 
differences also. Cardiac size is much smaller - the ventricular area is 100mm2 and the 
atrial surface area is less than 35mm2. Traditionally the induction of fibrillation in a 
heart of this size was impossible on the basis of critical mass hypothesis (by Garry in 
1914) as he suggested more than 100-200mm2 is required to induce fibrillation. But 
this hypothesis has been disputed (Vaidya et al. 1999;Wakimoto et al. 2001). The 
mouse heart rate is ~10 times faster than man and this is reflected in intrinsic 
differences between murine and human cardiac action potentials measured from 
individual cardiac myocytes (See Fig. 1.10). Repolarising K+ currents are different in 
mouse and man. The fast and slow components of the Ito, transient outward current is 
critical in mouse and inactivation of these results in the Long QT syndrome in mouse 
(Salama and London 2007). By comparison these currents are much less important in 
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man and instead replaced by IKs (encoded by KCNQ1 and KCNE1) and IKr (encoded 
by HERG1) which play a major contribution to ventricular repolarisation in man (and 
larger mammals). Despite these important differences, manipulation of several cardiac 
ion channels within the murine heart has provided insight into cardiac 
electrophysiology and highlighted the importance of ion channel dysfunction in a 
number of defined cardiac disease states (Kannankeril et al. 2006;Killeen, Thomas, 
Sabir, Grace, & Huang 2008;Salama & London 2007;Splawski et al. 2004). 
 
 
 
 
Genetic manipulation of the mouse genome can be done in 2 different ways. One is 
through transgenesis where naked DNA containing the gene sequence of interest is 
inserted into a fertilised embryo, and is expressed if the transgene is dominant. 
Promoters such as myosin heavy chain has been developed to drive cardiomyocyte 
specific expression of the transgene at particular development times, although this 
might integrate randomly and in varying copy numbers. Pharmacological agents such 
as tamoxifen can allow control of transgene induction through activation or 
Figure 1.10 Comparison of human and murine cardiac action potentials. 
Transmembrane action potentials recorded from human atria (A) and ventricle (V) (left) 
compared with murine cardiomyocytes (right). Waveform kinetics is 10 fold faster in 
mice and repolarisation signature is markedly different reflecting the relative species 
importance of different Kv channels in repolarisation.  At the bottom of each trace surface 
ECG traces are also shown. In humans an isoelectric interval can be seen between QRS 
and T-wave. In the mouse the T wave merges with the terminal component of the QRS. 
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inactivation of transcriptional proteins. A second method is gene targeting which 
depends on homologous recombination where the modified DNA sequence is inserted 
and replaces the normal sequences. This is usually done in stem cells which are then 
injected into blastocysts (16 cell staged embryo). This method produces both knock-
out and knock-in mutations depending on the site of integration. Conditional gene 
deletion is a method of tissue/ temporal specific targeting which utilises cre 
recombinase  to recognise a lox-P site which is 13 base pair inverted repeats separated 
by an 8 base pair asymmetrical spacer region (Yutzey and Robbins 2007). 
1.11 Animal models of heart failure 
 
Animal models of heart failure have been used extensively in the past decades to 
characterize the pathophysiological and genetic mechanisms of this remodelling and 
failure for therapies to circumvent this adverse effect. A vast number of animal 
models have developed to mimic cardiovascular diseases and investigate their 
physiological and pathological processes. The aim of animal modelling of heart failure 
is to simplify an extremely complex syndrome into manageable research questions. 
Animal models of heart failure have contributed greatly to our understanding and 
analysis of the physiological effects of cardiac dysfunction, which are of great 
importance in the overall heart failure phenotype, as opposed to isolated organs or 
cells. Because of relatively complete annotation and simple manipulation of the mouse 
genome, it is possible to have significant mechanistic insights into human disease. 
Mouse models are indispensable tools in many areas of medical research and the 
mouse is, most often, the animal system of choice in disease modelling. Also the 
tremendous progress in molecular genetics and biology has opened up new horizons 
for the management of heart diseases. 
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The main aim of mice models of heart failure is to understand the complex syndrome 
of heart failure and this needs a viable model whereby persistent change in myocardial 
structure and function can be studied and the progression of heart failure and LV 
dysfunction can be quantified. A mouse model of coronary ligation to induce MI was 
first described 3 decades ago (Zolotareva and Kogan 1978). After that models of 
permanent coronary ligation were developed by several groups which is reviewed 
very well by Patten and Hall (Patten and Hall-Porter 2009). The most commonly used 
mouse models for heart failure is by surgical intervention by banding an aorta or 
clipping a coronary artery or by angiotensin infusion (Lohmeier 2012;Michael, 
Entman, Hartley, Youker, Zhu, Hall, Hawkins, Berens, & Ballantyne 1995;Rockman 
et al. 1991). These models closely mimic human conditions of myocardial infarction 
(coronary ligation) and heart failure owing to hypertension (angiotensin infusion) or 
aortic valve stenosis (aortic banding). A genetic model of dilated cardiomyopathy was 
developed by Arber and colleagues in which homozygous deletion of muscle lim 
protein (an actin based cytoskeletal protein that regulates myogenic differentiation) 
causes LV hypertrophy, dilation, systolic dysfunction and heart failure. Another 
genetic model of heart failure is mice with cardiomyocyte specific overexpression of 
TNF-α (a circulating cytokine that contributes to heart failure) that leads to LV 
hypertrophy, dilatation, systolic dysfunction and heart failure (Kubota et al. 1997). 
Apart from these administration of single toxin or drug like ethanol (Berk et al. 1975) 
and doxorubicin (Delgado, III et al. 20 04) are also used to induce heart failure 
phenotype in mice. Different commonly used heart failure models are discussed in 
Materials and Methods (Table 2.1 Commonly used heart failure models). 
My study focusses primarily on the in vivo role of inhibitory G-protein Gαi2 and 
stimulatory G-protein Gαs predominantly in the SA node on heart rate, heart rate 
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variability and their responses to different pharmacological challenges. These mice are 
selective genetic models of bradycardia and tachycardia and I assess how they both 
respond to heart failure after myocardial infarction induced by coronary artery 
ligation. The role of RGSiGαi2 knock-ins and RGSiGαo knock-ins are also 
investigated. 
1.12 Hypothesis 
Neurotransmitters released from sympathetic and parasympathetic nerve terminals 
exert their effects via G-protein-coupled receptors in the sino-atrial node (SAN).  
1. In the SA node, the inhibitory G-protein Gαi2 slows down heart rate via muscarinic 
mediated vagal stimulation while the stimulatory G-proteins, Gαs, increases the 
heart rate by β adrenergic mediated signalling.  
 
2. Deletion of RGS has opposite effects on heart rate compared to deletion of Gαi2. 
 
3. Deletion of Gαs in the SA node leads to bradycardia and is protective in a heart 
failure. 
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1.13 Aims 
 To conditionally delete Gαi2 and/or Gαs in the SA node in mice. In the process 
I studied mice with cardiac specific deletion of Gαo and Gαi2. 
 
 To examine in vivo heart rate (HR) regulation by radio telemetry and 
pharmacological challenge in conditional deletion of Gαi2, Gαo and Gαs mice 
and in mice with knock-in of RGS-insensitive G-proteins. 
 
 To develop an MI model in mice and study LV contractile function in Gαi2 or 
Gαs mice using serial echocardiography. 
 
 
 
 
 
 
 
 
 
88 
 
 
 
 
 
Chapter 2 
MATERIALS AND METHODS 
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Materials and Methods 
2.1 Overview 
1. Animal breeding strategies and genotyping using a PCR based approach. 
2. Describe the set-up of ECG telemetry hardware and its application to the study 
of heart rate dynamics in a physiological setting in mice with tissue specific G-
protein transgenic deletion and RGS-insensitive knock-ins of Gαi2 and Gαo. 
3. RNA isolation and real time PCR of heart samples of knockout mice. 
4. Describe the methodological approach for performing a mouse MI model 
similar to MI in human. 
5. Describe echocardiographic settings and its usage in analysing ventricular 
function in mice. 
2.1.1 Animal breeding and general conditions 
Mice were maintained at UCL and QMUL animal core facilities under the U.K. Home 
Office guidelines relating to animal welfare. All mice were kept in a pathogen-free 
temperature controlled environment (21-23°C) with 12hr day/12hr night light cycles. 
Animals were allowed access to standard rodent chow and water add-libitum. Mice of 
both sexes were studied between 12-14 weeks of age under standardised conditions. 
Use of animals in all the studies was in accordance with the United Kingdom Animal 
(Scientific Procedures) Act of 1986. Mice showing signs of poor health and 
barbarisation were excluded from use. 
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2.1.2 Cardiac tissue-specific Go and Gi2 deletion using αMHC cre recombinase 
 
Go (-/-) mice demonstrate early postnatal death due to seizure activity and abnormal 
neurodevelopment which impairs the ability of Go (-/-) mice to feed appropriately. 
Given this neurological phenotype, published survival into adulthood is of the order of 
6% (Valenzuela et al. 1997). In Gi2 (-/-) mice growth retardation was observed, few 
litters were produced and occasional unexpected death was seen. In order to improve 
survival rates, mice with tissue specific (cardiac only) Go and Gi2 deletion were 
generated using a cre lox-P approach (see Fig. 2.1). Cre-recombinase is a gene product 
of the bacteriophage P1 and can identify specific 34bp DNA sequences (lox-P sites). 
Cre facilitates the deletion of DNA fragments flanked by two lox-P sites and splices 
together the cut ends. Cardiac specific cre expression has been published using an -
myosin heavy chain (MHC) promoter (Agah et al. 1997). Professor Micheal 
Schneider kindly donated an MHC cre line on a C57/black background for our 
experiments. Go and Gi2 floxed mice (Go flx/flx) (Gi2 flx/flx) on a Sv129 
background were generated and donated by Professor Lutz Birnbaumer. 
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By intercrossing of MHC cre mice with floxed Go (Go flx/flx) and floxed Gi2 
(Gi2 flx/flx), heterozygote (Go flx/wt) and (Gi2 flx/wt) mixed background mice 
lox-P1 lox-P2 
α MHC cre recombinase 
4 7 
4 7 5 6 
  
1 5 
α MHC cre recombinase 
 1 5 3 4 2 
lox-P1 lox-P2 
Gαo 
Deleting 155-240 of the 254aa Gαo 
Deleting 39-154 of the 355aa Gαi2 
Gαi2 
Figure 2.1 Cre lox-P mediated Gαi2 and Go deletion. Lox-P sites in the floxed allele of 
Gαi2 were placed into the intron upstream of exon 2 (lox-P1) and in the intron downstream 
of exon 4 (lox-P2). After cre-mediated excision this will leave an allele coding for an 
inactive Gαi2 that lacks sequences encoded in exons 2 through 4, i.e. amino acids 39-154 
of the 355aa Gαi2. In the Gαo floxed allele, the loxP sites are in the upstream of exon 5 
(loxP-1) and in the downstream of exon 6 (loxP-2). After cre-mediated excision this will 
leave an allele that codes for Gαo that lacks sequences encoded in exons 5 and 6, i.e. 
lacking amino acids 155-240 of the 254aa Gαo. In both disruptions, portions of the 
GTPase domain are lost and the proteins are predicted to misfold and to be degraded.  
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containing the MHC cre transgene were produced. Mice containing both the 
transgenes (Go flx/wt-MHC cre and Gi2 flx/wt-MHC were further crossed to 
obtain Go flx/flx/MHC cre
+ and Gi2 flx/flx/-MHC cre
+ mice and all other genetic 
combinations were used as controls. 
2.1.3 Specific Gi2 deletion in the cardiac conduction system  
 
I used a knock-in of tamoxifen inducible cre into the hyperpolarization activated 
cyclic nucleotide-gated cation channel 4 (HCN4) locus resulting in HCN4-KiT mice 
which effectively delete floxed genes in the pacemaker cells after treatment with 
tamoxifen (Hoesl et al. 2008). They were kindly provided by Professor Andreas 
Ludwig. Briefly the 5′ homology arm (2.3 kb immediately upstream of the HCN4 start 
codon) and the 3′ homology arm (4.7 kb encoding parts of exon 1 and intron 1) were 
sub-cloned from a P1 phage. The CreERT2 sequence followed by a SV40 
polyadenylation signal and a neomycin selection cassette was placed in-frame into the 
HCN4 start codon. The targeting vector was electroporated into embryonic stem cells 
and G418/ganciclovir resistant clones were screened by Southern blot. A positive 
clone was injected into C57BL/6blastocysts to generate chimeric mice which 
transmitted the modified locus to the germ line (Hoesl, Stieber, Herrmann, Feil, Tybl, 
Hofmann, Feil, & Ludwig 2008).  
By inter-crossing of HCN4-KiT cre with floxed Gi2 (Gi2 flx/flx), heterozygote (Gi2 
flx/wt) mixed background mice containing the HCN4-KiT cre transgene were 
produced. These were then further crossed with mice containing both the transgenes- 
to obtain Gi2 flx/flx HCN4-KiT cre mice and the other genetic combinations of wt 
cre – and wt cre + were used as controls. 
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2.1.4 Gs deletion in the cardiac conduction system  
To complement the studies of Gi2 deletion using the conduction system cre 
recombinase, mice with cardiac-specific deletion of Gs in the conduction system 
using the same conduction system cre (HCN4-KiT cre) were also studied. A 
description of the targeting strategy to produce Gs flx/flx lines has been described 
(Chen et al. 2005). They were kindly provided by Professor Lee Weinstein. After 
breeding with HCN4-KiT cre mice in our lab we generated Gs flx/flx cre
+ mice and 
littermate “controls”, which consisted of WT cre+ WT cre- (Fig. 2.2). We observed no 
prominent differences among the latter groups and thus pooled them into single 
littermate control populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to achieve selective deletion of Gi2 and Gs in the conduction system tissues 
double transgenic mice with Gi2 flx/flx HCN4 cre
+
 and Gs flx/flx HCN4 cre
+ were 
injected with tamoxifen (Sigma T5648-1G). Tamoxifen was freshly dissolved in 
1A 
  
1
  
2 3 
HCN4 cre mice 
1A 
 
 
3 2 
Deleting the functional exon 1 
Figure 2.2 Generation of conduction system-specific Gs mice. Floxed Gs mice were 
crossed with HCN4 cre mice. After successive rounds of breeding, we generated Gαs flx/flx 
cre+ mice and littermate “controls”, which consisted of wild-type, cre+ and wild-type, cre- .  
Gnas 
Gnas 
lox-P lox-P 
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sunflower oil (10mg in 900μl of sunflower oil and 100μl ethanol) and 1 mg 
tamoxifen/25g body weight was injected IP (intraperitoneal) on 5 consecutive days 
and mice were studied 7-10 days after the last dose. Mice of both sexes were used in 
this study. 
 
2.1.5 Transgenic RGS-insensitive Go (RGSiGo) and Gi2 (RGSiGi2) mice.  
It has been difficult to ascertain the full function of endogenous RGS proteins in vivo 
because of their functional redundancy (Fu, Huang, Zhong, Mortensen, D'Alecy, & 
Neubig 2006). Thus to investigate the role of endogenous RGS proteins in heart rate 
regulation, we used Gi2 RGSi and Go RGSi knock-in mice where the expression of 
the mutant protein is under the control of its own promoter. They were kindly donated 
to us by Professor Richard Neubig. These knock-ins have G subunits containing a 
G184S point mutation in their switch I region that prevents binding of RGS protein and 
subsequent G deactivation (Lan, Sarvazyan, Taussig, Mackenzie, DiBello, Dohlman, 
& Neubig 1998). Generation of Gi2 RGSi and Go RGSi knock-in mice are 
described here (Fu, Zhong, Nanamori, Mortensen, Huang, Lan, & Neubig 2004;Huang 
et al. 2006). Knock-ins maintain normal distribution and levels of Gαi2 and Gαo 
expression compared to transgenic models.  
2.2 Mouse genotyping 
Mice were tail clipped (~2mm) at 3-4 weeks of age. Genomic DNA was isolated from 
tail clips. Polymerase chain reaction (PCR) based genotyping was then performed on 
isolated DNA to confirm the genotype of individual mice. 
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2.2.1 DNA extraction of tail tips    
Mice were ear-marked for identity purposes and then tail tips were snipped with 
scissors and placed in ependorf tubes. Tail lysis buffer stock was made as follows. 
3.35ml 2M Tris-HCl pH 8.8, 
1.66ml 1M (NH4)2SO4,  
1.34ml 0.5M MgCl2 , 
0.5ml Triton X-100,  
92.2ml H20.  
To 1.0 ml of this stock 10μl of β-mercaptoethanol (Sigma M 3148) was added and 
150μl of this tail lysis buffer was then added to tail samples and the samples were 
heated to 100°C for 10 minutes in a heating block to denature mouse proteins. 
Samples were then cooled and 5μl of proteinase K (20mg/ml) was added at 55°C for 
12 hours to cause non-specific protein digestion. Samples were then reheated to 100°C 
for a further 10 minutes and then spun down at 13000rpm for 3minutes in a tabletop 
centrifuge to sediment tail debris. 1.0μl of sample (mouse genomic DNA) was used 
per genotyping PCR. 
2.2.2 DNA extraction from heart and SA node  
Ventricular heart tissues were obtained from Gi2 flx/flx α-MHC cre mice, Go flx/flx 
α-MHC cre mice and SA nodal tissue was obtained from the cardiac conduction 
system-specific Gαi2 and Gαs knock-out mice and processed as discussed above (for 
the tail) for genomic DNA extraction. 1.0μl of genomic DNA from ventricular heart 
tissue was subjected to PCR to confirm cre mediated deletion of Gαi2 and Gαo in the 
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heart and not in other tissues for Gi2 flx/flx αMHC cre mice and Go flx/flx αMHC 
cre mice. In addition 1.0μl of genomic DNA from SA nodal tissue was subjected to 
PCR to confirm cre-mediated deletion of Gαi2 and Gαs in the SA node of Gi2 flx/flx 
HCN4Ki-T mice and Gs flx/flx HCN4Ki-T mice at the genomic level. 
2.2.3 Go lox-P floxed allele, Gi2  lox-P floxed allele and αMHC cre genotyping 
Go lox-P (floxed allele) genotyping was performed using the following primers from 
Invitrogen 25nmole desalted: GnaoF1B 5’- AAG AAT AGA ACC TAG GAC TGG 
AGG - 3’ and GnaoR 5’-GCA GAC AAG TGA ACA AGT GAA ACC C-3’.A 
hotstart PCR strategy (using Qiagen hot start master mix- 203443) was used to detect 
the presence of a 1868bp band corresponding to WT, a 2142bp band corrseponding to 
the Go lox-P (floxed) allele and a 442bp band after cre recombinase activation (Fig. 
2.3). 
Gi2 lox-P (floxed allele) genotyping was performed using the following primers from 
Invitrogen 25nmole desalted: Gαi2 LoxF5’- GGA GCC TGG ACT TTG CTT CTG 
ACC-3’ and Gαi2 LoxR5’- GGC TAT GAT CCC AAA ACT CCC CG- 3’ Gαi2 LoxF2 
5’- GTG GTA AGC CTG TGT GTT TGT GAG AG-3’. A hotstart PCR strategy using 
Qiagen hot start master mix (Qiagen 203443 ) was used to detect the presence of a 
400bp band corresponding to WT, a 500bp band corresponding to the Gi2 lox-P 
(floxed) allele using: Gi2 LoxF and Gαi2 LoxR and a 400bp band after cre recombinase 
activation, using Gαi2 LoxF2 and Gi2 LoxR (Fig. 2.3). PCR conditions are summarised 
below. 
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Identification of α-MHC cre expression was determined using the following primer 
sets: cre F 5’-ATGAC AGACA GATCC CTCCT ATCTC C-3’ and cre R 5’-CTCAT 
CACTC GTTGC ATCAT CGAC-3’. The presence of the cre transgene was 
determined by the presence of a cre band (300bp).  
 
 
 
 
 
 
 
 
Gi2 lox-P allele PCR 
Qiagen hot startaq  10.0 μl  
Gαi2 LoxF5 (10µM)  2.5 μl   
 Gαi2 LoxR5 (10µM)  2.5 μl   
Deionised water  9.0 μl  
Genomic DNA  1.0 μl  
Go lox-P allele PCR 
Qiagen hot startaq  10.0 μl 
GnaoF1B (10µM)  2.5 μl 
GnaoR (10µM)  2.5 μl 
Deionised water 9.0 μl 
Genomic DNA  1.0 μl 
Go lox-P allele PCR programme 
Heated lid 110°C for 15min 
94°C for 15 min 
94°C for 1 min 
62°C for 1 min 
72°C for 2 min 
 
72°C for 10 min 
 
Samples stored at 8°C until gel run 
Gi2 lox-P allele PCR programme 
Heated lid 110°C for 15min 
94°C for 15 min 
94°C for 30 sec 
60°C for 30 sec 
72°C for 1 min 
 
72°C for 10 min 
 
Samples stored at 4°C until gel run 
35 cycles 35 cycles 
αMHC cre PCR 
NEB 10x buffer  10.0 μl  
25mM dNTP      1.0 μl  
100µM cre F        1.0 μl  
100µM cre R       1.0 μl  
NEB taq polymerase  1.0 μl  
Deionised water   84.0 μl  
Use 35 μl of above mix  
and genomic DNA 1.0 μl  
αMHC cre PCR programme 
Heated lid 110°C for 15min 
94°C for 5 min 
 
94°C for 1 min 
60°C for 1 min 
72°C for 1 min 
 
72°C for 10 min 
 
Samples stored at 8°C until gel run 
 
35 cycles 
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2.2.4 RGSiGαi2 and RGSiGαo genotyping 
RGSiGαo and RGSiGαi2 genotyping were performed using the following primers:  
Gaαi2 FlankLoxF 5’- CAC ACT TCA CCT TCA AGG AC-3’ 
Gaαi2 FlankLoxR 5’- CTG ATG CCT AGG TGA CAG AC-3’   
Gaαo FlankLoxF 5’- CGC AGG CTC TGA GGG CCT AAG-3’ 
Gaαo FlankLoxR 5’- TGC CTC ACC TCT CCG TCT CC -3’.  
Figure 2.3 Gel of PCR of Gi2 floxed, Go floxed and cre allele. Upper panel shows 
floxed allele and cre allele where floxed allele shows a higher bp band due to the presence of 
lox-P sites for Gαi2 (500bp) and Go (2.1kb). Cre allele is confirmed as a 300bp band. Lower 
panel shows floxed cre allele, where after cre mediated deletion shows 400bp band in the 
heart of Gi2 floxed cre allele and 442 bp in the heart of Go floxed cre allele. 
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Conventional PCR strategy was used to detect the presence of heterozygote yielding 
two bands one at 400bp and another at 200bp and wild type at 200bp alone for both 
RGSiGαo and RGSiGαi2 (Fig. 2.4). 
PCR reaction mix and conditions are a follows. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RGSiGi2 PCR 
NEB 10x buffer   2.5 μl  
2.5mM dNTP   2.5 μl  
Gaαi2 FlankLox F (10µM) 2.5 μl  
Gaαi2 FlankLox R (10µM)  2.5 μl  
NEB taq polymerase   0.2 μl  
Deionised water     13.8 μl  
Genomic DNA   1.0 μl  
RGSiGo PCR 
NEB 10x buffer   2.5 μl  
2.5mM dNTP        2.5 μl  
50mM MgCl2           1.0 μl 
Gaαo FlankLox F (10µM)  2.5 μl 
Gaαo FlankLox R (10µM)  2.5 μl  
NEB taq polymerase   0.2 μl  
Deionised water     12.8 μl  
Genomic DNA   1.0 μl  
RGSiGi2 PCR programme 
Heated lid 110°C for 15min 
95°C for 4 min 
 
95°C for 30 sec 
62°C for 30 sec 
72°C for 30 sec 
 
72°C for 7 min 
 
Samples stored at 8°C until gel run 
 
34 cycles 
RGSiGo PCR programme 
Heated lid 110°C for 15min 
95°C for 4 min 
 
95°C for 30 sec 
64°C for 30 sec 
72°C for 30 sec 
 
72°C for 7 min 
 
Samples stored at 8°C until gel run 
 
32 cycles 
100 
 
 
 
 
 
 
2.2.5 Gαs floxed and conduction system cre genotyping 
Gs lox-P (floxed allele) genotyping was performed using the following primers from 
Invitrogen 25nmole desalted: Gs LoxF  5’- TTCGG TCTCG TCCCC TTAGT TG-3’ 
and Gs LoxR 5’-AACAA ATCGC ACACC CCAGT GAGG-3’using  betaine (1.5M) 
in the PCR master mix  to obtain a WT  band corresponding to ~216bp and a Gs 
floxed band corresponding to ~264bp respectively. Cre mediated excision was 
confirmed by Gs cre F 5’-GAGAGCGAGAGGAAGACAGC-3’and  Gs cre R 5’-
AGCCCTACTCTGTCGCAGTC-3’ primers which gives a band of ~250bp upon cre 
mediated excision of exon 1 (Fig.2.5). 
Identification of HCN4 cre expression was determined using the following primer 
sets: HCN4KiF5′-CCCGCGCTGGAGTTTCAATA-3′ and HCN4KiR 5′-
CTTCGCCCAGTT GATCATGTG-3′. The presence of the conduction system cre 
transgene was determined by the presence of a cre band (383bp) (Fig.2.5). PCR 
conditions are summarised below.  
 
 
  
400bp
200bp
RGSiGi2 allele RGSiGo allele 
Figure 2.4 Gel of PCR of RGSiGαi2 and RGSiGαo genotyping. RGSiGαi2 and RGSiGαo 
both pcr shows heterozygote band of both 400bp and 200bp and 200bp alone for the wild 
type . 
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Gs lox-P allele PCR programme 
Heated lid 110°C for 15min 
94°C for 5 min 
 
94°C for 30 sec 
63°C for 30 sec 
72°C for 45 sec 
 
72°C for 7 min 
 
Samples stored at 8°C until gel run 
 
40 cycles 
Conduction cre allele PCR programme 
Heated lid 110°C for 15min 
94°C for 5 min 
 
94°C for 30 sec 
59°C for 1 min 
72°C for 1 min 
 
72°C for 10 min 
 
Samples stored at 8°C until gel run 
 
30 cycles 
Conduction cre PCR 
NEB 10x buffer  10.0 μl  
25mM dNTP      1.0 μl  
100µM cre F        1.0 μl  
100µM cre R        1.0 μl  
NEB taq polymerase  1.0 μl  
Deionised water    84.0 μl  
Use 35ul of above mix  
and genomic DNA  1.0 μl  
Gs lox-P allele cre PCR 
NEB 10x buffer  5.0 μl  
2.5mM dNTP       4.0 μl  
 Gs LoxF (10µM)  2.0 μl  
Gs LoxR (10µM)  2.0 μl  
NEB taq polymerase  0.2 μl  
Deionised water    6.8 μl  
Genomic DNA  1.0 μl  
  
 
 
 
 
 
 
 
 
 
 
Gαi2 after tam 
Figure 2.5 Gel PCR of G
cre pcr confirmed as a 300bp band. Lower panel shows cre mediated deletion in 
allele and Gαs floxed allele. 
higher bp band in heart due to the presence of lox
(1.5kb) and after cre mediated excision in SA node 
Gi2 floxed cre allele. C
bp band in heart due to the presence of lox
After cre mediated excision 
band in the SA of Gs floxed cre allele and 390 bp in the heart of G
 
Gα
αi2flx/flx, Gαsflx/flx and cre allele. A) shows c
B) Gi2 floxed allele and WT allele where floxed allele shows a 
-P sites for Gαi2 (1.8
shows floxed cre allele of 400bp band for 
) Gαs floxed allele and WT allele, where floxed allele shows a higher 
-P sites for Gαs (264bp) to WT
(after tamoxifen) in SA node shows floxed cre allele of 250bp 
s floxed
102 
 
s after tam 
onduction system 
Gαi2 floxed 
kb) to WT allele 
 allele (216bp). D) 
 cre allele. 
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2.3 Quantitative Real-time PCR on isolated ventricle and SA nodal tissue 
 
The advent of PCR by Kary B. Mullis in the mid-1980s revolutionized molecular 
biology. It is used to amplify and simultaneously quantify the targeted DNA molecule. 
The amount of an expressed gene in a cell can be measured by the number of copies 
of an mRNA transcript of that gene present in a sample. In order to detect and  
quantify gene expression from small amounts of RNA, extracted RNA is first reverse 
transcribed to cDNA using reverse transcriptase. Then by using specific primers for 
the gene of interest and a fluorescent labelled probe (e.g. taqman probe) fluorescence 
of the flurophore can be measured which will be proportional to the amount of cDNA 
present in the sample. The data generated can be analyzed by computer software to 
calculate relative gene expression (or mRNA copy number) Fig 2.6. 
 
RNA was isolated from the ventricles, brain and tail of Gi2 flx/flx αMHC cre
+, Go 
flx/flx αMHC cre+ and control mice and also from SA node and ventricle after 
tamoxifen treatment in both Gs flx/flx HCN4 cre
+, Gi2 flx/flx HCN4 cre
+ and their 
control mice using the RNeasy kit (Qiagen). Briefly, hearts were removed from each 
group of mice (control and KO), washed with cold PBS and immediately placed in 
liquid nitrogen. They were ground in liquid nitrogen with a pestle and mortar and then 
extraction of RNA using RNeasy kit (cat no. 74104 Qiagen) was carried out. cDNA 
was synthesized using the High capacity cDNA reverse transcription Kit (4368814  
Applied Biosystems). cDNA was quantified and 50ng of cDNA/20μl was used for the 
subsequent real time expression assay. All genes were assayed in triplicate and 
GAPDH was used as the house keeping gene. Real-time PCR was performed using 
Taqman gene expression Assays (Applied Biosystems) using either inventoried or 
made to order assays. The protocol followed was based on the information provided 
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by the supplier, which is available on their website 
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/cms_0412
80.pdf). By using Taqman gene expression assay (Assay ID: Mm03945887_s1) which 
spans exon 1, Gs cDNA was quantified. Gi2 cDNA was then quantified using the 
Taqman gene expression assay kit using custom designed primers spanning exon 2 
boundary TGG AGA GTC AGG GAA GAG CA and exon3 TAG ACC ACG GCA 
CGG TAC T (Applied Biosystems). Go cDNA was quantified using Taqman gene 
expression assay (Assay ID: Mm01249631_m1) which spans exon 5-6 of Go. All 
genes were assayed in triplicates and relative gene expression was quantified using the 
comparative CT method with GAPDH as the reference housekeeping gene. 
 
 
 
 
 
 
 
 
 
 
 
High capacity cDNA PCR programme 
Heated lid 110°C for 15min 
37°C for 60 min 
95°C for 5 min 
Samples stored at 8°C until use for 
Taq man gene expression assay. 
 
High capacity cDNA PCR 
Qiagen 10x RT buffer          2.0 μl  
25x dNTP mix (100mM)     0.8 μl 
10x random primers             2.0 μl  
Reverse transcriptase           1.0 μl   
RNase Inhibitor                    1.0 μl  
Nuclease free water              3.2 μl  
Use 10 μl  of above mix + 10 μl  of up 
to 0.2 μg of RNA per tube. 
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Figure 2.6 Real-time PCR using Taqman probe. The Taqman probe has a 
Quencher dye (Q) and a Reporter dye (R). The quenching dye disrupts the observable 
signal from the reporter dye when it is within a short distance. When the probe is 
annealed to the target and is intact there is no fluorescence. After binding of the 
Taqman® probe and primer to the target DNA, Taq polymerase creates a 
complementary strand.  As the primer anneals and extends to the probe, it cleaves the 
probe, due to 5’ nuclease activity of Taq and the reporter dye is released from the 
extending double-stranded DNA. Following the separation of the reporter dye and 
quencher dye, fluorescence can be detected. Figure adapted from life technologies - 
Taqman gene expression assays. 
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2.4 Murine electrocardiogram (ECG) telemetry & heart rate analysis 
Telemetric ECG recording in mice is essential in understanding the mechanisms 
behind arrhythmias, conduction disorders and sudden cardiac death. Implantable ECG 
telemeters offer the advantages of simple surgical implantation and long-term 
recording of signals in ambulatory mice. Continuous surface ECG tracings were 
recorded from mice using surgically implantable telemetry devices (Data Science 
International, DSI). Using this technology, continuous ECG sampling for up to 4 
months can be recorded from individual animals. Potential hazards of animal restraint 
and anaesthesia are removed and multiple electrophysiological parameters can be 
measured including basal HR, exercise induced HR (and HR recovery), the effects of 
pharmacological intervention on HR, circadian HR rhythms and heart rate variability 
patterns. ECG parameters such as PR or QT interval can also be readily measured in a 
physiological setting (see Fig. 2.7). Additionally long term recordings can be 
inspected for spontaneous arrhythmia. 
An ECG recording simply reflects the electrical potential difference between two 
adjacent electrode pairs. Signal is sampled at a programmable frequency from the 
probe and the ECG signal transmitted to a receiver mat by radio wave and digitised 
into a conventional ECG tracing with the aid of computer processing. Commercially 
available software (DATAQUEST ART v3.0/Chart v7.0) can then be used to 
delineate individual parameters from the raw ECG tracing e.g. heart rate. 
 
 
 
 
 
  
 
 
 
2.5 Telemetry probe implantation
 
Mice were individually caged for 48 hours prior to dev
was performed with close attention to good surgical technique and in an aseptic 
environment throughout. Inhalation 
murine anaesthesia was maintained with 1.7% isoflurane 
were placed on a sterile drape rested on a heating mat set to regulate the mouse 
temperature at 37°C. Mice were then secured with masking tape in a supine position. 
The abdominal wall was swabbed with 70% ethanol solution as a disinfectant and then 
an induction bolus of 
Baytryl) were administered by intraperitoneal injection. A m
performed, skin, muscle layer and 
cavity was then inspected to check sizing suita
Specifically designed murin
carefully placed within the abdominal cavity taking care not to disturb or compress 
Figure 2.7 Schematic 
telemetry device is implanted within the abdomen. ECG signal is transmitted by radio
to a receiver. The signal is then digitised and displayed 
the middle illustrates a mouse surface ECG rhythm st
moving mouse. 
 
 
 
 
 
 
 
ice implantation. 
anaesthesia by means of isoflurane was used and 
combined
buprenorphine (0.2mg/kg) and prophylactic antibiotics (5
idline laparotomy was 
peritoneum was carefully divided
bility for probe implantation. 
e telemetry probes (model TAE10-F20, DSI) were then 
diagram of murine telemetry and ambulatory ECG.
on a computer console. The trace in 
rip recorded in a conscious freely 
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bowel loops and other intra-abdominal visceral organs. Attached to the main probe 
were two electrode leads coated in insulating rubber. These were colour coded: 
colourless (negative) and red (positive). Two stab incisions were made in the upper 
anterior abdominal wall, either side of the major incision, to allow for the passage of 
the electrodes into the subcutaneous tissue plane. The abdominal wall was then closed 
using interrupted silk stitches. The ends of each electrode were cut to approximate 
length and a small sheath of insulting rubber cut back from the electrode tips to 
exposing bare metal wire. Two further incisions were performed, one in the anterior 
right shoulder position, and one at the cardiac apex. The leads were then 
subcutaneously tunnelled from the abdomen to these respective positions; the bare 
electrode tips were stitched to the chest wall muscle to ensure good tissue contact in a 
Lead II ECG configuration. Each incision was then closed in layers. At the end of the 
procedure (approximately 20 to 30 minutes) 200-300μl of prewarmed 5% dextrose/ 
saline was administered IP for post-operative hydration. Mice were then returned to 
housing cages placed on warming mats for surgical recovery. Additional analgesia 
was administered at 6hr and/or 24 hours post procedure if deemed necessary. Mouse 
recovery from the procedure was generally rapid (typically 1 to 2 days), however we 
elected to observe mice for at least 7-10 days prior to any ECG recording to ensure 
full surgical recovery prior to any physiological ECG recording. Each telemetry probe 
had a magnetic switch which could be turned on or off (to save battery life) with the 
aid of a magnetic wand at times of ECG recording. After switching the device on, 
mice cages were placed on receiving mats to allow for non-invasive ECG recording 
and the signal sampled at 2000Hz.  Before recording, mice were given a thirty minute 
“run in” period. For serial heart rate measurements, 15s recordings were measured 
every 30 minutes over 2 days using a “scheduled sampling” protocol. From this data- 
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set it was possible to observe diurnal changes in HR between day and night and also 
calculate mean HR.  
2.5.1 Heart rate variability assessment 
 
Heart rate variability is a measure of the mean changes in the interval or distance 
between one beat of the heart and the next. Heart rhythm, even in a mouse shows 
subtle beat to beat variations between successive R-R intervals (See Fig. 2.8). The 
inter beat interval (IBI) is the time between one R-wave (or heart beat) and the next, in 
milliseconds. The IBI is highly variable within any given time period. Measurements 
of such R-R interval variability during sinus rhythm under basal conditions, 
constitutes heart rate variability (HRV) analysis. HRV is used principally as a non-
invasive measurement of autonomic tone, measured as a modulation of sinus node 
function and can be used to specifically determine the parasympathetic contribution to 
HRV (Pumprla, Howorka, Groves, Chester, & Nolan 2002;Wickman, Nemec, 
Gendler, & Clapham 1998). HRV recordings were performed between 12-2pm only 
(during “lights on” to simulate daylight). Mice are largely nocturnal in nature; they are 
mainly active at night and rest/sleep during the day. Autonomic tone is known to 
modulate circadian HR rhythm (Stauss 2003), mice have reversed circadian rhythms 
compared to man reflecting their nocturnal nature, therefore we recorded HRV 
specifically during “midday” in order to capture heart rate dynamics at a time when 
HR would be slowest (and parasympathetic tone presumably highest) reflecting a true 
“basal/rest” physiological state. 
 
R-R interval was recorded from ECG tracings continuously over 20 minutes (divided 
by the software into ten 2 minute epochs) at 2000Hz sampling frequency. Data was 
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then imported in CHART v7.0 (ADInstruments), the current industry standard for 
analysis of physiological data and analysed using a HRV extension module. Raw 
tracings were manually inspected and any electrical signal interference/artefact 
manually edited. An R-wave detection algorithm was then applied to ensure all R-
waves were accurately detected (Fig. 2.8 A). The data set of consecutive R-R intervals 
(typically over ~12000 sinus beats per mouse recording) was then mathematically 
analysed in both the linear time and frequency-domains (Fig. 2.8 B), as has been 
applied by others to murine HRV analysis (Ecker et al. 2006;Gehrmann et al. 
2000;Uechi, Asai, Osaka, Smith, Sato, Wagner, Ishikawa, Hayakawa, Vatner, 
Shannon, Homcy, & Vatner 1998). 
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Figure 2.8 Representative ECG telemetry and power spectral density transformation. A 
raw ECG tracing recorded from a conscious freely moving mouse is shown (A). Using Chart 
data processing software, R wave signal is identified; successive R-R intervals are then 
calculated. The R-R interval data set can then be converted in the frequency-domain after 
Fourier transform to generate a power spectral density plot (PSD) demonstrating characteristic 
frequency distribution. Frequency bands are displayed on the x-axis. Characteristic frequency 
peaks can be seen in both the LF (0.4-1.5 Hz) band width and in the HF (1.5-4.0 Hz) range. 
The HF band is a selective marker of parasympathetic tone. 
 
2.5.2 Time-domain analysis 
 
The variations in heart rate may be evaluated by a number of methods. Perhaps the 
simplest to perform are the time-domain measures. In these methods, either the heart 
rate at any point in time or the intervals between successive normal complexes are 
determined. In a continuous ECG record, each QRS complex is detected, and the so-
called normal-to-normal (NN) intervals (that is, all intervals between adjacent QRS 
complexes resulting from sinus node depolarizations) or the instantaneous heart rate is 
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determined. Simple time-domain variables that can be calculated include the mean NN 
interval, the mean heart rate, the difference between the longest and shortest NN 
interval, the difference between night and day heart rate, and so forth (Thireau et al. 
2008). Time-domain measurements determine simple variance of R-R interval signal 
over the entire length of recording, they are relatively crude indices of variability but 
have been equated prospectively with clinical outcome in man (Stein, Borer, Okin, & 
Kligfield 1992). Classical indices include:  
 
R-R interval/ R-R variability where R is a point corresponding to the peak of the 
QRS complex of the ECG wave; and R-R is the interval between successive R’s, used 
to visualise R-R variation on a beat to beat level. It represents a successive R-R 
interval plot against successive beats number over the length of an ECG recording. 
Tachogram recordings give an overview of both short term and longer term signal 
oscillations. (Wickman, Nemec, Gendler, & Clapham 1998) 
 
Standard Deviation of the N-to-N interval: The N-to-N interval is the “normalized” 
beat to beat interval. The SDNN is the standard deviation of those intervals, a measure 
of their variability. The SDNN is expressed in milliseconds (ms) and it is an overall 
index of signal variation over the entire ECG tracing. (Uechi, Asai, Osaka, Smith, 
Sato, Wagner, Ishikawa, Hayakawa, Vatner, Shannon, Homcy, & Vatner 1998) 
 
Mean R-R: Averaged heart rate over the ECG recording (Fox et al. 2007). 
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pNN50: This index measures what percentage of the IBI differ from neighbouring 
intervals by 50 milliseconds or more. The pNN50 is expressed in percentages and is 
interpreted as a measure of cardiac parasympathetic modulation (Ewing et al. 1984) 
 
RMSSD: The square root of the mean of sum of square differences between adjacent 
normal R-R intervals. It is an index of beat to beat R-R interval variation used as a 
surrogate for rapid beat to beat changes in parasympathetic activity (Ecker, Lin, 
Powers, Kobilka, Dubin, & Bernstein 2006;Pumprla, Howorka, Groves, Chester, & 
Nolan 2002). This measure estimates high frequency variations in HR in short-term 
recordings that reflect parasympathetic regulation of the heart. 
2.5.3 Frequency-domain analysis 
 
It is difficult to obtain precise physiological data regarding changes in autonomic state 
solely from time-domain measurements. A more precise method involving frequency 
analysis has enabled investigators to delineate individual components of autonomic 
signal from R-R interval data using power spectral analysis. The most important 
concept in the frequency-domain analysis is the transformation. Transformation is 
used to convert a time-domain function to a frequency-domain function and vice 
versa. The most common transformation used in the frequency-domain is the Fourier 
transformation. Fourier transformation is used to convert a signal of any shape into a 
sum of infinite number of sinusoidal waves. Since analysing sinusoidal functions is 
easier than analysing general shaped functions, this method is very useful and widely 
used. While time-domain analysis shows how a signal changes over time, frequency-
domain analysis shows how the signal's energy is distributed over a range of 
frequencies. 
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An example is the Fourier transform, which decomposes a function into the sum of a 
(potentially infinite) number of sine wave frequency components. The 'spectrum' of 
frequency components is the frequency-domain representation of the signal.  
 
Power spectral analysis is reliant on fast Fourier transform (FFT). This mathematical 
transformation allows for the isolation of cyclical patterns within the signal (See Fig. 
2.8 B). With reference to HRV, murine HRV parameters have recently been defined; 
three different frequency-domain measures of HRV were computed. Cut-off 
frequencies for power in the low-frequency range (LF) and high-frequency range (HF) 
were based on those utilized in human studies multiplied by a factor of 10 for HR 
adjustment (the approximate ratio between murine and human HR) and defined as 
0.4–1.5 Hz and 1.5–4 Hz, respectively; total power was defined as 0.00–4 Hz. 
(Gehrmann, Hammer, Maguire, Wakimoto, Triedman, & Berul 2000). LF and HF 
were also measured in normalized units, which represent the relative value of each 
power component in proportion to the sum of the HF and LF components. A high 
frequency (HF) component occurs between 1.5 to 4.0 Hz in the mouse and is 
modulated purely by parasympathetic tone whereas a “lower frequency” signal (LF) 
occurring between 0.4 and 1.5Hz has dual sympathetic/parasympathetic modulation 
(Ecker, Lin, Powers, Kobilka, Dubin, & Bernstein 2006;Gehrmann, Hammer, 
Maguire, Wakimoto, Triedman, & Berul 2000;Wickman, Nemec, Gendler, & 
Clapham 1998). Conversion of R-R intervals by FFT produces a power spectral 
density plot. Frequency ranges (x-axis) and total number of events occurring at 
particular individual frequency (y-axis) (i.e. frequency of frequencies) is presented 
graphically on PSD plots (See Fig.2.8 B). PSD tracings characteristically have LF and 
HF peaks within frequency ranges. Variability for individual frequency components 
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e.g. between 1.5-4.0 Hz for HF for example, is determined by the integral sum 
(Power) of the area under the curve between pre-specified frequency cut-offs. 
Frequency-domain indices are summarised below. 
 
High Frequency range (HF) is associated with parasympathetic pathways and is 
synchronous with respiration. This frequency range is associated with the influence of 
blood pressure (baroreceptors) on heart rhythms, and meditative/slow breathing 
augments this range. The frequency range  is 1.5-4.0Hz (Wickman, Nemec, Gendler, 
& Clapham 1998). 
 
Low Frequency range (LF) is associated with sympathetic activation, or more 
probably the withdrawal of parasympathetic braking, and also by the influences of 
visceral and thermal regulation. Rumination and worry augment this range and the 
frequency range is from 0.4 – 1.5Hz. Some suggest that LF appears to be mediated by 
both the vagus and cardiac sympathetic nerves (Gehrmann, Hammer, Maguire, 
Wakimoto, Triedman, & Berul 2000). 
 
Very low frequency range (VLF) is associated with the slower-acting biological 
influences. Significance is unclear in the mouse and its frequency is less than 0.4 Hz. 
(Stauss 2003). 
Total Power (TP) is total variability over all defined frequency ranges similar to 
SDNN in the time domain. The total power of a signal, integrated over all frequencies, 
is equal to the variance of the entire signal (Uechi, Asai, Osaka, Smith, Sato, Wagner, 
Ishikawa, Hayakawa, Vatner, Shannon, Homcy, & Vatner 1998). 
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Some investigators have used the ratio of the low-to-high frequency spectra as an 
index of parasympathetic-sympathetic balance; however, this remains controversial 
because of our lack of complete understanding of the low frequency component 
(which seems to be affected by centrally generated brainstem rhythms, baroreceptor 
feedback influences, as well as both sympathetic and vagal input).  
2.6 Pharmacological studies  
After initial evaluation of basal heart rate variability dynamics in conscious 
telemetered littermate controls, pharmacological interventions were employed using  
atropine a classical muscarinic M2 receptor antagonist (#A0132 Sigma) propranolol, 
β-2AR antagonist ( #P0884 Sigma) carbachol, an M2 selective agonist (#C4382 
Sigma), CCPA (2 chloro-N6-cyclo-pentyladenosine), a selective A1-receptor agonist 
(#C7938 Sigma) and isoprenaline a β-AR agonist (#I5627 Sigma). 
2.6.1 Intrinsic heart rate determination 
Basal HR is modulated by autonomic tone, in man basal HR is predominantly 
modulated by vagal tone. To determine the relative importance of sympathetic and 
parasympathetic tone in the mouse we used telemetry in combination with dual 
autonomic blockade in conscious freely moving mice. HR was recorded over for 5 
minutes then atropine (1mg/kg) (to block parasympathetic) and propranolol (1mg/kg) 
(to block sympathetic) were administered simultaneously by IP to induce combined 
autonomic blockade; serial HR measurements were determined over the next 10 
minutes. Pharmacological action of these agents in the mouse occurs within 3 minutes 
after IP injection (De et al. 2004). 
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2.6.2 Pharmacological provocations  
Chronotropic responses were examined using the following: 
Carbachol (0.5mg/kg IP), a long acting muscarinic M2 receptor agonist.  
CCPA (0.1 mg/kg IP), a long acting specific A1 receptor agonist.   
Isoprenaline (3.0µg/kg IP), a β-AR agonist.  
Heart rate after pharmacological challenge was determined over a 30-minute time 
course or was measured until it had reached a steady state. After initial baseline heart 
rate stabilisation, HR was recorded over for 5 minutes; the drugs above were 
administered by IP. HR measurements were determined over the next 30 minutes. 
Before proceeding to any other drug protocol, a period of at least 48 hours recovery 
was allowed between experiments. 
2.7 Myocardial Infarction (MI) and murine left ventricular remodelling 
The advent of cell type specific, inducible KO or transgenic strategies has made the 
mouse an invaluable tool to study the pathogenesis of heart failure and to identify 
novel therapeutic targets. There are different ways to induce MI or develop heart 
failure models in mice and these are summarized in the table below (Patten & Hall-
Porter 2009). 
Table 2.1 Commonly used heart failure models 
Methods Models Description Reference 
Left Anterior 
descending Artery 
(LAD) occlusion 
Induces MI and 
HF 
Significant 
expertise and 
expense for mouse 
surgery but it has 
similar effects of 
human MI, leading 
to LV remodelling 
(Michael, Entman, 
Hartley, Youker, 
Zhu, Hall, 
Hawkins, Berens, 
& Ballantyne 
1995;Patten et al. 
1998;Patten & 
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hypertrophy and 
dilatation. 
Hall-Porter 2009) 
Transverse Aortic 
Constriction 
(TAC)/Aortic 
banding 
Pressure overload 
induced 
hypertrophy and 
HF 
Greater surgical 
expertise required 
but able to 
quantify the 
pressure gradient 
across aortic 
stricture that allow 
stratification of LV 
hypertrophy. 
(Rockman, Ross, 
Harris, Knowlton, 
Steinhelper, Field, 
Ross, Jr., & Chien 
1991;Rockman et 
al. 1994) 
Muscle Lim protein 
KO 
Induces dilated 
cardiomyopathy 
No surgery 
required, causes 
disturbed 
interaction 
between 
cytoskeleton and 
mitochondria 
affecting energy 
sensing and 
transfer and 
defects in 
mitochondrial 
structure is 
associated with CV 
diseases and 
cardiomyopathy. 
(Arber et al. 
1997;Ross, Jr. 
2002) 
Cardiomyocyte 
specific 
overexpression of 
TNFα- 
Induces dilated 
cardiomyopathy 
No surgery is 
required, 
overexpression 
leads to LV 
hypertrophy, 
dilatation, 
profound systolic 
dysfunction 
associated with 
heart failure and 
premature death. 
(Kubota, 
McTiernan, Frye, 
Slawson, Lemster, 
Koretsky, 
Demetris, & 
Feldman 1997) 
Cryo injury Induces MI Cryoinfarction was 
produced by 
applying a 
cryoprobe of 2 or 3 
mm in diameter  to 
the anterior LV 
free wall followed 
by freezing for 10 
s. technically 
simple, but may 
not always induce 
a trans mural 
(Strungs et al. 
2013;van den Bos 
et al. 2005) 
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lesion  and they 
recover without 
any  fibrosis, 
aneurysm and  
remodelling  
Ethanol/doxorubicin/ 
Homocysteine 
Induces heart 
failure 
Ethanol and 
doxorubicin are 
cardiotoxins and 
elevated levels of 
homocysteine 
develops heart 
failure in humans 
and can be induced 
in mice by 
heterozygous 
deletion of 
cystathionine β 
synthase 
(Berk, Block, 
Toselli, & Ullrick 
1975;Delgado, III, 
Nawar, Zewail, 
Kar, Vaughn, Wu, 
Aleksic, 
Sivasubramanian, 
McKay, Mann, & 
Willerson 
2004;Vacek et al. 
2009) 
 
Acute MI in humans results from coronary atherosclerosis and in a variety of animal 
models this condition can be mimicked by ligation of the left coronary artery 
(Tarnavski et al. 2004). Ligation of the left coronary artery (LAD) models heart 
failure following myocardial infarction by myocardial scar and subsequent congestive 
heart failure. This predicts a clear model of completed human myocardial infarction 
but has its own experimental drawbacks of high postoperative mortality, less 
reproducibility and technical challenges of a microsurgical procedure (Breckenridge 
2010). Although highly representative of ischemic cell death as occurs in humans, the 
ligation model is inherently associated with infarcts of variable size, requiring large 
group numbers of mice in studies that evaluate modelling therapies (van den Bos, 
Mees, de Waard, de, & Duncker 2005). Permanent ligation of LAD still remains the 
most widely studied model of murine MI. We decided to take up the challenge of 
technical difficulties and use this as a model of heart failure to study left ventricular 
remodelling in Gαs flx/flx HCN4 cre
+ and Gαi2 flx/flx HCN4 cre
+ mice. 
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2.8 Murine in vivo model of myocardial infarction 
The MI model employed for this study comprised of occlusion of LAD coronary 
artery. The main surgical procedure is described by Fisher and Marber (Fisher and 
Marber 2002) and modifications were made as described in (Van Laake et al. 2007). 
General advice was taken from the Handbook of Laboratory Animal Management and 
Welfare by Sarah Wolfensohn and Lloyd and the veterinary officer at the surgical 
facility. 
 
All surgical procedures were conducted in a controlled sterile surgical theatre and 
aseptic operating practices were adhered to throughout the procedure. Instruments 
were autoclaved prior to the operating session and a hot bead steriliser was used to 
sterilise instruments between animals. A heating mat covered with a sterile material 
drape was used for all surgeries. Animals were prepared for surgery by chlorohexidine 
wipe to clean the neck and chest region. Additional chlorohexidine washes were 
observed prior to skin opening and immediately following skin closure. ECG was 
recorded throughout the procedure where ECG electrodes were positioned on both 
forelimbs (positive and negative) and the right hind limb (reference lead) and 
monitored by Power lab coupled to chart 7.0. Temperature was monitored by a rectal 
thermoprobe and was maintained at 37oC ± 0.5. Surgical depth of anaesthesia was 
assessed before initiating and throughout the procedure and was confirmed by loss of 
pedal reflex to toe-pinch stimulus. In addition breathing rate was observed as an 
important indication of anaesthetic depth; where slow shallow and deep gasping 
breath were suggestive of over dosing of anaesthesia. Artificial ventilation was 
provided throughout the main surgical procedure by means of a MiniVent mouse 
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ventilator (HSE-HA MiniVent Mouse Ventilator # 730027 Harvard Apparatus, 
March-Hugstetten, Germany) (Fig. 2.9) 
2.8.1 Anaesthesia: Mice were anaesthetised with isoflurane vaporised in oxygen. 
Induction of anaesthesia was in a gas chamber supplied with 1.5L/minute and 5% 
isoflurane. Intermediate maintenance of anaesthesia via nose cone (modified 2ml BD 
syringe) was supplied with 1.5L/minute and 2% isoflurane. Long term anaesthesia, via 
the ventilator was supplied with 1.5L/minute and 2% isoflurane and a tidal volume of 
300μl at 120cycles /minute. Rapid intubation was imperative in order to maintain 
surgical anaesthesia during this period of no direct isoflurane administration.  
 
 
 
 
 
 
. 
 
 
2.8.2 Intubation: Mice were placed in the supine position with neck extended using a 
suture hooked around the incisor and secured using adhesive tape. Analgesia was 
provided by buprenorphine (Vetergesic 0.1mg/kg intra muscular) at the start of the 
procedure to ensure effective analgesia at recovery. A small skin incision of no greater 
Figure 2.9 Surgical set up for in vivo MI model A) Animals were placed on a heated 
operating table connected to constant ECG recording Power lab and rectal temperature 
continually monitored. A high powered surgical microscope was used to aid all surgery. B) 
Mice were intubated and connected to a small animal Mini ventilator supplied with 
isoflurane saturated with oxygen and ventilator exhaust was connected to a scavenger 
system. 
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than 1 cm was made to the neck directly above the visible midline of the underlying 
salivary glands. The skin and sub maxillary glands were gently teased apart and the 
underlying paratracheal blunt to expose the trachea. The ventilation cannula was 
passed through the mouth into the trachea. Successful intubation was confirmed once 
the cannula could be directly visualised inside trachea and further confirmed by 
observing regular chest movements upon ventilation. In the event of unsuccessful 
intubation, the ventilation cannula was removed and further attempts were made. Ideal 
intubation was completed within two attempts with no visible trauma to trachea or 
surrounding tissues. 
2.8.3 Chest opening: For access to the LAD, the mouse was repositioned by crossing 
the left leg over the body (Fig. 2.10 A). A skin incision was made laterally across the 
chest at the approximate position of the 3rd and 4th intercostal space. The major and 
minor pectoral muscles were blunt dissected and reflected outward using hook stays; 
caution was taken to preserve the integrity of pectoral muscles for optimal chest 
closure. The fourth intercostal space was identified by evaluation of lung position- the 
fourth space being the one prior to the curvature of the base of the lung and confirmed 
by the presence of a large branching vessel along the surface of the rib. Dissection was 
performed by creating a small hole using sharp pointed scissors followed by insertion 
of a small animal retractor. Access to the LAD was facilitated by opening of the 
pericardium using blunt tweezers. The LAD is identifiable by its bright red colour and 
occasionally its pulsating appearance, if not in a visible position, it was approximated 
from experience. LAD was under run by 8.0 prolene suture (#W2775 ETHICON), 
ideally 2 mm below the tip of the left atrium (Fig. 2.10 B). The suture was double-
knotted in order to occlude the LAD. Successful MI upon occlusion was confirmed 
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primarily by myocardial colour change from red to pink and ST segment elevation 
Fig. 2.10 B. 
 A                                                                  B 
 
 
 
 
 
The intercostal space was closed using two 5-0 mersilk sutures (#W595 ETHICON). 
Ventilation positive end pressure was applied by submersion of the ventilator outlet 
tube in 2cm of water. This served to re-inflate the lungs and thus helps to improve the 
respiratory function upon recovery. Effective intercostal space closure was confirmed 
by application of tissue adhesive Vet bond to the suture sites. The major and minor 
pectoral muscles were unfolded back to cover the underlying intercostal space and 
skin was closed by 5-0 mersilk sutures. Further doses of vetergesic (0.1mg/kg 
intramuscular) were administered if needed at 6 and 24 hrs following the surgery. 
Upon withdrawal of isoflurane and initiation of independent breathing extubation was 
Figure 2.10 LAD occlusion - mouse positioning and ST elevation. A) Positioning of 
the mouse to expose the LAD: the left leg was crossed over the body to the right so that 
when opened below the armpit between the 3 and 4th intercostal space the LAD is 
exposed. B) LAD occlusion at 2mm below left atrium and lower panel shows normal 
ECG pattern before MI and ST segment elevation after MI visualized on Lab chart 
windows by means of ECG leads tied on the limbs. 
Before occlusion               After occlusion 
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facilitated by gentle removal of ventilation cannula. Supplemental oxygen was 
provided by a nose cone for 5 minutes. Animals commonly regained consciousness 
within 3-5 minutes and mice were expected to be active with in an hour. Animals were 
allowed to recover for two weeks and were subjected to echocardiographic 
measurements (described below). 
2.9 Murine Echocardiography 
Echocardiography is a useful non-invasive tool to visualise cardiovascular structures 
and evaluate cardiac function in mice. It is an extremely versatile method for 
cardiovascular research by allowing the evaluation of left ventricular (LV) systolic, 
diastolic, regional and vascular function in mouse cardiomyopathy models (Asai et al. 
1999;Iwase, Bishop, Uechi, Vatner, Shannon, Kudej, Wight, Wagner, Ishikawa, 
Homcy, & Vatner 1996;Iwase, Uechi, Vatner, Asai, Shannon, Kudej, Wagner, Wight, 
Patrick, Ishikawa, Homcy, & Vatner 1997), myocardial ischemia models (Odashima 
et al. 2007) and chronic pressure overload induced by transverse aortic constriction 
(TAC) models (Depre et al. 2006;Gelpi et al. 2009). Classic methods of evaluating 
ventricular function by means of ventricular catheterization (Lorenz and Robbins 
1997), nuclear imaging using positron emission tomography (PET) (Inubushi et al. 
2004) and magnetic resonance imaging (Chin et al. 2007;Voelkl et al. 2011) require 
instrumentation and microsurgical techniques and are difficult to perform more than 
once in the same animal. Also ultrasound imaging provides a fast and inexpensive 
alternative to all the instrumentation described above when performing longitudinal 
follow-up studies of cardiac remodelling. 
Echocardiography was performed using a Vevo 770 ultrasound system (Visualsonics, 
Toronto, Canada) equipped with a real-time micro-visualization scan probe head 
(RMV-707B) working at a frame rate of 100 frames per second. The transducer used 
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has a central frequency of 30MHz, focal length of 12.7mm and 55um of nominal 
spatial resolution. The Vevo 770 is equipped with ECG gated kilohertz visualisation 
software (EKVTM) which synthesises high temporal resolution B-mode images by 
combining several ECG synchronised heart cycles. The EKV image reconstruction 
software produced B-mode sequences at up to 1000 frames per second (Benavides-
Vallve et al. 2012). 
2.9.1 Animal preparation 
Mice were anesthetized with isoflurane, at a concentration of 4% (induction) and 1.5% 
(maintenance) in 100% oxygen. Each animal was placed on a heating table in a supine 
position with the extremities tied to the table through surgical tape (TransporeTM). The 
hair from the chest was removed using a chemical hair remover (Veet hair removal gel 
cream). Warmed ultrasound gel (Aquagel lubricating Gel from Parker Labs, New 
Jersey) was applied to the thorax surface to optimize the visibility of the cardiac 
chambers. Temperature was monitored by rectal thermoprobe and was maintained at 
37oC ± 0.5 by adjusting the temperature on the heating table. Surgical depth of 
anaesthesia was assessed before initiating and throughout the procedure and was 
confirmed by loss of pedal reflex to toe-pinch stimulus. The heart rate (HR) of the 
animals was carefully monitored and the isoflurane levels during the 
echocardiographic study as this have an effect on the echo measurements. By placing 
the transducer along the long-axis of the LV, and directing it to the right side of the 
neck of the mouse, two-dimensional LV long-axis is obtained. Then the transducer is 
rotated clockwise by 90° perpendicular to IVS (interventricular septum), and the LV 
short-axis view is visualized (Fig. 2.11 A). 2D-guided LV M-mode at the papillary 
muscle level is recorded from either the short-axis view and/or the long-axis view 
view at the level of papillary muscles (Fig. 2.11 B and C). 
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2.9.2 Measurements 
Measurements were done 3 times - before the start of the study, after tamoxifen 
injection and then after MI. Measurements were made using the leading edge to 
leading edge method according to the guidelines and standards of the American 
Society of Echocardiography (Sahn et al. 1978). LV function can be assessed both 
structurally and functionally. Structurally by means of measuring LV chamber 
dimensions and functionally by means of calculations based on these measurements. 
To accomplish this measurement, wall thickness and chamber dimension are 
determined from M-mode tracings Fig. 2.12. LV wall thickness is evaluated in the 
interventricular septum (IVS) and the posterior wall (LVPW). End-diastolic 
measurements (Interventricular septal thickness diastolic (IVSd), left ventricular 
posterior wall thickness diastolic (LVPWd) and left ventricular internal dimension 
diastolic (LVIDd) are obtained at the point of maximal LV diastolic dimension. LV 
end-systolic dimensions (IVSs, LVPWs, and LVIDs) are obtained at the time of most 
anterior systolic excursion of the LVPW associated with minimal chamber dimension. 
All LV dimensions are presented as the average of measurements using the leading-
edge technique of 3 to 5 consecutive selected sinus beats. 
LV 
LV 
A B C 
Figure 2.11 Diagrams for basic mouse echocardiographic views. A) Position and direction 
of the probe for LV long axis and LV short axis. B) LV long axis view (Parasternal Long axis 
view) and C) LV short axis view (parasternal short axis view). 
Papillary 
muscles 
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The most common parameters used to evaluate the systolic function of the LV are the 
fractional shortening (FS%), ejection fraction (EF%) and cardiac output (CO) 
(Rottman et al. 2007). In the absence of regional wall motion abnormalities, FS% and 
EF% are predictably related. In mice however, the extent of the typical cavity 
obliteration and the associated error introduced in the volumetric measurements is far 
greater than in humans. Consequently, the use of FS% is more appropriate (Rottman, 
Ni, & Brown 2007) The FS% and EF% are routinely calculated using the Teichholz 
method, (Teichholz et al. 1974) which assumes that the left ventricular cavity can be 
represented as a 3D ellipsoid of revolution. However, this might not be a reasonable 
assumption when the LV adopts the complex shapes caused by regional wall motion 
abnormalities that are common after MI. Therefore, an alternative approach to 
calculating EF% exists, based on the shape independent Simpson's rule (Gao et al. 
2000;Ino et al. 1989;Kanno et al. 2002) where the LV endocardial border is traced in 
multiple slices both in systole and diastole, and the volumes are computed from these 
tracings. Using the above method, the LV function can also be measured as the 
Figure 2.12 Wall dimension measurements on M-mode echocardiography. 
Echocardiographic measurements for determination of left ventricular function from M-
mode measurements obtained with conscious transthoracic echocardiography in mice. 
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percentage of change in left ventricular cross-sectional area between diastole and 
systole (fractional area change, FAC%), which has been found to correlate well with 
EF% both in normal and abnormal subjects (Domanski et al. 1992). The standard 
method to estimate FAC% uses cross-sectional area short-axis views at different 
ventricular levels. FS% and EF% and FAC% are then calculated from M-mode-
derived LV dimensions using the formula below (Gardin et al. 1995;Pollick et al. 
1995;Syed et al. 2005;Tanaka et al. 1996). 
EF%=100x[(LVIDd3-LVIDs3)/LVIDd3] 
FS%=100x[(LVIDd-LVIDs)/LVIDd] 
FAC%= 100x(Endo aread-Endo areas)/Endo aread 
LV mass=1.05[(IVSd+LVIDd+PWD)3-LVIDd3] 
2.10 Tissue processing and TTC staining 
After MI studies the heart was excised, washed in cold PBS, frozen at -80 for 10 min,  
the atria were removed, and the heart was sectioned into five to six transverse slices 
from the apex to the base by placing in a mold in the shape of the heart. The slices 
were arranged on a tissue culture dish in the order from apex to base. The slices were 
then incubated with 2ml of 1% 2,3,5-triphenyltetrasodium chloride (TTC #T8877 
Sigma) in PBS for 30 min at 37°C, fixed in 4% formalin for 24 h, washed with PBS 
and scanned. TTC stains viable myocardium brick red as it is reduced by NADH, 
whereas necrotic myocardium appears pale yellow (Basalay et al. 2012). The infarcted 
area was determined by computerized planimetry using Image J software, where the 
infarcted area and total area are assessed and the infarct size is expressed as a % of 
total area.  
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2.11 Statistical Analysis 
Data are reported as mean ± S.E.M. Statistical significance of multiple treatments was 
determined by 1-way or 2-way ANOVA followed by non-parametric Kruskal-Wallis 
and Dunn’s post-hoc analysis. Non-parametric tests were used as the data was 
assumed not to follow a Gaussian distribution. Statistical significance between 2 
groups was determined by 2-tailed Student’s t tests, as appropriate. In all instances, 
P<0.05 was considered significant. Statistical analysis was carried out using the 
commercially available software, Prism version 4.0 (Graph Pad software, San Diego, 
California; www.graphpad.com). 
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Chapter 3 
RESULTS I 
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3.1 In vivo cardiac modulation in RGS-insensitive Go knock-in mice (RGSiGαo) 
and RGS-insensitive Gαi2 knock-in mice (RGSiGαi2)  
Activation of the GIRK channels by βγ subunits released from Gαi contributes 
approximately 50% of the in vivo bradycardic response to vagal stimulation (Fu, 
Huang, Zhong, Mortensen, D'Alecy, & Neubig 2006). The strength and duration of G- 
protein signalling is attenuated by RGS proteins acting as GAPs for Gα subunits but 
the relative contribution of different Gα subunits to in vivo cardiac automaticity is 
poorly defined. RGS proteins are functionally redundant, which makes single KO of 
limited value or will underestimate the overall role RGS protein function in vivo. 
Another difficulty in unravelling the function of RGS proteins has been the complex 
interactions of the many subtypes of both G-proteins and RGS proteins. It was 
proposed recently that RGS proteins represent potential new therapeutic targets for 
cardiovascular diseases (Riddle, Schwartzman, Bond, & Insel 2005). However, it has 
been difficult to ascertain the full physiological role of endogenous RGS proteins in 
vivo in part because of their functional redundancy (Lan, Sarvazyan, Taussig, 
Mackenzie, DiBello, Dohlman, & Neubig 1998).  
To determine the full contribution of RGS proteins as a group to biological responses 
mediated by a particular G-protein (e.g. Go and Gi), we took advantage of a Gα-
subunit point mutation first found in the yeast Saccharomyces cerevisiae (DiBello et 
al. 1998) that prevents RGS binding to the Gα subunit and GAP activity. These RGS-
insensitive (RGSi) mutant Gα subunits, which contain a G184S point mutation in their 
switch I region prevents binding of RGS proteins and subsequent Gα deactivation. 
The analogous mutation (Gly184 to Ser) in mammalian Gαo and Gαi1 prevented the 
GAP activity of RGS4 and RGS7 and blocked RGS4 binding to aluminium fluoride-
activated Gα subunits (Lan, Sarvazyan, Taussig, Mackenzie, DiBello, Dohlman, & 
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Neubig 1998). These mutations do not affect other functions of the Gα subunit, such 
as the intrinsic GTPase activity of the G-protein or its coupling to βγ subunits, 
receptor and downstream effectors (Day et al. 2004;Fu, Zhong, Nanamori, Mortensen, 
Huang, Lan, & Neubig 2004). Thus, the only known effect of the G184S mutation in 
Gαo and Gαi2 is to prevent RGS action on Gα. Several publications using 
overexpression of these RGS-insensitive Gα subunits revealed profound slowing of 
the channel response kinetics and/or increased potency of agonist responses in 
neurons (Chen and Lambert 2000;Clark et al. 2003;Jeong and Ikeda 2000). In this 
chapter, I have studied the heterozygotes of RGSiGi2 and RGSiGo knock-in mice as 
the homozygotes were not viable. The effects on the in-vivo regulation have not been 
previously described and whether these mice are predisposed to spontaneous 
arrhythmia such as atrial fibrillation is unknown. 
3.2 RGSiGαo and RGSiGαi2 mice lost diurnal variation in heart rate  
RGS-insensitive knock-in mice of Gi2 and Go (RGSiGi2 and RGSiGo) had a 
phenotype slightly different from control. These mice exhibited normal growth, but 
were hyperactive and exhibited day time tachycardia and were fertile. Homozygotes 
couldn’t survive due to neonatal/embryonic lethality.  
Using ambulatory telemetry studies we found that RGSiGαo and RGSiGαi2 both 
exhibited high heart rate during both night and day (RGSiGαo day 601 bpm ± 28.8, 
*P<0.05, night 617 bpm ± 30.7, n=8, RGSiGαi2 day 612 bpm ± 33.9, *P<0.05, night 
615 bpm ± 15.8, n=8, WT controls day 430 bpm ± 39.2, night 535 bpm ± 46.8, n=8)  
showing that they have lost their normal diurnal variation in the heart rate as seen in 
Fig. 3.1. The night time heart rate was also found to be higher in both RGSiGαo and 
RGSiGαi2 though not significantly different when compared with the littermate 
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control night time heart rate. The effects of autonomic tone on HR are complex. 
Ambient temperature and levels of physical activity modulate sympathovagal balance. 
Specifically, it is possible for mice to have high vagal tone under some conditions like 
exercise training and temperatures of thermoneutrality ~30°C (De, Wichi, Jesus, 
Moreira, Morris, Krieger, & Irigoyen 2004;Just et al. 2000;Swoap et al. 2008). These 
animals were found to be hyperactive (data not shown, visual observation) and a high 
heart rate in them may reflect a high sympathetic tone. Recent studies with 
homozygous RGSiGαi2 knock-in mice also showed increased heart rate during day 
time and increased contractility on echocardiography reflecting a high sympathetic 
tone (Huang, Fu, Charbeneau, Saunders, Taylor, Hankenson, Russell, D'Alecy, & 
Neubig 2006). Enhanced tachycardia in RGSiGαi2 mice was not expected, since Gi 
mediates GIRK activation, which slows heart rates. The increased heart rate is likely 
due to central nervous system effects. 
 
 
 
 
 
 
 
 Figure 3.1 Loss of diurnal heart rate response in RGSiGαo and RGSiGαi2 mice. 
RGSiGαo and RGSiGαi2 lost their diurnal variation in heart rate compared with littermate 
wild type controls on the same genetic background (n=8, *P<0.05). Diurnal variation 
between day and night was well preserved in wild type controls.  
day night
* 
* 
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3.3 ECG analysis reveals shorter R-R intervals in RGSiGαo and RGSiGαi2 mice 
compared to control  
ECG traces measured in RGSiGαo and RGSiGαi2 mice using chart 7.0 software shows 
that R-R interval was shorter as would be expected given the higher mean heart rate in 
RGSiGαo and RGSiGαi2 mice compared to their littermate controls (Fig.3.1). 
Measurements were taken over a 20 minute recording time at rest during the day. In 
both RGSiGαo and RGSiGαi2 knock-in mice, RGS is unable to bind to Gαi and Gαo to 
bring it back to its GDP bound inactive form, as a result it is constitutively expressed 
so one would expect bradycardia from these mice, however I found that both set of 
knock-in mice lost their diurnal variation (above Fig.3.1) with an increase in heart 
rate, which is also reflected clearly in the R-R interval measurements (Fig.3.2). 
RGSiGαo had R-R interval of 104.4 ms ± 7.2, n=8 *P <0.05 and RGSiGαi2 101.8 ms ± 
7.4, n=8 *P<0.05 while control had R-R interval of 114.9 ms ± 15.9, n=8 (Table 3.1). 
Other ECG parameters like the PR interval and QRS duration didn’t show any 
significant difference between the 2 knock-in groups and control mice. I did not 
observe any episodes of spontaneous arrhythmia. 
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Figure 3.2 Representative ECG traces from RGSiGαo and RGSiGαi2 mice .RGSiGαo 
and RGSiGαi2 mice (upper panel) shows shorter R-R intervals compared to their control 
mice (lower panel). 
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3.4 HRV analysis reveals loss of HRV in RGSiGαo but no change in RGSiGαi2 
mice compared to control  
HRV analysis in the time and frequency-domain reveals differences in heart rate, LF 
and HF domain in RGSiGαo and RGSiGαi2 when compared with the controls. More 
specifically heart rate was found to be higher in both knock-in groups (RGSiGαo 600 
bpm ± 41.1, n=8 *P<0.05 and RGSiGαi2 598 bpm ± 62.2, n=8 *P<0.05) compared to 
controls (545 bpm ± 38.9, n=8). SDNN -standard deviation of mean NN intervals - 
that correlates very well with LF component of HRV was found to be similar in 
RGSiGαo, RGSiGαi2 and control mice (Table 3.1). RMSSD (root mean square of 
successive NN intervals) is a measure of parasympathetic activity and represents 
vagal-mediated cardiac control that correlates well with the HF domain of the 
RGSiGo RGSiGi2 Control
n=8 n=8 n=8
RR (ms) 104.4±7.2* 101.8±7.4* 114.9±15.9
PR (ms) 35.95±2.9 35.19± 5.4 35.82±5.6
ECG QRS (ms) 9.86±1.5 9.34±0.93 9.40±1.45
QTc (ms) 62.3±9.7 54.2±8.3 54.75±8.16
HR (bpm) 600±41.4* 598±62.2* 545.8±38.9
SDNN 5.51±3.2 4.02±1.5 3.72±1.0
HRV RMSSD 6.8±2.1 9.8±3.2 5.9±2.8
LFnu 63.1±8.7* 50.3±11.2 55.3±9.7
HFnu 31.89±3.9* 38.7±7.7 42.4±8.6
 
Table 3.1 ECG and HRV parameters in conscious ambulatory telemetered RGSiGαo 
and RGSiGαi2 mice. Table shows shorter R-R intervals in RGSiGαo and RGSiGαi2 mice 
compared to their controls. No difference in rest of the ECG parameters. Heart rate was 
found to be higher in both RGSiGαo and RGSiGαi2. LFnu was higher and HFnu was 
lower in RGSiGαo compared to controls. All observations are mean  S.E.M and are 
compared against control, HR - heart rate, SDNN is standard deviation of normalized RR 
interval, LFnu is normalized LF frequency, HFnu is normalized HF frequency and 
*P<0.05). 
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frequency of HRV was found to be unaltered. LF frequency which is driven by both 
the sympathetic and the parasympathetic systems was found to be higher in RGSiGαo 
(63.1 nu ± 8.7, n=8 *P<0.05) compared to RGSiGαi2 (50.3 nu ± 11.2, n=8) and the 
control group (55.3 nu ± 9.7, n=8). Interestingly in the same group RGSiGαo the HF 
component of the HRV signature was found to be lower (31.89 nu ± 3.9, n=8 
*P<0.05) compared to RGSiGαi2 (38.7 nu ± 7.7, n=8) and control group (42.4 nu ± 
8.6, n=8) (Fig. 3.3 and Table 3.1). The selective loss of HF power of HRV was also 
observed with the global KOs of Gi2  mice in our lab (Zuberi, Birnbaumer, & Tinker 
2008) which show an impairment of the parasympathetic activity as Gi2 plays a 
major role in parasympathetic modulation of the heart rate. In my study, I couldn’t see 
any difference in the HF component of HRV in RGSiGαi2 mice although an improved 
HF signal was expected.  
 
 
 Figure 3.3 HRV signatures in RGSiGαo and RGSiGαi2 mice.  Loss of HRV in RGSiGαo  
mice (n=8) with an increase in LF power (*P<0.05) and a loss of HF power (*P<0.05) 
compared with WT (n=8) littermate controls. While the LF and HF power was more or less 
the same in RGSiGαi2 (n=8). 
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Power spectral analysis of the LF and HF signature of HRV in RGSiGαo and 
RGSiGαi2 also showed a similar picture as shown in Fig. 3.4. Power spectral density 
plots shows spectral peaks in both the LF and HF range for the control group, for 
RGSiGαo there is an increase in LF and loss of HF and in RGSiGαi2 LF and HF were 
well preserved. RGSiGo showed a HRV phenotype different from that of control. No 
arrhythmias were seen on the ECG traces of both RGSiGαo and RGSiGαi2 knock-in 
mice. Gαo is the mainly expressed in the brain and central nervous system so the 
effects we observed with these knock-in mice suggest a central effect. 
 
 
 
 
 
 
Figure 3.4 Representative PSD from RGSiGαo and RGSiGαi2 mice. PSDs showing a 
loss of HF and increase in LF in RGSiGαo (upper left panel) and preserved LF and HF 
power in RGSiGαi2 (upper right panel) while control shows good spectral peaks for LF and 
HF (lower panel).  
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3.5 Enhanced bradycardic response to carbachol (M2 receptor agonist) with 
RGSiGαo and RGSiGαi2 mice 
Carbachol, an M2R agonist slows down the heart rate in wild type mice. My results 
showed an enhanced bradycardic response in both RGSiGαo (34 ± 3%, n=8 *P<0.05) 
and RGSiGαi2 (39 ± 2%, n=8 **P<0.01) compared to wild type (14 ± 2.5%, n=8), and 
the inhibition with carbachol was more with RGSiGαi2 (Fig. 3.5), probably due to the 
fact that Gαi2 is the predominant cardiac isoform. This reveals that the loss of RGS 
regulation on both Gαi2 and Gαo due to mutation, leads to an enhanced bradycardic 
action of carbachol. Both Gαi2 and Gαo were able to elicit M2R mediated bradycardic 
response. No specific types of conduction block or arrhythmias were observed in these 
groups treated with carbachol. Similarly, studies with embryonic stem cell-derived 
cardiomyocytes of RGSiGαo and RGSiGαi2 showed enhanced muscarinic bradycardic 
responses when challenged with the M2R agonist, carbachol (Fu, Huang, Zhong, 
Mortensen, D'Alecy, & Neubig 2006). Dramatic sensitivity to M2 receptor activation 
suggests that Gi2 appears to be a critical link between the M2R and GIRK channels in 
mediating vagal responses. 
3.6 A1 receptor agonist (CCPA) showed increased inhibition with RGSiGαo mice 
but not with RGSiGαi2 mice 
It has been reported previously that in animals and ES-cell derived cardiomyocytes, 
Gαi2 signalling due to loss of RGS regulation preferentially amplifies M2R mediated 
responses, but not of A1R (Fu, Huang, Zhong, Mortensen, D'Alecy, & Neubig 
2006;Fu, Huang, Piao, Lopatin, & Neubig 2007) . In vivo telemetry studies with 
RGSiGαo and RGSiGαi2 further confirm these findings (Fig. 3.5) but A1R mediated 
inhibitory response is higher in RGSiGαo (42 ± 4%, n=8 **P<0.01) compared to 
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RGSiGαi2 (19 ± 3%, n=8 *P<0.05). Interestingly RGSiGαi2 appears to play a lesser 
role in the adenosine receptor-mediated bradycardic response as the inhibitory 
response was even lower than wild type (30 ± 3%, n=8). Thus loss of RGS control on 
Gαo enhanced bradycardic response to A1R and confirms the specificity of Gαo for 
A1R.  
 
             Carbachol (M2R)                                                              CCPA (A1R) 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Inhibition of heart rate by M2R and A1R on RGSiGαo and RGSiGαi2 mice. % 
inhibition on heart rate was found to be significantly higher in both RGSiGαo (n=8) and 
RGSiGαi2 (n=8) with the M2R agonist, carbachol compared to WT (n=8) (Gαo*P<0.05, Gαi2 
**P<0.01). Effect of the A1R agonist, CCPA was specific towards Gαo (**P<0.01) as seen by 
its inhibition on heart rate, rather inhibition on Gαi2 was even less than that of WT (*P<0.05). 
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Discussion 
3.7 RGSiGαi2 and RGSiGαo mice showed enhanced resting tachycardia and 
bradycardic responses with agonists 
Interestingly, RGSiGαi2 and RGSiGαo were found to be tachycardic and lost their 
diurnal variation in heart rhythm and this suggest a role of the central nervous system 
in controlling the heart rate in these knock-ins and the results were counterintuitive. 
Studies by Huang et al. on RGSiGi2 also found they were tachycardic along with 
growth retardation, reduced viability, smaller size and multiple neurologic defects 
pointing to the fact that cardiovascular phenotypes were an outcome of increased 
central sympathetic tone (Huang, Fu, Charbeneau, Saunders, Taylor, Hankenson, 
Russell, D'Alecy, & Neubig 2006). However, carbachol still has a negative 
chronotropic effect. Gαo is the predominant isoform in the brain and expressed at 
higher levels than other inhibitory G-proteins in neuronal tissue (Wettschureck & 
Offermanns 2005) and Go may in some way regulate central control of autonomic 
tone. But a small amount of Go is also expressed in cardiac tissues and is found to 
play an important role in the regulation of automaticity and contractility of the heart 
by regulation of ICa, L (Ye et al. 1999). On the other hand, Gαi2 is also expressed in 
neuronal tissues but global deletion of Gαi2, did not have a gross neurological 
phenotype (Zuberi, Birnbaumer, & Tinker 2008). Owing to its significance in the 
central nervous system, it is possible that a defect in the central nervous system in Gαo 
or Gαi2 signalling, could potentially affect regulation of HRV. It is also worthy to 
postulate the influence of  such central effects on the phenotype with inactivation  of 
other inhibitory G-proteins, and these questions will only be definitively answered by 
tissue-specific  gene-targeting approaches. In in vivo models there is a possibility of 
142 
 
developing various developmental adaptive measures to balance out the effects of the 
absence of one gene by another to rescue the pathways. Nevertheless, there were 
practical problems working with these mice, as breeding was difficult.  
It has also been previously reported that in intact animals and in embryonic stem cell 
derived cardiomyocytes augmented Gαi2 signalling due to the loss of RGS regulation 
preferentially amplifies M2 receptor-mediated responses (Fu, Huang, Zhong, 
Mortensen, D'Alecy, & Neubig 2006). As observed in our studies an enhanced 
bradycardic response to carbachol in both RGSiGαi2 and RGSiGαo may be due to 
enhanced GIRK channel activation though this wasn’t formally tested. These data 
suggest a role of RGS in regulating muscarinic receptor-mediated Gαo and Gαi2 
bradycardic responses and the loss of RGS inhibition could enhance Gαo and Gαi2 
signalling in cardiac tissue and most probably in the SA node. This observation needs 
to be further confirmed by looking at various ion channels by patch clamping 
techniques.  Moreover, cardiac overexpression of Gαs leads to tachycardia (Uechi, 
Asai, Osaka, Smith, Sato, Wagner, Ishikawa, Hayakawa, Vatner, Shannon, Homcy, & 
Vatner 1998), so one would expect that enhanced Gαi function via these knock-ins 
should have the opposite effect. Thus, these observations of the increased heart rate 
and the observed hyperactivity (not recorded, visual observations) are likely due to 
central nervous system effects rather than effects on cardiac function.  
Studies on embryonic stem cell-derived cardiomyocytes demonstrated that enhanced 
bradycardia in RGSiGαi2 cardiomyocytes is primarily due to increased GIRK currents 
upon M2R activation. The response to carbachol was also studied ex-vivo and led to 
increased AV conduction block (Fu, Huang, Zhong, Mortensen, D'Alecy, & Neubig 
2006). We didn’t observe any arrhythmias with RGSiGαi2 and RGSiGαo mice. GIRK 
currents are involved in the parasympathetic control of heart rate and have been 
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implicated in the development of atrial fibrillation (AF). Studies have suggested 
abnormal activation of GIRK currents is associated with AF (Fu, Huang, Piao, 
Lopatin, & Neubig 2007). GIRK currents are constitutively active in the heart of 
chronic AF patients (Dobrev et al. 2005). Since GIRK currents are preferentially 
activated upon by M2 receptor-mediated signalling (vagal stimulation), when the 
effects of RGS proteins on Gαi2 are inhibited, it is possible that RGSiGαi2 mutant mice 
may have increased risk of AF as well. Hence further characterization of RGSiGαi2 
and RGSiGαo mice may be justified to explore this question using in vivo 
electrophysiological studies such as cardiac pacing to see whether they are prone to 
atrial fibrillation and AV conduction block.  
As the results from the initial screening on RGSiGαi2 and RGSiGαo knock-ins using 
telemetry (HRV and ECG) were unexpected and inconclusive, I screened another 
group of mice where Gαi2 and Gαo is knocked down specifically in the heart, and this 
is  discussed in the next chapter. 
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Chapter 4 
RESULTS II 
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4.1 Heart rate modulation in cardiac-specific deletion of Gi2 and Go with 
αMHC cre 
Various attempts have been made to address the identity of the molecular players in 
vagal-mediated heart rate slowing. It is generally agreed that the M2 muscarinic 
receptor is the major isoform responsible for vagally-mediated bradycardia in 
conduction tissues, and this is supported by studies on mice with global genetic 
deletion of the gene encoding for this protein (Fisher et al. 2004). However, the 
identity of the inhibitory Gα isoform(s) involved in heart rate slowing in vivo remains 
unclear. It is known that Gαi1, Gαi2 and Gαi3 isoforms are widely expressed and Gαi2 is 
the predominant cardiac isoform (DeGeorge & Koch 2008;Gohla, Klement, Piekorz, 
Pexa, vom, Spicher, Dreval, Haussinger, Birnbaumer, & Nurnberg 2007). Using ES 
cell-derived cardiomyocytes with targeted inactivation of specific G-protein α 
subunits, it has been shown that expression of both αi2 and αi3 is required for 
muscarinic and adenosine receptor-mediated regulation of IKAch in intact cells (Sowell, 
Ye, Ricupero, Hansen, Quinn, Vassilev, & Mortensen 1997). Another study showed 
that Gαi3 when expressed in heterologous expression systems (Xenopus Oocytes) 
seems to couple GIRK channel activation particularly efficaciously (Ivanina et al. 
2004) and lastly, murine Gαo deletion has been reported to selectively impair 
parasympathetic responses (Duan, Christe, Milstone, & Mortensen 2007). With 
regards to cardiac pacemaking function, the identity of the inhibitory Gα-subunit 
protein(s) involved in modulating parasympathetic control of intrinsic cardiac 
automaticity remains undetermined. Previous findings from our lab concluded that 
Gi2 had a major role in heart rate dynamics as there was a selective defect of 
parasympathetic heart rate modulation in mice with Gi2  deletion Table 4.1 (Zuberi, 
Birnbaumer, & Tinker 2008). 
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There were several disadvantages of working with mice with global genetic deletion 
of Gαi2 (-/-) and Gαo (-/-); 
1. The effect seen may be due to deletion in the central and peripheral 
nervous system as Gαi2 and Gαo was globally deleted in all tissues.  
 
2. With Gαi2 (-/-) growth retardation was observed, very few litters 
were produced and occasional unexpected death was seen. 
Gαi2 Gαo 
Tachycardic  Tachycardic (both day and night) and loss 
of diurnal variation in heart rate. 
Selective attenuation of the HF domain of 
HRV which corresponds to 
parasympathetic drive 
Loss of the LF component of HRV 
HRV signature is similar to mice treated 
with tertiapin Q and atropine 
HRV signature is different from mice 
treated with tertiapin Q and atropine. 
Negative chronotropic effect of carbachol 
is abolished 
Carbachol had negative chronotropic 
effect 
They had prolonged QT interval making 
them more susceptible to ventricular 
arrhythmia 
Being expressed, high levels in neuronal 
tissue, HRV signature is similar to those 
seen in patients with brain stem death 
An increase in L-type Ca channel activity 
and an increase in ventricular action 
potential duration shown by patch- 
clamping studies on isolated ventricular 
myocytes. 
 
Table 4.1 Comparison of the effects of global KOs of Gαi2 and Gαo on heart rate 
dynamics. Work carried out in our lab showing the differences between global KOs 
of Gαi2 and Gαo (Zuberi et al. 2008). 
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3. With Gαo (-/-) survival rate was poor, they showed more of a 
neurological phenotype, seizures were observed and they didn’t 
survive beyond 2 months.  
From the Go studies we hypothesised given the phenotype of global Go deletion 
(tachycardia, loss of diurnal heart rate variation and LF power attenuation) that Go 
may play an important role in central (brainstem) modulation of HRV and Gαi2 may 
be of interest in the cardiac context. Global deletion may have important systemic 
effects which could add confusion to the interpretation of data. To overcome this 
problem targeted organ (cardiac) specific deletion, using cre lox-P technology which 
deletes Gαi2 and Go specifically in the cardiac tissue, has been used in my 
experiments. Hence, I moved to using conditional genetic deletion of Gαi2 and Go in 
cardiac tissue using αMHC cre recombinase. 
4.2 Cardiac specific-deletion of Gi2 and Go with αMHC cre    
Given the practical problems of working with global Gi2 (-/-) and Go (-/-) mice, a 
conditional KO mouse line was generated with cardiac-specific Gi2 and Go 
deletion, using an MHC cre mouse crossed with Gi2/Go floxed mice. In order to 
determine if Gi2 and Go-mediated signalling directly influences HRV at the level of 
the heart (rather than centrally), the HRV signature was determined against an 
appropriate control group. It is important to note that these mice were of a mixed 
background strain (combined C57/black and Sv129 cross) which may influence 
interpretation.  
Conditional Gi2 and Go-deleted mice (Goflx/flx cre
+ and Gi2flx/flx cre
+) had a 
phenotype similar to control. These mice exhibited normal growth, normal behaviour 
and were fertile. Proof of cardiac specific-deletion at a molecular level (shown in Fig. 
148 
 
4.1), confirmed a substantial decrease in mRNA expression for Gi2 (16 fold) and Go 
(6 fold) using real-time PCR (RT-PCR) (Zuberi et al. 2010). At the genomic level 
deletion is shown and discussed in materials and methods (Fig. 2.3). 
                                                                                                                                                                                                                                                          
 
 
 
4.3 Preservation of diurnal variation in heart rate in Gi2 flx/flx cre
+ and Go  
flx/flx cre+ mice 
Using telemetry recordings in conscious mice no significant differences in mean heart 
rate were observed both at night and during the day with respect to the cardiac-
specific inhibitory Gi2 and Go subunit isoform. Mice are largely active at night and 
sleep during the day and their increased nocturnal heart rate reflects this. There wasn’t 
Figure 4.1 RT-PCR showing deletion of Gi2 and Go in the cardiac tissue. Relative 
expression of Gi2 and Go with respect to WT as a calibrator (=1).Taqman probe directed to 
deleted exons of 2-3 of Gi2 shows a significant reduction in expression (
**P<0.01) and 
probe directed to deleted 5-6 of Go also shows a significant reduction (
*P<0.05) in 
expression. GAPDH was used as the house keeping gene. 
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a significant difference in the heart rate between Gi2 flx/flx cre
+
 and Go flx/flx cre
+  
compared to control during the night (Gi2 flx/flx cre
+ 519 bpm ± 50, n=6, Go flx/flx 
cre+  485 bpm ± 37.6, n=6, and control 530.5 bpm ± 28.3, n=8, P>0.05) and day time 
(Gi2 flx/flx cre
+ 455 bpm ± 50, n=6, Go flx/flx cre
+ 456 bpm ± 37.6, n=6 and 
control 479 bpm ± 28.3, n=8, P>0.05) heart rate was compared (Fig. 4.2). All of the 
groups maintained a diurnal variation in the heart rate with a higher night heart rate 
compared to day time, even though it was not statistically significant. 
 
 
 
 
 
4.4 HRV in mice with cardiac-specific Gi2  and Go deletion with αMHC cre is 
similar to control 
Mice with cardiac specific Go deletion (Goflx/flx cre
+) and Gi2 deletion 
(Gi2flx/flx cre
+) have a HRV phenotype which is very similar to control, in both the 
time and frequency-domains (See Table 4.2). Specifically in the frequency-domain 
normalized HF power (HFnu) appears to be preserved in Gi2 flx/flx cre
+ mice (35.6 
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Figure 4.2 Preservation of diurnal variation in the heart rate in Gi2 flx/flx cre
+, Go 
flx/flx cre+ and WT littermate controls. No difference was seen in diurnal variation 
between Gi2 flx/flx cre
+ (n=6) Go flx/flx cre
+ mice (n=6) compared with their litter mate 
controls (n=8) (P>0.05). 
Gi2 flx/flx cre
+  Go flx/flx cre
+   control 
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ms2 ± 6.31, n=6) and Go flx/flx cre
+ mice (43.7 ms2 ± 10.3, n=6) compared with 
littermate controls (38.20 ms2 ± 8.8, n=6, ns). Normalized LF power (LFnu) was also 
seen to be similar in Gi2 flx/flx cre
+ mice (61.9ms2 ± 6.17, n=6) and Go flx/flx cre
+ 
mice (50.1ms2 ± 13.7, n=6) compared with control (60.0ms2 ± 8.23, n=6, ns).  
Deletion of specific inhibitory Gi2 and Go subunits exhibited similar HRV 
characteristics that were not significantly different from wild type controls under basal 
conditions in the time-domain as well (Fig. 4.3 and Table 4.2). Tachogram tracings 
and measurements in the time-domain in Gi2 flx/flx cre
+ and Go flx/flx cre
+ mice 
show no R-R variability compared with controls (Fig. 4.3 and Table 4.2). Gi2 flx/flx 
cre+ and Go flx/flx cre
+ mice showed no significant R-R variability under basal 
conditions compared with controls. 
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Power spectral analysis of LF and HF of Gαi2 flx/flx cre
+ and Gαoflx/flx cre
+ also 
reflects the data above (Fig. 4.4). Power spectral-density plots reveal spectral peaks 
within both the LF and HF range for all Gi2 flx/flx cre
+, Go flx/flx cre
+ mice and 
control mice and no significant difference was found between the groups. It is possible 
that outbreeding of these mice results in a more physiological genotype facilitating 
larger degrees of HRV than observed in the inbred Sv129 strain and emphasizes that 
even within mice strains, significant differences in HRV signature can occur. 
Figure 4.3 HRV in Gαi2 flx/flx cre
+ and Gαo flx/flx cre
+ mice presented in the time-
domain recorded from conscious freely moving mice. Representative tracing of 
tachograms from a control, Goflx/flx cre
+ and Gi2flx/flx cre
+ mice over a 10 min 
recording time shows no significant R-R variability among the three groups. 
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On the ECG parameters measured in Gαi2 flx/flx cre
+ and Gαoflx/flx cre
+ using Chart 
7.0 software also showed no significant difference between Gαi2flx/flx cre
+, Gαoflx/flx 
cre+ and their WT littermate controls (Table 4.2). Additionally mean heart rate 
determined over a 20 minute continuous recording showed no significant difference 
between all three groups. 
 
 
 
 
Figure 4.4 HRV in Gαi2 flx/flx cre
+ and Gαo flx/flx cre
+ mice presented in the frequency-
domain recorded from conscious freely moving mice. Representative power spectral plot 
traces of a control, Goflx/flx cre
+ and Gi2flx/flx cre
+ mice over a 10 min recording time. 
Good spectral peaks were observed for both LF and HF in both Gαi2 flx/flx cre
+ and 
Gαoflx/flx cre
+
 mice which were similar to the peaks observed in control mice. 
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Gαi2 flx/flx cre
+  
n=6  
Gαo flx/flx cre
+  
n=4  
control  
n=8  
ECG  
PR(ms)  
QRS(ms)  
 QTc (ms)  
RR(ms)  
36.3±1.78  
10.2±0.68  
65.5±10.2  
116.3±17  
35.6±3.02  
10.6±1.62  
63.5±10.7  
124.8±18  
37.7±1.66  
9.1±0.35  
61.4±9.1  
120.3±14  
HRV 
HR(bpm)  
SDNN  
LFnu  
HFnu  
546±68.9  
10.4±1.98  
61.9±6.17  
35.6±6.31  
551±62  
12.7±4.06  
50.1±13.7  
43.7±10.3  
508±65.4  
10.9±3.12  
60.0±8.23  
38.2±8.8  
Table 4.2 HRV and ECG parameters measured in the time and frequency-domains 
during conscious ambulatory telemetry of Gαi2 flx/flx cre
+, Gαo flx/flx cre
+ and their 
WT littermate controls. All observations are  S.E.M and are compared against control. 
HR (heart rate), SDNN (standard deviation of normalized RR interval), LFnu (normalized 
LF frequency), and HFnu (normalized HF frequency). nHF and nLF are normalised to 
exclude VLF and presented in normalised power units. No significant differences were 
found between Gαi2flx/flx cre
+ mice, Gαoflx/flx cre
+ mice and their WT litter mate 
controls. 
154 
 
Discussion 
4.5 Mice with cardiac specific-deletion of Gi2 and Go with αMHC cre exhibited 
no specific phenotype differences from their littermate controls. 
In contrast to the finding in our lab with global knock-outs (Zuberi, Birnbaumer, & 
Tinker 2008), cardiac-specific deletion of either Gαi2 or Gαo didn’t show any 
difference in the parameters such as, ECG, HRV and diurnal variation in heart rate. 
There could be many reasons for these findings.  
• The phenotype observed in the global knock-outs may be due to an effect from 
deletion in peripheral nervous system and or central nervous system.  
• The cre-mediated deletion of Gαi2 and Go may not be perfect for the entire 
region of heart, specifically it may be poor in SA nodal cells.  
• Other chronic compensation may be possible in these cardiac-specific knock-
outs as a developmental modification and the observations could be adaptive. 
Previous studies in our lab with global knock-outs of Go (-/-) showed LF power 
attenuation, significant increase in heart rate both during the night and day and loss of 
diurnal heart rate rhythm. The observed phenotype is similar to that seen in examples 
of brainstem dysfunction (Baillard et al. 2002) and has features consistent with a 
central role for Go in modulating HRV. Conditional Go-deleted mice (Go flx/flx 
cre+ve) had a phenotype similar to control. Specifically there were no features of a 
gross neurological phenotype as observed with global Go deletion (Zuberi, 
Birnbaumer, & Tinker 2008). These mice exhibited normal growth, normal behaviour 
and were fertile. Selective cardiac Go deletion exhibited normal diurnal heart rate 
fluctuation and preserved HRV phenotype. Proof of the cardiac-specific deletion at a 
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molecular level is shown in chapter 2 by genomic PCR as well as a substantial 
decrease in mRNA expression for Go using real-time pcr (Fig 4.1). One possible 
explanation is that, Go is by far the predominant inhibitory Gα within brain tissue 
and so may in some way regulate central control of autonomic tone. 
Similarly the cardiac-specific deletion of Gαi2 (Gαi2 flx/flx cre
+) showed a phenotype 
that was not the same as observed with the global knock-out of Gαi2 (-/-) in our lab, 
rather there was no difference in these group compared to wild type controls. With 
global knock-outs of Gαi2 (-/-) we did observe increased heart rate, selective 
abolishment of HF domain of HRV and lack of negative chronotropic response to 
carbachol. Gαi2 (-/-) mice also exhibited prolonged QT on telemetry ECG 
measurements and were prone to ventricular arrhythmia to account for the sudden 
death phenotype by in vivo electrophysiological studies. Patch clamp studies 
performed on ventricular myocytes of Gαi2 (-/-) mice also showed prolongation of 
ventricular action potential duration in Gαi2 (-/-) mice and enhanced L-type Ca
2+ 
currents, which further confirms L type Ca2+ channel activity as the mechanism of QT 
interval prolongation (Zuberi, Nobles, Sebastian, Dyson, Lim, Breckenridge, 
Birnbaumer, & Tinker 2010). However with Gαi2 flx/flx cre
+ we didn’t observe any 
such phenotype (such as prolonged QT on the ECG, spontaneous ventricular ectopic 
beats or sudden death) so further characterisation was not carried out. 
I would like to mention here that these mice (Go flx/flx cre
+ and Gαi2 flx/flx cre
+) 
have not been completely characterised at present in terms of expression at the protein 
level due to a lack of suitable and specific antibodies. Additionally, the efficacy of the 
cardiac cre in this setting needs to be formally tested. For example in our experiments 
partial/incomplete cre-mediated Gαi2 and Gαo deletion in the SA node could explain 
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the observed phenotype, as G-protein and GIRK channels and their downstream 
effects are more prominent in the atrial and nodal tissues. Also in the literature, in 
studies where a cross of αMHC cre and a Lac Z reporter strain have reported 
incomplete deletion within the SA node (Herrmann et al. 2007). Therefore, the 
possible explanation for an absence of differences between the floxed cre and control 
mice could be attributed to incomplete deletion in the nodal cells. Also in addition, the 
mosaic nature of the transgene expression, (Guo et al. 2002) line-to-line variations in 
the level of expression, effects of the genomic site of integration and wide differences 
in the copy number of the transgene can all contribute to differences in phenotypic 
expression (Chien 2001).  
Lack of difference in HRV and ECG parameters in cardiac-specific deletion of Gαi2 
and Gαo using αMHC cre mice suggests that, probably one of the reasons for not 
seeing the expected difference is that deletion may not be complete in cardiac 
pacemaker cells. It also throws light on the fact that a ventricular phenotype is not 
enough to see the effect of any cardiovascular change or rather it seems to be some 
mechanism outside the ventricles. Also, Go seems to be more prominent in brain 
tissues than in the heart, as results indicate more of its role in the central nervous 
system. As a result of this, I decided to use Gαs knock-out mice, which should exhibit 
effects opposing to those of Gαi2 in the remainder of my studies and a colleague 
Richard Ang pursued further study of Go mice and its tissue-specific expression in 
brain. Also, I moved on to try another cre mice (conduction system cre HCN4 -KiT) 
which deletes Gαi2 and Gαs in the conduction system upon administration of 
tamoxifen. These mice (with specific deletion of Gαi2 and Gαs in the conduction 
system tissues) were used to assess the effect of deletion of Gαi2 and Gαs on HRV and 
the data is presented and discussed in the next chapter 5.  
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5.1 Heart rate modulation in conduction system-specific deletion of Gi2 and Gs 
with a conduction system cre (HCN4 cre+) 
The HCN4 cre+ mice line is the new strain added in this chapter. The HCN4 gene 
encodes for the hyperpolarization-activated cyclic nucleotide-gated potassium and 
sodium channels, mutations in which have been linked to sick sinus syndrome 2, also 
known as atrial fibrillation with bradyarrhythmia or familial sinus bradycardia (Laish-
Farkash et al. 2010;Schulze-Bahr et al. 2003). Hyperpolarization-activated cyclic 
nucleotide-gated (HCN) channels, mediate the If current in the heart (and Ih in 
neurons) (Herrmann, Stieber, Stockl, Hofmann, & Ludwig 2007;Ludwig et al. 1998) 
and they are thought to be key players in generating and regulating pacemaker 
activity. Sympathetic activation by β-AR in sinoatrial node cells accelerates heart rate 
by increasing cAMP levels and these channels are modulated by direct binding of 
cAMP (DiFrancesco & Tortora 1991) suggesting that the cAMP-mediated 
enhancement of HCN channel activity is largely responsible for this increase in heart 
rate (DiFrancesco 1993). Four genes encoding HCN channels have been identified 
(HCN1–4). HCN4 is the most highly expressed HCN isoform in the sinoatrial node 
(Moosmang et al. 2001) where different isoforms of G-proteins exert their heart 
modulatory functions.  
Here, we have investigated the role of Gαi2 and Gαs for cardiac pace-making by 
combining a temporally controlled gene-knock-out approach with analyses of heart 
rate and rhythm in intact animals by ambulatory telemetry recordings. My colleague 
Richard Ang helped me to maintain the number of Gαi2 flx/flx HCN4 cre
+ mice when 
I was on maternity leave. Gαs was chosen to ascertain if it has the opposing effects to 
Gαi2. 
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5.2 Study plan for tamoxifen-induced cre deletion in the conduction system 
A study plan was drawn initially to study the effects of HCN4 cre-mediated deletion 
in the conduction system of Gαi2 flx/flx HCN4 cre
+ and Gαs flx/flx HCN4 cre
+ mice 
(Fig. 5.1). 
 
 
 
 
5.3 Real time PCR shows deletion of Gαi2 and Gαs in SA nodal tissues 
We performed quantitative real-time RT-PCR on RNA extracted from the SA node 
and ventricle using Taqman probes targeted at the floxed exons in Gαi2 (exons 2-3) 
Figure 5.1 Study plan for tamoxifen-induced cre deletion in the conduction 
system. Telemetry probes were implanted in 12-14 weeks of Gi2 flx/flx HCN4 cre
+ 
and Gs flx/flx HCN4 cre
+ mice and allowed them to recover from surgery for a 
week. Telemetry recordings were carried out followed by tamoxifen injection for 5 
consecutive days. After 7-10 days, telemetry recordings were performed again. Later, 
pharmacological agents were administered to see their effects on these mice.  
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and Gαs (exon 1) and  this  showed the deletion of Gαi2 and Gαs  in nodal tissues. We 
normalized measurements in the Gαs flx/flx HCN4 cre
+ and Gαi2 flx/flx HCN4 cre
+ 
mice to expression in control mice (both after the administration of tamoxifen) in 
ventricle and SA node. There was a significant reduction in relative Gαs and Gαi2 
RNA expression in the SA node but not ventricle (Gαs flx/flx HCN4 cre
+ SA node= 
0.18, (95%CI 0.17-0.18, **P<0.01), ventricle=1.01, (95%CI 0.99-1.03), and Gαi2 
flx/flx HCN4 cre+ SA node=0.11 (95%CI 0.09-0.24, **P<0.01), ventricle=1.04 
(95%CI 0.80-1.36); n=2 and 3 mice respectively in triplicate for all groups) (Fig. 5.2). 
We also confirmed the deletion at the genomic level from genomic DNA isolated 
from cardiac ventricle and SA node and performed PCR which confirmed cre-
mediated deletion of exon1 of Gnas and exons 2-4 in Gnai2 in the SA node but not in 
the ventricle or tail (Materials and Methods Fig. 2.5). 
 
 
 
 
 
 
Figure 5.2 Real-time PCR showing cre-mediated deletion in SA node tissues of Gi2 
and  Gs mice. Both Gi2 flx/flx HCN4 cre
+ and Gs flx/flx HCN4 cre
+ mice showed low 
of expression of Gi2 and Gs respectively after tamoxifen injection in the SA node 
compared to ventricles. All genes were assayed in triplicates and relative gene expression 
was quantified using the comparative CT method with GAPDH as the reference 
housekeeping gene (n=2 for SA node and n=3 for ventricles, **P<0.01). 
** ** 
Gi2 flx/flx HCN4 cre
+  Gs flx/flx HCN4 cre
+  
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5.4 Diurnal variation in heart rate was lost in mice with conduction system-
specific deletion of Gi2 and Gs  
After injection of tamoxifen for 5 consecutive days to achieve cre-mediated deletion 
in conduction system tissues, telemetry studies were done in conscious mice. These 
showed significant differences in mean heart rate observed both at night and during 
the day in control mice with respect to Gi2 and Gs. Mice are largely active at night 
and sleep during the day and the increased nocturnal heart rate reflects this. In Fig. 
5.3, I have compared heart rate before and after tamoxifen in both control and flx/flx 
HCN4 cre+ mice Gi2 and Gs. Both Gi2 flx/flx HCN4 cre
+ and Gs flx/flx HCN4 
cre+ lost diurnal variation with similar night and day time heart rates. Significant 
diurnal variation in heart rate was observed in control after tamoxifen treatment (489 
bpm ± 25 day; 545 bpm ± 20 night, n=9, **P<0.01), but not in Gi2 flx/flx HCN4 cre
+ 
(552 bpm ± 23.8 day; 578 bpm ± 42 night, n=12), although Gi2 flx/flx HCN4 cre
+ 
maintained diurnal variation in heart rate before tamoxifen treatment (502 bpm ± 28 
day; 541 bpm ± 25 night, n=12 **P<0.01). Also there was an increase in the heart rate 
after tamoxifen in Gi2 flx/flx HCN4 cre
+ during the day (552 bpm ± 23.8 day) 
compared to before tamoxifen (502 bpm ± 28 day; n=12 **P<0.01). The same pattern 
of increase in the heart rate was seen after tamoxifen treatment during the day in Gi2 
flx/flx HCN4 cre+ (552 bpm ± 23.8 day n=12 *P<0.01) mice compared to control (489 
bpm ± 25 day; n=9) (Fig. 5.3 A). Thus, mice with conduction-specific deletion of Gi2 
by tamoxifen-inducible conduction system cre (Gi2 flx/flx HCN4 cre
+) were 
tachycardic during night and day.  
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Similarly before tamoxifen, Gs flx/flx HCN4 cre
+ and control mice exhibited 
significant diurnal variation in heart rate (**P<0.01). However after tamoxifen 
significant diurnal variation in the heart rate was observed only in control mice (560 
bpm ± 15 day; 630 bpm ± 16 night n=8 *P<0.05), but not in Gs flx/flx HCN4 cre
+ 
(452 bpm ± 25 day; 470 bpm ± 16 night n=8) (Fig. 5.3 B). Also there was a decrease 
in the heart rate after tamoxifen in Gs flx/flx HCN4 cre
+ during the day (452 bpm ± 
25 day) compared to before tamoxifen (592 bpm ± 37 day; n=8, *P<0.05). Significant 
reduction in the night time heart rate was also observed in this Gs flx/flx HCN4 cre
+ 
group before (687 bpm ± 40 night) and after tamoxifen (470 bpm ± 16 night n=8, 
***P<0.001. It is clear from Fig. 5.3B that mice with conduction-specific deletion of 
Gs (Gαs flx/flx HCN4 cre
+) were bradycardic during the night and the day.  
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A   Gα
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B   Gα
s
 
Fig 5.3 Mean day and night heart rate in mice with selective Gi2 and Gs deletion in the 
conduction system. Panel A. Mean heart rate measured in Gi2  flx/flx HCN4 cre
+ mice 
(n=12) and its litter mate controls (n=9) during day and night. Panel B summarises mean heart 
rate in Gs  flx/flx HCN4 cre
+ (n=8) during day and night with respect to control (n=8). Both 
Gi2 flx/flx HCN4 cre
+ and Gs flx/flx HCN4 cre
+ mice  lost their diurnal variations in heart 
rate compared to their respective control groups after tamoxifen treatment and was found to 
be tachycardic and bradycardic respectively. 
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5.5 HRV analysis reveals selective loss of the HF component in conduction 
system-specific Gi2 knock-out mice. 
After getting positive results with respect to heart rate in these mice, I went on to 
compare heart rate variability in these conditional KOs of Gi2 and Gs in both the 
time and frequency-domain. Compared to conditional KOs using αMHC cre mice, 
where there was no difference in LF and HF components of HRV, the conditional KO 
of Gi2 flx/flx HCN4 cre
+ using tamoxifen inducible cre mice showed loss of the HF 
component of the HRV signature, (Gi2 flx/flx HCN4 cre
+ before tam 42.05 ms2 ± 5.9; 
and after tam 30.21ms2 ± 2.2; n=12 **P<0.01) while in controls the HF component 
was preserved after tam (control before tam 37.73 ms2 ± 5.25; and after tam 45.95 ms2 
± 4.5 n=9) (Fig. 5.4 A). There was no change in any other parameters of HRV time-
domain as reflected in the Table 5.1. Also selective deletion of Gi2 in the nodal cells 
preserved the LF component in Gi2 flx/flx HCN4 cre
+ (before tam 47.5 ms2 ± 5.08 
and after tam 44.7 ms2 ± 5.97, n=12) which was similar to control (before tam 36.6 
ms2 ± 6.14; after tam 35.4 ms2 ± 3.31 n=9) (Fig. 5.4 B). It is to be noted that there 
were a few outliers in both groups of control and Gi2 flx/flx HCN4 cre
+ because of 
which there is a huge variation in SE. The controls used here is a pool of Gi2 wt/wt 
cre+ and Gi2 wt/wt cre
–. Selective attenuation of HF power was also observed with 
the global KOs of Gi2 (Zuberi, Birnbaumer, & Tinker 2008) which shows an 
impairment of parasympathetic activity. Gi2 plays a major role in the 
parasympathetic modulation of the heart rate, so it is not surprising the HF component 
which represents the vagal (parasympathetic) tone of the HRV signature was lost in 
the absence of Gi2. 
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5.6 HRV analysis reveals selective loss of the LF component in conduction 
system-specific Gs knock-out mice. 
 
Similar to mice with selective deletion of Gi2 deletion (Gi2 flx/flx HCN4 cre
+), mice 
with conduction system-specific Gs deletion (Gs flx/flx HCN4 cre
+) have a HRV 
phenotype which is different from controls (pool of Gs wt/wt cre
+ and Gs wt/wt cre
-
) in both the time and the frequency-domains. The conditional Gs KO (Gs flx/flx 
Figure 5.4 HF and LF power in Gi2 flx/flx HCN4 cre
+ mice before and after 
tamoxifen A. Loss of the HF component of HRV in Gi2 flx/flx HCN4 cre
+ mice after 
tamoxifen compared to before tamoxifen and controls. B. Preservation of LF component of 
HRV in Gi2 flx/flx HCN4 cre
+ before and after tamoxifen similar to that of litter mate 
controls (n=12 Gi2 flx/flx HCN4 cre
+ mice, n=9 controls). 
A 
B n=12 
  
Gα
i2 
floxed cre+ 
n=9  control 
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HCN4 cre+) mice showed a loss of the LF component of the HRV signature, (Gs 
flx/flx HCN4 cre+  before tam: 55.16 ms2 ± 5.97; and after tam 37.08 ms2 ± 3.83; n=8, 
*P<0.05) while there wasn’t much change in the LF component before and after tam 
in controls (before tam 40.01 ms2 ± 3.43; and after tam 45.27 ms2 ± 3.17, n=8) (Fig. 
5.5 A). There was no change in any other parameters of the HRV time-domain as 
shown in the Table 5.1. In contrast to Gi2, selective deletion of Gs in the nodal cells 
preserved the HF component of the signature in Gs flx/flx HCN4 cre
+ (before tam, 
42.7ms2 ± 7.52 and after tam 41.72 ms2 ± 4.60 n=8) which was similar to control 
(before tam 48.63 ms2 ± 3.75; after tam 45.61 ms2 ± 4.44 n=8) (Fig. 5.5 B). Here, like 
Gi2 flx/flx HCN4 cre
+ there are a few outliers in Gs flx/flx HCN4 cre
+ because of 
which there is a variation in SE. It is noteworthy that mixed strained animals appear to 
have greater HRV ( 4-5 fold larger) than pure inbred strains emphasising the 
importance of a mixed strain littermate comparison group.   
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In both Gαs flx/flx HCN4 cre
+ and Gαi2 flx/flx HCN4 cre
+ mice, HRV was altered 
after tamoxifen treatment. This was detectable in an individual mouse in power 
spectral density analysis (Fig. 5.6). Specifically there was a selective loss of 
normalised low frequency (LF) power in Gαs flx/flx HCN4 cre
+ mice seen as loss of 
spectral peaks in the low frequency range (0.4-1.5Hz) (Fig. 5.6 A- before tam and B- 
after tam), while in contrast in Gαi2 flx/flx HCN4 cre
+ mice there was a selective loss 
in normalised high frequency (HF) power perceived as loss of spectral peaks in high 
frequency range (1.5-4.0) (Fig. 5.6 C- before tam and D- after tam and Table 5.1).  
A 
Figure 5.5 HF and LF power in Gs flx/flx HCN4 cre
+ mice before and after tamoxifen 
A. Loss of LF component of HRV in Gs flx/flx HCN4 cre
+ mice after tamoxifen compared 
to before tamoxifen and controls B. Preservation of the HF component of HRV in Gs flx/flx 
HCN4 cre+ mice before and after tamoxifen similar to that of litter mate controls (n=8 Gs  
flx/flx HCN4 cre+ mice, n=8 controls). 
B 
n=8  Gα
s 
floxed cre+ 
n=8  Control 
A 
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Measurements in the time-domain in Gi2 flx/flx HCN4 cre
+ and Gs flx/flx HCN4 
cre+ mice showed no significant variation in SDNN and RMSSD compared with 
controls (Table 5.1). However, more revealingly in the frequency-domain, there was 
loss of HF power after tam in Gi2 flx/flx HCN4 cre
+ (30.21nu ± 2.2, n=12 *P<0.05) 
compared with controls (45.95 nu ± 4.55, n=9) and loss of LF with Gs flx/flx HCN4 
cre+ mice (37.08 nu ± 3.82, n=8 *P<0.05) compared with controls (45.27nu ± 3.17, 
n=8) (Table 5.1). In the frequency-domain, TP and VLF power were unchanged.
Figure 5.6 HRV from power spectral density (PSD) plots in Gαs flx/flx HCN4 cre
+
 
and Gαi2 flx/flx HCN4 cre
+
 mice. Representative power spectrum density traces for A) 
Gαs flx/flx HCN4 cre
+
 mice before tam, B) Gαs flx/flx HCN4 cre
+
 mice after tam where 
there is loss of LF power, C) Gαi2 flx/flx HCN4 cre
+
 mice before tam and D) Gαi2 flx/flx 
HCN4 cre+ mice after tam where there is loss of HF power after its administration. 
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Animal ID SD nn(ms) 
 
RMSSD(ms) 
 
TP(ms2) 
 
VLF(ms2) LF(ms2) HF(ms2) nLF(nu) 
 
nHF(nu) 
 
 
 
Gαs flx cre before tam 
    2.92±0.65 2.08±2.51 131±5.58 
 
 
 
60.23±9.2 
 
 
 
39.53±7.6 
 
 
 
30.21±7.9 55.16±5.9 42.7±7.52 
 
 
Gαs flx cre after tam 
 5.05±1.00 7.14±6.11 160±82 
 
 
 
85.12±9.9 
 
 
 
36.4±8.9 
 
 
 
37.35±6.7 37.08±3.82* 41.72±4.60 
 
 
Gαs control before tam 
 14.75±3.50 15.20±3.63 297±84 
 
 
 
185.35±15.2 
 
 
 
42.23±8.1 
 
 
 
57.26±12.7 40.01±3.43 48.63±3.75 
 
 
Gαs control after tam 
 12.51±5.27 7.58±0.62 200±5.72 
 
 
 
101.98±5.9 
 
 
 
48.6±7.8 
 
 
 
45.23±7.2 45.27±3.17 45.61±4.44 
 
 
Gαi2 flx cre before tam 
 23.8±7.57 11.7±2.66 215±81.4 
 
 
 
97.7±8.2 
 
 
 
56.1±9.2 
 
 
 
49.5±5.8 47.5±5.08 42.05±5.9 
 
 
Gαi2 flx cre after tam 
 31.4±6.64 13.6±5.49 1302±432 
 
 
 
1201±110 
 
 
 
44.6±7.8 
 
 
 
31.2±6.7 44.7±5.97 30.21±2.2* 
 
Gαi2 control before tam 
 
11.80±4.50 8.24±0.81 134±15.8 
 
 
 
65.6±12.7 
 
 
 
25.01±5.2 
 
 
 
21.76±5.9 36.6±6.14 37.7±5.25 
 
Gαi2 control after tam 
 
5.778±5.92 7.12±0.97 248±5.5 
 
 
 
171.2±10.2 
 
 
 
27.1±3.4 
 
 
 
36.2±7.2 35.4±3.31 45.95±4.55 
Table 5.1 Summarised HRV parameters for mice with conditional Gi2 deletion and Gs deletion compared with littermate controls in time and 
frequency-domains. All observations are  S.E.M and are compared against control, P<0.05 = *. RMSSD (root mean square of successive differences), 
SD NN (Standard deviation of “normal” sinus rhythm R-R/n-n intervals, TP (Total Power), VLF power (very low frequency <0.4Hz), LF power (low 
frequency 0.4-1.5Hz),  HF power high frequency 1.5-4.0 Hz), nHF and nLF are normalised to exclude VLF and presented in normalised power units 
(n=12 for Gi2  flx/flx HCN4 cre
+ mice, n=8 for its controls and n=8 for Gs flx/flx HCN4 cre
+ mice and its controls).  
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5.7 No change in ECG parameters measured by ambulatory telemetry in mice 
with conduction system-specific deletion of Gi2 and Gs  
Sudden death syndromes and ventricular arrhythmia often result from abnormal 
ventricular repolarisation. We observed sudden death in several mice with global 
deletion of Gi2 (-/-) mice (Thesis Zia Zuberi). This prompted us to closely examine 
the surface ECG characteristics in these mice. We examined ECG parameters and 
there were no significant difference in PR interval, QRS duration or any evidence of 
spontaneous arrhythmia such as heart block (Table 5.2). However unexpectedly we 
observed a significantly shorter QTc in the Gs flx/flx HCN4 cre
+ mice (after tam 
40.08 ms ± 2.07; before tam 62.28 ms ± 2.08, n=8 *P<0.05) compared to littermate 
controls (before tam 67.75 ms ± 0.55 n=8; after tam 67.05 ms ± 4.46 n=8) despite 
relative bradycardia, which would be expected to prolong QT interval, but this was 
not investigated further in this study. R-R interval was found to be longer in Gs 
flx/flx HCN4 cre+ mice after tam (148.8 ms ± 4.05 n=8) compared to before tam (96.9 
ms ± 2.46, n=8 *P<0.05) and littermate controls, (before tam 95.57 ms ± 0.064; after 
tam 101.1 ms ± 0.95, n=8) which is in line with the bradycardia observed in these 
mice. Similarly in Gi2 flx/flx HCN4 cre
+ mice, R-R interval was found to be shorter 
after tam (98.94 ms ± 7.8, n=12) compared to before tam (113.0 ms ± 8.4, n=12 
*P<0.05) and littermate controls (before tam 119.9 ms ± 10.1; after tam 123.7 ms ± 
1.7, n=9). The shorter R-R interval observed in these Gi2 flx/flx HCN4 cre
+ mice is 
in agreement with the tachycardic phenotype observed in them. 
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Analysis ECG traces of Gi2 flx/flx HCN4 cre
+ before tamoxifen and after tamoxifen 
show significantly shorter R-R intervals, after tamoxifen (Fig. 5.7). On the other hand 
in Gs flx/flx HCN4 cre
+ mice showed longer R-R intervals after tamoxifen. Both the 
observations aligns very well with the heart rate measurements in these groups as Gi2 
flx/flx HCN4 cre+ mice were found to be tachycardic (shorter R-R intervals in ECG 
traces ) and Gs flx/flx HCN4 cre
+ mice were found to be bradycardic (longer R-R 
intervals in ECG traces), compared with their littermate controls. 
 
 
Animal ID PR(ms) 
 
QRS(ms) 
 
QTC(ms) 
 
R-R(ms) 
 
 
Gαs flx cre before tam 
 32.50±1.50 9.84±1.1 62.28±2.08 96.9±2.46 
 
Gαs flx cre after tam 
 32.60±1.22 9.92±0.87 40.08±2.07* 148.8±4.05* 
 
Gαs control before 
tam 
 34.96±0.82 11.35±0.66 67.75±0.55 95.57±0.064 
 
Gαs control after tam 
 38.81±0.44 9.93±0.27 67.05±4.46 101.1±0.95 
 
Gαi2 flx cre before tam 
 33.12±0.49 10.41±0.63 69.84±4.98 113.1±8.4 
 
Gαi2 flx cre after tam 
 34.06±0.88 9.96±0.37 69.21±3.43 98.94±7.8* 
 
Gαi2 control before 
tam 
 35.07±0.31 9.52±0.452 61.63±3.78 119.9±10.1 
 
Gαi2 control after tam 
 36.33±1.04 10.12±0.35 62.36±3.76 123.7±1.7 
Table 5.2 Mean ECG parameters in conscious ambulatory mice with conditional Gi2 
deletion and Gs deletion compared with littermate controls. All observations are  
S.E.M., P<0.05 = *. A mouse QT correction formula (QTc) was used to allow for 
comparison of QT relative to heart rate (QT/ ((R-R/100) ^0.5). (n=12 for Gi2 flx/flx HCN4 
cre+ mice, n=9 for control, n=8 for Gs flx/flx HCN4 cre
+ mice and n=8 for controls).  
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5.8 Intrinsic heart rate determination 
In a separate group of experiments, heart rate was determined using telemetry 
combined with dual pharmacological autonomic blockade (atropine and propranolol). 
For complete autonomic blockade, atropine and propranolol were administered 
together in Gi2 flx/flx HCN4 cre
+ mice and Gs flx/flx HCN4 cre
+ mice before and 
after treatment with tamoxifen and compared to control littermate mice. Fig. 5.8A and 
Table 5.3 show that that there was no significant change in intrinsic heart rate in both 
Gαs flx/flx HCN4 cre
+ and Gi2 flx/flx HCN4 cre
+, though all maintained a higher 
0.1
s 
0.1s 0.1s 
0.1s 
Shorter RR 
interval 
Shorter RR 
interval 
Longer RR 
interval 
Longer RR 
interval 
A 
Figure 5.7 Representative ECG traces from Gs flx/flx HCN4 cre
+ and Gi2 flx/flx HCN4 
cre
+
 mice Panel A) Gs flx/flx HCN4 cre
+
 mice ECG traces before and after tam shows 
longer R-R intervals after tam. Similarly, panel B shows Gi2 flx/flx HCN4 cre
+ mice traces 
before and after tam with shorter R-R intervals after tam. 
B 
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heart rate after the administration of atropine and propranolol, showing a vagal 
predominance in these mice. We also examined the effects of the combined atropine 
and propranolol treatment on HRV before and after tamoxifen administration in Gs 
flx/flx HCN4 cre+ and Gi2 flx/flx HCN4 cre
+ mice. The administration of the two 
drugs led to a decrease in HRV across all the frequency spectra (Table 5.3). There was 
no difference between the two genotypes in this behaviour before (not shown) or after 
tamoxifen administration (Fig. 5.8 and Table 5.3). In Fig. 5.8B, representative power 
spectra shows abrogation of HF and LF power in both Gs flx/flx HCN4 cre
+ and Gi2 
flx/flx HCN4 cre+ mice after atropine and propranolol administration.  
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Figure 5.8 Autonomic blockade in Gi2 flx/flx HCN4 cre
+
 and Gs flx/flx HCN4 cre
+
 
mice. A) The intrinsic heart rate after autonomic blockade with atropine and propranolol in 
Gαs flx/flx HCN4 cre
+ and Gαi2 flx/flx HCN4 cre
+ mice (n=6 in both groups). The data are 
mean ± S.E.M. B) Representative PSD traces for Gαs flx/flx HCN4 cre
+ mice (upper panel a- 
Gαs flx/flx HCN4 cre
+ before AP, b- after AP) and for Gαi2 flx/flx HCN4 cre
+
 mice (lower 
panel c- Gαi2 flx/flx HCN4 cre+ before AP, d- after AP shows loss of spectral power in 
both Gαs flx/flx HCN4 cre
+ and Gαi2 flx/flx HCN4 cre
+ mice. 
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Animal 
ID 
Mean 
NN(ms) 
HR(bpm) SDNN 
(ms) 
RMSSD TP(ms2) VLF(ms2) LF(ms2) LFnu HF(ms2) HFnu LF/HF 
 
 
 
Gαi2 
before 
AP 
 
107.8±7.1 
 
535±29 
 
8.5±2.9 
 
4.87±0.78 
 
130±23.1 
 
86.2±9.5 
 
32.9±9.7 
 
75.1±9.3 
 
10.2±3.2 
 
23.3±4.7 
 
3.2±0.84 
 
 
Gαi2 
after 
AP 
 
100.3±9.6 
 
597±21 
 
7.4±1.9 
 
3.89±0.28 
 
56.4±10.7
** 
 
37.6±5.68
* 
 
12.2±5.4 
** 
 
65.4±10 
 
5.2±1.2 
* 
 
27.6±6.9 
 
2.2±0.35 
 
 
Gαs 
before 
AP 
 
108.2±7.2 
 
555±29 
 
8.8±3.8 
 
5.78±0.34 
 
104±8.9 
 
81.0±10.2 
 
12.8±4.8 
 
55.65±8.2 
 
10.2±24 
 
44.3±8.3 
 
1.25±0.32 
 
 
Gαs 
after 
AP 
 
98.63±10 
 
606±29 
 
4.9±0.64 
 
3.33±0.87 
 
23.7±9.8 
** 
 
14.07±6.6
* 
 
5.4±1.4 
* 
 
56.3±9.7 
 
3.1±0.24 
* 
 
32.5±5.8 
 
1.7±0.34 
 
Table 5.3 HRV parameters after atropine and propranolol (autonomic blockade) in Gi2 flx/flx HCN4 cre
+
 and Gs 
flx/flx HCN4 cre
+
 mice. There was decrease in LF, HF and total power for both Gs flx/flx HCN4 cre and Gi2 flx/flx 
HCN4 cre mice after tamoxifen, leading to a decrease in HRV. AP- atropine and propranolol, ** indicates P<0.01, * 
indicates P<0.05. (n=6 in both Gs flx/flx HCN4 cre
+ and Gi2 flx/flx HCN4 cre
+ mice) 
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5.9 Pharmacological modulation of heart rate 
 
Previous studies in our lab with global Gi2 (-/-) mice has shown a selective defect in 
HF power in Gi2 (-/-) mice and selective attenuation of cardio-inhibitory response to 
carbachol (0.5mg/kg) (Zuberi, Birnbaumer, & Tinker 2008). In light of the above 
observation we went on to examine the M2 Gi2 and β1-Gαs pathway using an in vivo 
pharmacology approach to look for differential chronotropic response to agonist 
challenge.  
We measured the chronotropic response after the administration of isoprenaline and 
carbachol in Gαs flx/flx HCN4 cre
+ and Gαi2 flx/flx HCN4 cre
+ mice, respectively, 
after treatment with tamoxifen and compared this to control littermate mice (Fig. 5.9). 
The positive chronotropic response to isoprenaline was abrogated but not abolished in 
Gαs flx/flx HCN4 cre
+ mice and there was only a small nonsignificant reduction in the 
negative chronotropic response to carbachol in Gαi2 flx/flx HCN4 cre
+ mice. There 
was no evidence of conduction block or arrhythmias occurring after drug 
administration. 
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Figure 5.9 Response of heart rate to pharmacological agents. The percentage change in 
heart rate in Gαs flx/flx HCN4 cre
+ (n=8) and control (n=8) mice after isoprenaline 
administration (left panel) and for Gαi2 flx/flx HCN4 cre
+
 (n=11) and control (n=9) mice 
(right panel) after carbachol administration (right panel). The data are shown as mean ± 
S.E.M. ***=P <0.001. 
 
*** 
*** 
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Discussion 
5.10 Mice with conduction system-specific knock-out of Gαi2 and Gαs with 
tamoxifen-induced cre showed patterns in HRV and ECG different from 
controls. 
 
The results from this chapter show that selective deletion of Gαs and Gαi2 in the 
conduction system of the mouse impairs physiological heart rate regulation. Mice are 
more active at night and more sedentary during the day and this is reflected in their 
diurnal variation in heart rate. The higher mean rate at night reflects their increased 
movement and higher sympathetic drive. Mice with the selective deletion of Gαs in the 
conduction system showed loss of normal diurnal variation and were found to be no 
longer tachycardic at night and thus relatively bradycardic compared to control. On 
the other hand, mice with selective deletion Gαi2 in the conduction system also lost 
normal diurnal variation and were relatively more tachycardic during the day 
consistent with a drop in parasympathetic modulation of the SA node. I also looked 
into the intrinsic heart rate using pharmacological blockade of the autonomic nervous 
system with atropine and propranolol and found that the intrinsic heart rate was not 
significantly different between the two groups of mice. This result shows that in-vivo 
the fundamental inherent pacemaker is not determined by Gαs and Gαi2 and pathways 
downstream of the G-protein. 
 
A physiological variation in heart rate is shown in a number of frequency-domains. 
Compared to frequency-domains in human, a high frequency (HF) component (0.15 to 
0.4 Hz), a low frequency (LF) component (0.04 to 0.15 Hz) and a very low frequency 
component (<0.04 Hz) are distinguished in the mouse. The frequencies defining each 
band are ten-fold higher than in man (Thireau, Zhang, Poisson, & Babuty 2008). The 
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high frequency component is generally thought to reflect vagal input whilst the low 
frequency component reflects both sympathetic and vagal input. My data support a 
scenario where physiological Gαi2-mediated signalling in the SA node reflects the HF 
component and Gαs signalling reflects the LF component and these two are distinct 
with little crosstalk. In other words this would correspond to delineation between 
parasympathetic and sympathetic accounting largely for most of HF and LF power 
respectively. It is worth noting that we use a standard normalisation procedure and 
once this is done the correlation between LF and sympathetic activity is clearer (Anon 
1996). HRV is a widely used non-invasive technique to assess autonomic tone 
particularly in human studies and has prognostic significance in patients after 
myocardial infarction, with hypertension and in many other diseases ( 1996;Thayer et 
al. 2010). 
 
I would like to compare here HRV data between mice with conditional genetic 
deletion of Gαs and Gαi2 in the SA node, before and after drug administration and in 
mice with global genetic deletion of Gαi2. The global genetic deletion of Gαs in mice 
is embryonically lethal and thus the animal was unavailable to study for any heart 
phenotype (Weinstein, Xie, Zhang, & Chen 2007). In mice with global genetic 
deletion of Gαi2, the administration of atropine, tertiapin and propranolol and atropine 
(together) suppressed HRV in the time domain and in the frequency-domain and 
generally had effects across all three frequency spectra  (Zuberi, Birnbaumer, & 
Tinker 2008). In contrast, the effect of conditional deletion in the SA node was more 
subtle and was revealed when variation in VLF was removed by the normalisation of 
HF and LF. It can be seen that VLF accounts for the majority of the power in the HRV 
signal. There are some technical issues that need to be considered. Non-stationarities 
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in the HRV signal can be a confounding factor, e.g. monitoring HRV throughout the 
day as human subjects go about their daily activities may overestimate the 
sympathetic contribution (Berntson et al. 1997;Magagnin et al. 2011). We seek to 
minimise this effect by using the recommended approaches i.e. monitoring the mice at 
rest during the day (12pm-2pm) for a short recording period. Furthermore, it is 
important the mice are allowed to recover from surgery (generally 7-10 days) and 
resume normal activity after probe implantation before measurements are made. These 
factors are the same between our current and previous studies and thus the differences 
are likely real. Factors outside the SA node such as effects in the central and 
peripheral nervous system which have an important influence on HRV could be a 
factor in the observed differences. For example, Gαi2 is expressed in the nervous 
system and drugs such as propranolol with a high lipophilicity cross the blood brain 
barrier. In this regard the HCN4-KiT mouse does not lead to deletion of genes in the 
brain after the administration of tamoxifen (Hoesl, Stieber, Herrmann, Feil, Tybl, 
Hofmann, Feil, & Ludwig 2008). 
 
It is important to clearly define in vivo the molecular isoforms responsible for 
physiological heart rate regulation. The Gnas gene locus is complex with imprinting, 
though not in cardiac tissues, and roles of a long and extra-long isoforms of Gnas in 
signalling are not clear (Weinstein, Xie, Zhang, & Chen 2007). The data here clearly 
implicate canonical Gαs though the mice do not distinguish long and short forms of 
Gαs. Our results are consistent with recent studies in pigs using adenoviral transfer of 
small interfering RNA to Gαs where they found a suppression in heart rate (Lugenbiel 
et al. 2012). Furthermore, there has been debate about the inhibitory G-protein 
isoform underlying physiological heart rate modulation (Ang, Opel, & Tinker 
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2012;Zuberi, Birnbaumer, & Tinker 2008). The fundamental issue is that a wide 
variety of different approaches and experimental systems have been used ranging 
from expression in heterologous system, knock-outs in differentiated embryonic stem 
cells and genetically modified mice. Our data here support an important role for Gαi2 
but do not exclude a contribution from other isoforms.  
 
After selective deletion of Gαi2 in the conduction system the heart rate slowing 
response to carbachol is relatively well preserved whilst with Gαs the response to 
isoprenaline was significantly attenuated but not abolished. This contrasts with the 
situation in the global knock-out of Gαi2 where it was significantly attenuated. The 
studies with isoprenaline and carbachol are a pronounced pharmacological challenge, 
e.g. with carbachol the heart rate falls to levels much below that normally seen 
physiologically even in normal situations such as sleep. It is known that the sino-atrial 
node is actually quite an extensive and heterogeneous structure and that the primary 
pacemaking site moves from one region to another as the sympathovagal balance 
changes (Monfredi et al. 2010;Shibata et al. 2001). Thus it is possible that the 
pacemaking site shifts to a small region that is not solely dependent on the deleted G-
protein or a site in which the HCN4 promoter driven cre-mediated deletion is not so 
complete (Sebastian et al. 2013).  
 
There is great interest in the role that heart rate per se has in the outcome of heart 
failure after the use of ivabradine in the SHIFT trial (Bohm et al. 2010). These mouse 
lines may be useful resources in addressing this interesting question as they have 
changes in heart rate generated independently of pharmacological manipulation. I 
follow up this question in the next chapter.  
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6.1 Ventricular remodelling in Gαs flx/flx HCN4 cre
+ and Gαi2 flx/flx HCN4 cre
+  
mice after myocardial infarction  
 
My next step was to further explore the role of the Gαi2 and Gαs genes in a murine 
model of myocardial infarction and heart failure. Gαi2 flx/flx HCN4 cre
+ mice were 
found to be tachycardic and Gαs flx/flx HCN4 cre
+ mice were bradycardic. The aim 
was to see whether the bradycardic phenotype in the absence of Gs is protective in 
Gαs flx/flx HCN4 cre
+ or tachycardia in the absence of Gi2 is detrimental to the Gαi2 
flx/flx HCN4 cre+ when challenged with MI. Here, we have explored the role of heart 
rate, Gαi2 and Gαs in the SA node in ventricular remodelling after myocardial 
infarction by combining the same temporally controlled gene-knock-out approach 
described earlier in Materials and Methods (for Gαi2 and Gαs using tamoxifen- 
inducible knock-outs) by assessing their ventricular function using serial 
echocardiography. 
 
6.2 Survival rates in Gαi2 flx/flx HCN4 cre
+ and Gαs flx/flx HCN4 cre
+ mice after 
MI  
 
Mice were first subjected to echocardiography to analyse their baseline measurements 
of ventricular function and the outline  of the study is described in Fig. 6.1. The 
survival rates are also shown in the Fig. 6.1. Control mice had a survival rate of 66-
68% while Gαi2 flx/flx HCN4 cre
+ mice and Gαs flx/flx HCN4 cre
+ mice had survival 
rates of 38% had 45%, respectively. These differences are not statistically significant 
(P>0.05 Fishers exact test). I would like to mention here that these deaths occurred 
soon after the procedure (2-3 days) and an initial post mortem examination in 6 mice 
found cardiac rupture to be the likely reason for death after MI. This is well described 
in this model (Gao, Dart, Dewar, Jennings, & Du 2000). 
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6.3 M- mode Echocardiography shows impaired LV function 
 
After MI, the left ventricular wall definitions (IVS, LVID and LVPW in both systole 
and diastole) are less well defined as seen in Fig. 6.2. There are several factors for 
this. The orientation of the heart changes after MI and while imaging the heart, there is 
interference from the rib cage which affects the quality of the image scan. Other 
reasons include, an  infarcted anterior wall being invisible due to wall thinning, no 
wall motion or  postoperative adhesion (Gao, Dart, Dewar, Jennings, & Du 2000). 
Left ventricle contraction is decreased and  LV dimensions are increased after MI. 
 
 
Figure 6.1 Study plan for the myocardial infarction protocol.  Mice in different groups 
were subjected to echocardiography followed by tamoxifen injection for 5 days, after which 
echocardiographic measurements were again carried out and mice were then subjected to 
MI, allowed to recover for 14 days then echo'd again. Finally, tissues were harvested for 
TTC staining. 
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6.4 Gαs flx/flx HCN4 cre
+ mice were found to be bradycardic and Gαi2 flx/flx 
HCN4 cre+ mice were found to be tachycardic under anaesthesia. 
 
Mice in all groups (before and after tamoxifen) were subjected to echocardiographic 
analysis. We found that under isoflurane-induced anaesthesia heart rates were higher 
in Gαi2 flx/flx HCN4 cre
+ mice (486 bpm ± 22.9, n=7 *P<0.05) compared to controls 
(393 bpm ± 15.8, n=11) and were lower in Gαs flx/flx HCN4 cre
+ mice  (357 bpm ± 
18.8, n=9 *P<0.05) compared to controls (411 bpm ± 12.7, n=10) after administration 
of tamoxifen. Since mice are anaesthetised heart rate is typically lower among all 
groups (Fig. 6.3). After MI, the pattern of tachycardia remains unchanged in Gαi2 
flx/flx HCN4 cre+ mice (407 bpm ± 13.8, n=7 *P<0.05) compared to controls (351 
bpm ± 15.9, n=11) and Gαs flx/flx cre
+ mice (311 bpm ± 17.9, n=9 *P<0.05) 
compared to controls (389 bpm ± 10.89, n=10) remained bradycardic. Thus, it seems 
that under anaesthesia as well when conscious, heart rates in Gαi2 flx/flx HCN4 cre
+ 
and Gαs flx/flx HCN4 cre
+ mice are found to be tachycardic and bradycardic, 
respectively after tamoxifen. 
Figure 6.2 Representative M-mode image of a control mouse before and after MI. A) 
Before MI well defined wall dimension of left ventricle are displayed. B) After MI clear wall 
definition is lost showing the signs of infarction. 
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Figure 6.3 Heart rate in Gαs flx/flx HCN4 cre
+ and Gαi2 flx/flx HCN4 cre
+ mice before 
and after tam and before and after MI under anaesthetic conditions. Gαs flx/flx HCN4 
cre+ mice (n=9) were found to be bradycardic after tam (upper left panel) and remained 
bradycardic after MI ( upper right panel) compared to control (n=10) (*P<0.05). On the 
other hand Gαi2 flx/flx HCN4 cre
+ mice (n=7) were found to be tachycardic after tam 
(lower left panel) and remained the same after MI compared to control mice (n=11) (lower 
right panel). 
Gαs 
Gαi2 
187 
 
6.5 Fractional shortening was not changed in Gαs flx/flx HCN4 cre
+ mice while it 
was reduced in Gαi2 flx/flx HCN4 cre
+ mice post MI 
 
Fractional shortening (FS) was calculated from the dimensions of the left ventricle 
obtained by M-mode echocardiography as explained in Materials and Methods and is 
a common parameter to evaluate systolic function of the left ventricle. Before 
tamoxifen, FS% was found to be similar in both control, Gαs flx/flx HCN4 cre
+ mice 
(n=9) and Gαi2 flx/flx HCN4 cre
+ mice (n=7). However after tamoxifen, in Gαs flx/flx 
HCN4 cre+ mice there was an increase in FS% (before tam 36.05 ± 1.34 after tam 
45.00 ± 1.18, n=9 **P<0.01) compared to controls (before tam 35.95 ± 2.79, after tam 
36.37±2.52), n=10) (Fig. 6.4A). After MI there was reduction in FS% observed in the 
control group (before MI 36.37 ± 2.52, after MI 28.8 ± 1.32, n=10 *P<0.05), FS% 
wasn’t much lower compared to before MI in Gαs flx/flx HCN4 cre
+ mice (before MI 
45.00 ± 1.18, after MI 41.65 ± 1.90 n=9 ) Fig. 6.4A. This suggests that that absence of 
Gαs in conduction system tissues is protecting the heart when challenged with MI. On 
the other hand in Gαi2 flx/flx HCN4 cre
+ mice after tamoxifen there was no change in 
FS% compared to their littermate controls (control 39.42 ± 2.52, n=11 and with Gαi2 
flx/flx HCN4 cre+ 37.80 ± 1.95, n=7) Fig. 6.4B. However, after MI there was a 
significant reduction in FS% in both the control (before MI 39.42 ± 2.52 after MI 
27.89 ± 2.26, n=11 **P<0.01) and Gαi2 flx/flx HCN4 cre
+ mice (before MI 37.80 ± 
1.95, after MI 29.66 ± 1.57, n=7 *P<0.05). Absence of Gαi2 in the conduction system 
was not found to be worse for outcome, even though there was reduction in FS but 
compared to controls there wasn’t a significant difference.  
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A 
B 
Figure 6.4 FS% in Gαs flx/flx HCN4 cre
+ and Gαi2 flx/flx HCN4 cre
+ mice before and 
after tam and before and after MI A) FS is increased in Gαs flx/flx HCN4 cre
+
 mice 
(n=9) after tam (left panel) and after MI (right panel) compared to control (n=10). B) There 
was no change in FS after tam (left panel) in Gαi2 flx/flx HCN4 cre
+
 mice (n=7) but there 
was a significant reduction of FS in both Gαi2 flx/flx HCN4 cre
+ mice and control mice 
(n=11) after MI (right panel) (**P<0.01,*P<0.05). 
Gαi2 
Gαs 
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6.6 There is no change in ejection fraction in Gαs flx/flx HCN4 cre
+ mice, while it 
is decreased in Gαi2 flx/flx HCN4 cre
+ mice post MI 
 
Ejection fraction (EF), another parameter of ventricular function was also found to be 
enhanced in Gαs flx/flx HCN4 cre
+ mice, after tamoxifen and after MI it remained 
more of less the same, while it was found to be decreased in Gαi2 flx/flx HCN4 cre
+ 
mice. Ventricular function is impaired after MI which is reflected in EF% of littermate 
controls in both the groups. After tamoxifen, in Gαs flx/flx HCN4 cre
+ mice there was 
an increase in EF% (75.05 ± 3.96, n=9 *P<0.05) compared to controls (63.71 ± 6.79, 
n=10) Fig. 6.5A. After MI, there was a reduction in EF% observed in control group 
(before MI 63.71 ± 6.79, after MI 49.40 ± 1.32, n=10 **P<0.01) compared to Gαs 
flx/flx HCN4 cre+ mice (before MI 75.05 ± 3.96, after MI 71.46 ± 2.17, n=9). EF% 
was found to be significantly lower in controls after MI compared to Gαs flx/flx 
HCN4 cre+ mice (control 49.40 ± 1.32, n=10 and Gαs flx/flx HCN4 cre
+ mice 71.46 ± 
2.17, n=9 **P<0.01). In Gαi2 flx/flx HCN4 cre
+ mice there was no difference in EF% 
before and after tamoxifen in both controls and Gαi2 flx/flx HCN4 cre
+ mice (Fig. 
6.5B). But after MI, EF% was decreased in both control (before MI 61.58 ± 3.77, after 
MI 52.36 ± 2.93, n=11*P<0.05) and Gαi2 flx/flx HCN4 cre
+ mice (before MI 62.59 ± 
3.08, after MI 44.58 ± 3.93, n=7 **P<0.01) and the degree of reduction was found to 
be more in Gαi2 flx/flx HCN4 cre
+ mice than in their controls. 
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Figure 6.5 EF% in Gαs flx/flx HCN4 cre
+ and Gαi2 flx/flx HCN4 cre
+ mice before and 
after tam and before and after MI. A) EF% is increased in Gαs flx/flx HCN4 cre
+ 
 mice 
(n=9) after tam (left panel) and after MI (right panel) compared to control (n=10). B) 
There was no change in EF% after tam (left panel) in Gαi2 flx/flx HCN4 cre
+ mice (n=7) 
but there was a significant reduction of EF% in both Gαi2 flx/flx HCN4 cre
+
 mice and 
control mice (n=11) after MI (right panel), (*P<0.05, **P<0.01). 
B 
A Gαs 
Gαi2 
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6.7 FAC% was found to be enhanced in Gαs flx/flx HCN4 cre
+ mice, while there 
was no change in Gαi2 flx/flx HCN4 cre
+ mice 
 
Left ventricular function can also be measured as a percentage of change in left 
ventricular cross-sectional area between diastole and systole, which is called fractional 
area change (FAC %) shown in Fig. 6.6 (upper panel). FAC% measured on the LV 
short axis 14 days post MI showed a decrease in FAC% in the littermate control 
groups of both Gαs flx/flx HCN4 cre
+ mice and Gαi2 flx/flx HCN4 cre
+ mice (Fig. 
6.6B). In the Gαs flx/flx HCN4 cre
+ group post MI, there was a trend towards an 
enhancement in FAC% although this was not significant statistically (Fig. 6.6B). 
However, in controls in the same group, there was an obvious decrease in FAC% after 
MI (29.28 ± 3.12) compared to before MI (37.43 ± 2.89, n=9 *P<0.05). A comparison 
of the FAC% between Gαs flx/flx HCN4 cre
+ mice and their littermate controls post 
MI was statistically significant  (controls after MI, 29.28 ± 3.12, n=9, Gαs flx/flx 
HCN4 cre+ after MI, 43.14 ± 3.94, n=10 **P<0.01). There could be a possibility that 
the absence of Gαs may be having a protective role in heart failure. On the other hand, 
Gαi2 flx/flx HCN4 cre
+ control group did show a significant reduction in FAC% post 
MI (before MI 40.32 ± 2.68, after MI 33.89 ± 2.97, n=11*P<0.05), while Gαi2 flx/flx 
HCN4 cre+ mice, even though there was reduction in FAC% after MI it didn’t reach 
statistical significance (before MI 41.82 ± 2.97, after MI 37.12 ± 3.27, n=7).  
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A 
B 
Figure 6.6 Measurement of FAC% by tracing the endocardial border and FAC% in 
Gαs flx/flx HCN4 cre
+ and Gαi2 flx/flx HCN4 cre
+ mice before and after MI. A) Upper 
panel shows traces of the endocardial border during systole (left) and diastole (right) on B-
mode echocardiography. B) FAC % is decreased in control mice (n=10*) while there was 
not much change in Gαs flx/flx HCN4 cre
+ mice (n=9) after MI. B) FAC % was found to be 
decreased in both control (n=11*) and Gαi2 flx/flx HCN4 cre
+
 mice (n=7) though it was 
significant only in the control group (*P<0.05, **P<0.01). 
Gαs Gαi2 
193 
 
6.8 Structural analysis of the left ventricular chamber shows changes in Gαs 
flx/flx HCN4 cre+ mice but not in Gαi2 flx/flx HCN4 cre
+ mice 
 
Left ventricular remodelling can also be assessed from the measurements of chamber 
dimensions of the left ventricle on M-mode echocardiography. Chamber dilatation is 
one of the commom features of LV remodelling after MI, and this is caused by the 
redistribution of increased regional wall stress to preserve the cardiac function (Sutton 
and Sharpe 2000). This is assessed by means of left ventricular dimesions during 
systole and diastole. In our study with Gαs flx/flx HCN4 cre
+ mice, only the control 
group showed a significant increase in posterior wall thickness after MI (before MI 
1.25mm  ± 0.091, after MI 1.47mm ± 0.01,n=10 *P<0.05), while in Gαs flx/flx HCN4 
cre+ mice there was a trend towards a decrease in posterior wall thickness after MI 
(before MI 1.36mm ± 0.09, after MI 1.12mm ± 0.08, n=9) (Fig. 6.7A). But when 
compared with controls, Gαs flx/flx HCN4 cre
+ mice after MI there was a significant 
difference between both groups in terms of posterior wall thickness (control post MI 
1.47mm ± 0.01, n=10, Gαs flx/flx HCN4 cre
+ post MI 1.12mm ± 1.01, n=9 **P<0.01) 
Decreased posterior wall thickness in Gαs flx/flx HCN4 cre
+ mice after MI (compared 
to control) may indicate that left ventricular hypertrophy does not occur in the absence 
of Gαs. While in the case of Gαi2 flx/flx HCN4 cre
+ mice there was an increase in 
posterior wall dimensions after MI in both the control and Gαi2flx/flx HCN4 cre
+ mice 
compared to before MI (control before MI 1.135mm ± 0.04, control after MI 1.39mm 
± 0.02, n=11 *P<0.05, Gαi2flx/flx HCN4 cre
+ before MI 0.93mm ± 0.03; after MI 
1.22mm ± 0.06, n=7 *P<0.05) (Fig. 6.7B).  
 
Measurement of left ventricular internal dimension during diastole (LVIDd) also 
revealed ventricular chamber dilation. As seen in Fig. 6.7C (lower panel) in Gαs 
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flx/flx HCN4 cre+ mice, the increase in LVIDd was not significant after MI (4.37mm 
± 0.148) compared to before MI (3.88mm ± 0.16,n=9), while in the littermate control 
mice showed a significant increase in chamber dimension after MI (4.63mm ± 0.11) 
when compared to before MI 3.78mm ± 0.13,n=10 **P<0.01). But there was no 
difference between control (4.63mm ± 0.11, n=10) and Gαs flx/flx HCN4 cre
+ mice 
(4.37mm ± 0.148, n=9) after MI. While with Gαi2 flx/flx HCN4 cre
+ mice there was 
an increase in dimensions in both control (before MI 3.71mm ± 0.08, after MI 
4.54mm ± 0.09, n=11 **P<0.01) and Gαi2 flx/flx HCN4 cre
+ mice (before MI 4.00mm  
± 0.11, after MI 4.68mm ± 0.22, n=7 **P<0.01) after MI compared to before MI (Fig. 
6.7D). 
These data suggest that LV remodelling is occurring in Gαi2flx/flxHCN4 cre
+ mice 
after MI and Gαs flx/flx HCN4 cre
+ mice are protected against remodelling. Further 
research is needed to further characterize these observations in Gαs flx/flx HCN4 cre
+ 
mice. 
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B A 
Figure 6.7 LVPWd and LVIDd measurements in Gαs flx/flx HCN4 cre
+ and Gαi2 
flx/flx HCN4 cre
+
 mice before and after MI. A) LVPWd before and after MI in Gαs 
flx/flx HCN4 cre
+
 mice shows an increase in values for control (n=10*) but not in Gαs 
flx/flx HCN4 cre+ mice (n=9*) after MI while B) in Gαi2 flx/flx HCN4 cre
+ mice (n=7) 
shows increase in LVPWd similar to control mice (n=11) after MI C) LVIDd before and 
after MI in Gαs flx/flx HCN4 cre mice shows an increase in values for control (n=10*) but 
not in Gαs flx/flx HCN4 cre
+ mice (n=9*) after MI while D) in Gαi2 flx/flx HCN4 cre
+ mice 
(n=7) shows increase in LVIDd similar to that seen in control mice (n=11) after MI   
(*P<0.05, **P<0.01). 
C D 
Gαs Gαi2 
Gαs Gαi2 
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6.9 Hypertrophy was observed in Gαi2 flx/flx HCN4 cre
+ mice but not in Gαs 
flx/flx HCN4 cre+ mice post MI 
 
Hypertrophy of heart is a common feature after MI and it is a measurement of LV 
remodelling post MI. So we measured heart:body weight ratio after the studies. As 
expected from the results above we found an increase in heart weight: body weight 
ratio in Gαi2 mice after MI (6.87 ± 0.462, n=7) and it was not different from the 
control group (6.67 ± 0.258, n=11) (Fig. 6.8 upper panel). While with Gαs after MI 
there was no increase in heart weight:body weight ratio, while control mice showed an 
increase in ratio after MI (Gαs flx/flx HCN4 cre
+ mice 5.13 ± 0.587, n=9 *P<0.05, 
control 6.08 ± 0.287, n=10) (Fig. 6.8). LV mass calculated from echocardiography 
also showed an increase in Gαi2 floxed cre
+ group (before MI 164.5 ± 6.58; after MI 
205 ± 6.17, n=7 *P<0.05) and the control group (before MI 144.5 ± 4.69, after MI 210 
± 4.2, n=11*P<0.05), even though there was no difference between both control and 
Gαi2 flx/flx HCN4 cre
+ mice after MI (bottom right Fig. 6.8). In Gαs flx/flx HCN4 cre
+ 
mice, only the control group showed an increase in LV mass after MI (before MI 
148.4 ± 3.58, after MI 225 ± 3.89, n=10 *P<0.05) while in floxed cre+ mice there was 
no change (before MI 178 ± 4.04, after MI 170 ± 5.48, n=9) but when Gαs flx/flx 
HCN4 cre+ mice were compared with controls after MI there was significant increase 
of LV mass in control group (control after MI 225 ± 3.89, n=10; Gαs flx/flx HCN4 
cre+ mice after MI 170 ± 5.48, n=9 * P<0.05) (bottom left Fig. 6.8). Hypertrophy was 
observed as a part of ventricular remodelling in Gαi2 floxed cre
+ mice but not in Gαs 
flx/flx HCN4 cre+ mice. 
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6.10 Triphenyltetrasodium chloride (TTC) staining reveals infarct size was found 
to be similar in all groups 
TTC staining at the end of the studies and its subsequent analysis of area using image 
J software reveals infract size was found the same among controls (14.4 ± 1.90; n=21 
(pooled together), Gαs flx/flx HCN4 cre
+ mice 14.5 ± 0.87, n=9 and Gαi2 flx/flx HCN4 
cre+ mice (17.49 ± 1.61, n=7) Fig. 6.9C. This infarction size was less compared to 
other studies where they have reported ~30% infarction of left ventricle.(Michael et al. 
Figure 6.8 Heart weight:body weight and LV mass in Gαs flx/flx HCN4 cre
+ and Gαi2 
flx/flx HCN4 cre+ mice before and after MI. upper panel shows heart weight:body weight 
in both Gαs floxed cre
+ mice (left) and Gαi2 floxed cre
+ mice (right). Bottom panel left shows 
LV mass by echocardiography reveals an increase in LV mass was observed only with the 
control group not with Gαs floxed cre
+ mice (*P<0.05) while in Gαi2floxed cre
+ mice and its 
controls show an increase in LV mass. 
Gαs 
 
Gαi2 
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1999).This could be reason for less adverse results with Gαi2 flx/flx HCN4 cre
+ mice, 
even though with this infarct size we could see some effect in Gαs flx/flx HCN4 cre
+ 
mice. Fig. 6.9A shows the measurement of area of infarct using Image J and 
comparison between an infarcted heart, 6.9B non-infarcted heart and 6.9D shows scar 
in one of the hearts isolated after MI before TTC staining. Another important point 
that needs to be mentioned here is that the strain differences in mice are an important 
factor in determining the outcome of infarct. Here Gαi2 flx/flx cre
+ mice and Gαs 
flx/flx cre+ mice were on Sv129 back ground and HCN4 cre+ was on c57 back ground. 
Studies have shown that infarct rupture, a feature of MI is of high incidence in Sv129 
background strain and this is associated with high systolic blood pressure in them after 
infarct compared to other strains. Also in these mice, the incidence is higher in males 
compared to females. The survival rate post MI was found to be low in Sv129 strain 
compared to C57 background (Gao et al. 2005;van den Borne et al. 2009). The mixed 
background nature of mice used here could be a factor in explaining some differences 
with other studies.  
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Subject losses are a main feature to any surgical model. It is a big challenge to keep 
these losses to a minimum for scientific, humane and economic reasons. In the 
literature, LAD ligation is recommended 2 mm below the left atria, to achieve roughly 
40-50% of infarction (Tarnavski, McMullen, Schinke, Nie, Kong, & Izumo 2004) but 
in my hands when I tried to reproduce that the survival rate was poor. So I modified 
the position of ligation to 3 mm from the left atria, with that I was able to achieve a 
reasonable survival rate. I examined the process of LV remodelling after MI and our 
findings do throw some light on cardiac structural and functional adaptation following 
Figure 6.9 TTC staining and % infarct size after MI. Upper panel A) infarcted zone 
after MI, B) non infarcted tissue after MI, C) % infarct size calculated using Image J 
software and D) infarcted heart showing scar tissue after the MI. 
C 
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MI in the cardiac conduction system-specific knock-outs of Gαs and Gαi2. LV 
remodelling followed by MI is a progressive process involving chamber dilatation of 
LV, infarcted wall thinning and compensatory thickening of non-infarcted wall 
(Sharpe 1992). These are the processes to redistribute the regional wall stress to 
restore stroke volume and to preserve cardiac function. In patients, serial 
echocardiographic studies following MI showed that LV dilatation can be observed as 
early as 3 days and can last up to 30 days and the dilatation involved both infarcted 
and non-infarcted regions (Eaton et al. 1979). In the initial days after MI, regional 
dilatation and infarction expansion contribute to ventricular enlargement. Cardiac 
rupture was one of the features observed in mice that died few days after MI. Cardiac 
rupture could be a result of infarction expansion in an extreme form in which the 
expanded infarct zone is not able to maintain the integrity of ventricular wall before 
the deposition of collagen and scar formation (Schuster and Bulkley 1979). LV 
remodelling after MI in mice is a time dependent process and early remodelling 
results in high risk of rupture of the myocardium and those that survived the rupture 
had the remodelling going on with chamber dilatation and the thickness of the anterior 
wall reduced by 50% (Gao, Dart, Dewar, Jennings, & Du 2000). 
 
Echocardiography is an inexpensive, easily applicable and readily interpreted tool in 
evaluating ventricular function in mice, using techniques and indices familiar from 
human echocardiography (Rottman, Ni, & Brown 2007). One limitation in the study is 
the use of anaesthesia for echocardiography. Generally, anaesthesia produces cardiac 
and respiratory depression as well as fluctuations in body temperature via either a 
direct or indirect action on the central nervous system and heart. And in animals with 
cardiac pathology such as MI in mice, alteration of the autonomic nervous system by 
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anaesthetics may further jeopardize cardiovascular function complicating 
interpretation of haemodynamic data and potentially underestimating LV function 
(Yang et al. 1999). By maintaining the isoflurane levels (1-1.5%) and keeping the 
heating pad at 42oC, we could carefully maintain the heart rate at a more or less 
uniform rate for all groups.  
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Discussion 
6.11 LV dysfunction and remodelling was not observed with Gαs HCN4 cre
+ mice 
after MI  
I measured EF, FS and FAC in the Gαs HCN4 cre
+ mice and found all of them to be 
preserved compared to control after MI. In addition, FS% and EF% and were found to 
be increased in Gαs flx/flx HCN4 cre
+ mice after tamoxifen prior to infarction. Thus, 
there may a rate-dependent change in LV function occurring in them as a result of 
deletion of Gαs in nodal cells. This may reflect a negative Bowditch staircase, where 
there is increased contractility of cardiac muscle with a decrease in heart rate, which is 
known to occur in the mouse. Lack of Gαs possibly prevents the β AR signalling and 
its subsequent activation of AC leading to low amount of cAMP, and this could be 
protective in a heart failure scenario. 
 
After MI the survival was lower in this group (45%) compared to its controls (68%) 
though not statistically significant. Mortality was largely due to cardiac rupture in the 
first 2-3 days as observed in post mortem of animals that had died. Cardiac rupture is 
one of the known reasons for early mortality from MI (Gao, Dart, Dewar, Jennings, & 
Du 2000). There was no trend towards larger infarcts in the control group as observed 
by staining in all animals after the study. Furthermore chamber dimensions were 
preserved and there was no evidence of hypertrophy in response to MI. Thus, despite a 
similar sized infarct these mice have preserved LV function and there was no evidence 
of pathological remodelling. There was no change in LV dilation as indicated by no 
change in LVIDd and LVPWd measurements after MI in Gαs flx/flx HCN4 cre
+ mice 
after 14 days post MI. The bradycardia in these mice may protect the heart against the 
subsequent ischemic insult. The precise mechanisms by which absence of Gαs in the 
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SA node and the consequent bradycardia mitigates against adverse LV remodelling 
remain to be explored.  
Telemetry studies in Gαs flx/flx HCN4 cre
+ mice showed that mice with conduction 
system-specific deletion of Gαs ambulatory heart rates lower than its control 
littermates. After MI, we also found that Gαs flx/flx HCN4 cre
+ mice were 
bradycardic but there were no signs of ventricular arrhythmias was observed after MI. 
These data suggest that conduction system deletion of Gαs does not increase 
susceptibility to ventricular arrhythmias. 
6.12 LV remodelling was not remarkable in Gαi2 HCN4 cre
+ mice after MI 
In the context of myocardial ischemia and the progression towards heart failure the 
role of Gi signaling is not clearly understood. One salient characteristic of the failing 
heart is up-regulation of Gαi2 at the protein and transcript levels (Feldman et al. 1988). 
Till now, however, the picture is not clear about the beneficial or maladaptive nature 
of this up-regulation (Baker et al. 2001). Activation of many Gi-coupled receptors 
(adenosine, sphingosine-1-phospahete, opioid etc.) can reduce ischemia-reperfusion 
injury. Studies also show absence of Gαi2 specifically in myocytes, results in increased 
susceptibility to I/R injury and increased apoptotic cell death in mice with 
cardiomyocyte-specific loss of expression of Gαi2 (Degeorge, Jr., Gao, Boucher, 
Vinge, Martini, Raake, Chuprun, Harris, Kim, Soltys, Eckhart, & Koch 2008). In our 
lab we observed sudden death in mice with global deletion of Gαi2 for reasons 
unknown. These observations all point to a protective role of Gαi2 in heart failure. 
Mice lacking the Gαi2 specifically in conduction system tissues have allowed us to 
directly address the role of Gαi2 signaling in the SA node in response to stress in the 
form of myocardial infarction. 
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FS%, EF% and FAC% were reduced after MI in Gαi2 flx/flx HCN4 cre
+ mice but 
these didn’t reach statistical significance compared with the controls. There was a 
significant difference in chamber dilatation in the LV marked by an increase in  
LVIDd and LVPWd measurements in Gαi2 flx/flx HCN4 cre
+ mice after 14 days post 
MI, although not significant when compared with control. This suggests LV 
remodelling is happening to an extent which is comparable to control. It also suggests 
that moderate tachycardia is not substantially detrimental or that we may need larger 
numbers of mice to detect it. Studies using an RGS-insensitive mouse model (Gαi2 
G184S) where there is enhanced Gαi2 signaling showed detrimental effects, after 
isoprenaline-induced injury marked by increased fibrosis, and increased cardiac 
fibroblast activity ERK and cell proliferation (Kaur et al. 2012). Increased levels of 
Gαi2 in these models didn’t show any protective effects as expected. But another study 
demonstrates a significant increase in mRNA levels of Gαi2 in human end-stage heart 
failure caused by idiopathic dilated cardiomyopathy and ischemic cardiomyopathy 
without changes in Gαi3 and Gαs mRNA levels (Eschenhagen, Mende, Nose, Schmitz, 
Scholz, Haverich, Hirt, Doring, Kalmar, & Hoppner 1992). The ambiguous 
significance of Gαi2 signalling in myocardial injury muddles efforts to regulate its 
function as a therapeutic strategy. Studies on protective roles of Gαi2 signalling used 
cardiac myocytes or in vivo genetic manipulations specific to cardiac myocytes and 
didn’t take into account other cell types like fibroblasts which are also key cells in 
cardiac remodelling.  
 
 Gαi2 flx/flx HCN4 cre
+ mice showed an increase in heart weight : body weight and an 
increase in LV mass, which shows hypertrophy and was observed to same extent in 
both control and Gαi2 flx/flx HCN4  cre
+ mice due to some adaptive changes. 
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LVhypertrophy is a compensatory mechanism to reduce wall stress and to maintain 
normal cardiac function for a period of time. 
 
Ambulatory telemetry studies in Gαi2 flx/flx HCN4 cre
+ mice showed that mice with 
conduction system-specific deletion of Gαi2 had heart rates higher than to its control 
littermates. After MI also, we found that, Gαi2 flx/flx HCN4 cre
+ mice were 
tachycardic but no signs of ventricular arrhythmias were witnessed on the ECG traces 
during echocardiography. From these observations it is difficult to dissect out the role 
of SA node deletion Gαi2 in heart failure. Previous studies in our lab on global Gαi2 
knock-out shows no evidence of functional impairment in contractile function or other 
abnormalities as assessed using echocardiography in Gαi2 (-/-) mice compared to 
control wild-type mice (Zuberi, Nobles, Sebastian, Dyson, Lim, Breckenridge, 
Birnbaumer, & Tinker 2010).  
 
6.13 Role of calcium in cardiac hypertrophy  
In response to stress, increased work load or from pathological conditions such as MI 
and hypertension, the heart undergoes a growth process known as hypertrophy which 
eventually gives rise to pathological ventricular remodelling and dilatation. A major 
cause of cardiac hypertrophy in the context of LV remodelling after MI is possibly 
due to Ca2+ signalling (discussed below). 
Binding of catecholamines, endothelin-I, angiotensin-II (released in response to 
neurohormonal and compensatory mechanism in heart failure) to GPCRs coupled to 
Gαq/11 leads to activation and mobilization of Ca
2+ through the inositol 1,4,5-
triphosphate (Ins(1,4,5)P3) pathway Fig (6.10). Ca2+ can also be released from  
excitation-contraction coupling in myocytes, enhanced myocardial stress and also 
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from PKA-mediated release of Ca2+ as the heart tries to improve its function by 
enhanced β-AR signalling. Increased release of calcium in the myocyte can recruit 
other players like calcium calmodulin (CaM), calcium calmodulin-dependent protein 
kinase II (CaMKII), calcineurin (CaN) and nuclear factor of activated T cells (NFAT). 
Gαq/11 signalling activates phospholipase C (PLC), which catalyses the synthesis of 
Ins(1,4,5)P3 and diacyl glycerol (DAG). Ins(1,4,5)P3 induces intracellular Ca2+ 
release which then activates CaMKinase or calcineurin, which mediate cardiomyocyte 
growth. Calcineurin is a calcium-dependent protein phosphatase that dephosphorylates 
NFAT transcription factors. NFAT forms complexes with the cofactors GATA-4 or 
myocyte enhancer factor-2 (MEF-2) to transactivate the transcription of hypertrophic 
target genes (Heineke and Molkentin 2006;Maillet et al. 2013). 
Also involved are histone deacetylases (HDACs), which are regulated by 
phosphorylation and shuttle between the cytoplasm and nucleus. When 
phosphorylated, by CaMKIIδ and PKD, these enzymes are bound and are sequestered 
in the cytoplasm; dephosphorylation results in translocation to the nucleus where in 
association with MEF-2 transcription factors they deacetylate histone proteins and 
inhibit transcription factors. This way they regulate cardiac specific gene expression 
and class II HDACs repress cardiac growth via MEF-2. In the heart, phosphorylation 
of these HDACs appears to be particularly mediated by CaM kinases in response to an 
increase in intracellular/nuclear Ca2+, further leading to activation of MEF-2 (Clerk, 
Cullingford, Fuller, Giraldo, Markou, Pikkarainen, & Sugden 2007). 
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Figure 6.10 Role of Ca2+ in the hypertrophy signalling pathway. Ca2+ is released from 
excitation-contraction coupling, Gαq/11 and Gαs signalling activates CaM, CaMKIIδ and 
calcineurin and in the nucleus it activates several transcription factors which in turn switch on 
hypertrophic gene activation leading to cardiomyocyte growth. ECC- excitation contraction 
coupling, PLC-Phospholipase C, MAPKK-Mitogen activated protein kinase, Endo-1-Endothelin -
1, Ang II- angiotensin –II, JNK-c-Jun N-terminal kinase, ℗-phosphorylation, HDAC- histone 
deacetylase. 
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Other mediators of pathological cardiac hypertrophy are the p38 and c-Jun N-terminal 
kinase (JNK) branches of the MAPK cascade, which phosphorylate and activate the 
GATA-4 transcription factor. Prolonged p38 or JNK activation in the heart leads to 
cardiomyopathy and heart failure. Catecholamines can also activate AC to induce 
activation of PKA, which then phosphorylates an array of intracellular targets, leading 
to increased calcium release and enhanced contractility; the end result of this appears 
to be cardiomyopathic, as it results in increased myocyte apoptosis and necrosis 
(Maillet, van Berlo, & Molkentin 2013). 
In Gαi2 flx/flx HCN4 cre
+ mice due to their higher heart rate, they might be more 
prone to hypertrophy which in turn leads to apoptosis and heart failure as there is 
more Ca2+ available in these mice as a result of their phenotype. On the other hand 
Gαs flx/flx HCN4 cre
+ mice are protected due to their bradycardic nature and less Ca2+ 
is available in their ventricular myocytes, so they are less likely to develop 
hypertrophy and further downstream effects. To investigate further this hypothesis, 
targeting a few genes in the hypertrophic signalling pathway like CaMKIIδ, and 
calcineurin may perhaps help us in understanding the role of Ca2+ in determining the 
observed phenotype in these mice. 
The positive adaptive response seen with the MI model in Gαs flx/flx HCN4 cre
+ mice 
tempts us to investigate further these results in a different experimental model like 
hypertrophy-induced heart failure by Transverse Aortic Constriction (TAC) to further 
confirm these findings. 
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Summary 
 
Mice with cardiac specific deletion of Gαi2 and Gαo using αMHC cre didn’t show any 
difference in HRV and ECG. This could be due to incomplete cre-mediated deletion 
of Gαi2 and Gαo specifically to the SA nodal cells. Another possible explanation is 
other chronic compensation may be possible in these cardiac specific knock-outs as a 
developmental modification and the observations could be adaptive. 
Interestingly, studies with RGSiGαi2 and RGSiGαo suggested possible role of the 
central nervous system in controlling the heart rate, as they were found to be 
tachycardic, hyperactive and they lost their diurnal variation in heart rhythm. However 
despite this there was an enhanced bradycardic response to carbachol in both 
RGSiGαi2 and RGSiGαo.  
The selective deletion of Gαs in the conduction system results in loss of normal 
diurnal variation with the mice no longer tachycardic at night and thus relatively 
bradycardic compared to control. In contrast, mice with selective deletion of Gαi2 in 
the conduction system also lost normal diurnal variation but this occurs because they 
are relatively more tachycardic during the day consistent with a decline in 
parasympathetic modulation of the SA node. After selective deletion of Gαs in 
conduction system the response to isoprenaline was significantly attenuated but not 
abolished whilst with Gαi2 deletion the heart rate slowing response to carbachol is 
relatively well preserved. Specifically, there was a selective loss of normalised low 
frequency (LF) power in Gαs flx/flx HCN4 cre
+ mice seen as loss of spectral peaks in 
the low frequency range,(0.4-1.5Hz) while in contrast in Gαi2 flx/flx HCN4 cre
+ mice 
there was a selective loss in normalised high frequency (HF) power perceived as loss 
of spectral peaks in high frequency range (1.5-4.0). Thus, deletion of Gαs and Gαi2 in 
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the conduction system of the adult mouse impairs physiological heart rate regulation 
in the intact awake animal. 
Data from M-mode echocardiography suggests that SAN-specific knock-out of Gαs 
attenuates LV dilation and preserves LV contractile function after MI. FS% and EF% 
were found to be increased in Gαs flx/flx HCN4 cre
+ mice after tamoxifen which 
shows a possible increase in contractility is occurring in them as a result of deletion of 
Gαs in nodal cells which may be protective in nature. So in these mice after MI 
absence of Gαs in the conduction system tissues is helping them to overcome the 
effects of LV remodelling. On the other hand, FS% and FAC% showed a decrease 
after MI in Gαi2 flx/flx HCN4 cre
+ mice but didn’t reach a significance when 
compared with the controls.  There was significant difference in chamber dilatation in 
LV marked by increase in the measurement of LVIDd and LVPWd measurements 
after MI in Gαi2 flx/flx HCN4 cre
+ mice after 14 days post MI, although not 
significant when compared with control.  
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Future directions 
 
Cardiac specific deletion of Gs and Gαi2 in the conduction system (Gs flx/flx HCN4 
cre+ and Gαi2flx/flx HCN4 cre
+) showed some interesting phenotypes of being 
tachycardic and bradycardic respectively and a loss of HF power of HRV with Gαi2 
HCN4 cre+ mice and a loss of LF power of HRV with Gαi2 HCN4 cre
+ mice. It would 
be interesting to know how these changes in heart rate and the conduction system, 
remodel the ventricle and affect the expression and function of protective signalling 
pathways.  
Studies with RGS sensitive knock-ins of Gαi2 and Gαo showed a potential role of the 
central nervous system in controlling the heart rate, as they were found to be 
tachycardic and they lost their diurnal variation in heart rhythm. Also we observed in 
our studies an enhanced bradycardic response to carbachol in both RGSiGαi2 and 
RGSiGαo which could be due to enhanced GIRK channel activation and suggests it 
has a role in cardiac automaticity. This observation needs to be further confirmed by 
looking at various ion channels like e.g. GIRK by patch clamping techniques (single 
cell electrophysiology). As an effector for parasympathetic control of heart rate GIRK 
currents have been implicated in the development of atrial fibrillation (AF) and 
several lines of evidence have suggested that abnormal activation of GIRK currents is 
associated with AF (Dobrev, Friedrich, Voigt, Jost, Wettwer, Christ, Knaut, & Ravens 
2005). Since GIRK currents are preferentially activated upon M2R activation when 
actions of RGS proteins on Gαi2 are impaired, it is conceivable that RGSiGαi2 mutant 
mice may have an increased risk of AF as well. By using in vivo electrophysiological 
studies (cardiac pacing) further characterization of RGSiGαi2 and RGSiGαo needs to 
be done to see whether they are prone to atrial fibrillation and AV conduction block. 
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Studies with MI models of Gαi2 and Gαs with tamoxifen inducible conduction cre, 
found to be promising with respect to Gαs HCN4 cre
+ mice. It would be supportive 
and favourable to determine the degree of apoptosis and hypertrophy in Gαi2 flx/flx 
HCN4 cre+ and Gαs flx/flx HCN4 cre
+ mice. Also, further characterization of these 
mice by histology, gene expression studies and biochemical assays needs to be done. 
Calcium handling properties of the cells may have altered with prolonged bradycardia 
(Gαs flx/flx HCN4 cre
+) and tachycardia (Gαi2 flx/flx HCN4 cre
+) in these mice after 
the MI or even before that (after tamoxifen treatment), so assessment of the activation 
status of calcium dependent calmodulin kinase II (CaMKII) is another potential 
candidate to explore. Since we found that the absence of Gαs in the conduction system 
tissues is protective in the context of MI, it would be of great relevance if I could 
prove the same in another model of heart failure and hypertrophy such as transverse 
aortic banding. 
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